Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16840188,overall response rate,"Best response included five CR, six PR, one SD and one PD with an overall response rate of 85% and complete response rate of 38%.","Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840188/),%,85,284,DB00635,Prednisone
,16840188,complete response rate,"Best response included five CR, six PR, one SD and one PD with an overall response rate of 85% and complete response rate of 38%.","Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840188/),%,38,285,DB00635,Prednisone
,15049798,Half-life (T(1/2)),"Half-life (T(1/2)) and terminal T(1/2) were 9.7 (7.1-24.6) and 10.8 (4.4-95.2) hours (median, range) respectively at month 1, and were 9.6 (5-17.8) and 12.1 (4.7-71.0) hours respectively at month 3.",Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049798/),h,9.7,1318,DB00635,Prednisone
,15049798,Half-life (T(1/2)),"Half-life (T(1/2)) and terminal T(1/2) were 9.7 (7.1-24.6) and 10.8 (4.4-95.2) hours (median, range) respectively at month 1, and were 9.6 (5-17.8) and 12.1 (4.7-71.0) hours respectively at month 3.",Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049798/),h,9.6,1319,DB00635,Prednisone
,15049798,terminal T(1/2),"Half-life (T(1/2)) and terminal T(1/2) were 9.7 (7.1-24.6) and 10.8 (4.4-95.2) hours (median, range) respectively at month 1, and were 9.6 (5-17.8) and 12.1 (4.7-71.0) hours respectively at month 3.",Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049798/),h,10.8,1320,DB00635,Prednisone
,15049798,terminal T(1/2),"Half-life (T(1/2)) and terminal T(1/2) were 9.7 (7.1-24.6) and 10.8 (4.4-95.2) hours (median, range) respectively at month 1, and were 9.6 (5-17.8) and 12.1 (4.7-71.0) hours respectively at month 3.",Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049798/),h,12.1,1321,DB00635,Prednisone
,12780669,area under the concentration-time curve (AUC0-12),"The am and pm doses were independently adjusted to achieve a 12-h area under the concentration-time curve (AUC0-12) of 6600-7200 nghr/mL and morning trough level (C0) of 250-325 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[nghr] / [ml],6600-7200,3025,DB00635,Prednisone
,12780669,trough level (C0),"The am and pm doses were independently adjusted to achieve a 12-h area under the concentration-time curve (AUC0-12) of 6600-7200 nghr/mL and morning trough level (C0) of 250-325 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[ng] / [ml],250-325,3026,DB00635,Prednisone
,12780669,AUC0-12,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[nghr] / [ml],7810,3027,DB00635,Prednisone
,12780669,AUC0-12,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[nghr] / [ml],9057,3028,DB00635,Prednisone
,12780669,AUC0-12,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[nghr] / [ml],7674,3029,DB00635,Prednisone
,12780669,AUC0-12,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[nghr] / [ml],7132,3030,DB00635,Prednisone
,12780669,AUC0-12,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[ngl] / [h],6503,3031,DB00635,Prednisone
,12780669,C0,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[ng] / [ml],301,3032,DB00635,Prednisone
,12780669,C0,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[ng] / [ml],316,3033,DB00635,Prednisone
,12780669,C0,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[ng] / [ml],275,3034,DB00635,Prednisone
,12780669,C0,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[ng] / [ml],273,3035,DB00635,Prednisone
,12780669,C0,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[ng] / [ml],224,3036,DB00635,Prednisone
,11294518,flow rate,"The mobile phase consisted of 16% isopropanol in water containing 0.1% trifluoroacetic acid, set at a flow rate of 1.2 mL/min.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),[ml] / [min],1.2,3291,DB00635,Prednisone
,11294518,imprecision,"Mean intra-assay and interassay imprecision levels were 6.0% and 7.2%, respectively, for prednisolone, 5.8% and 7.2% for prednisone, and 5.6% and 7.9% for cortisol.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,7.2,3292,DB00635,Prednisone
,11294518,imprecision,"Mean intra-assay and interassay imprecision levels were 6.0% and 7.2%, respectively, for prednisolone, 5.8% and 7.2% for prednisone, and 5.6% and 7.9% for cortisol.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,5.8,3293,DB00635,Prednisone
,11294518,imprecision,"Mean intra-assay and interassay imprecision levels were 6.0% and 7.2%, respectively, for prednisolone, 5.8% and 7.2% for prednisone, and 5.6% and 7.9% for cortisol.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,5.6,3294,DB00635,Prednisone
,11294518,imprecision,"Mean intra-assay and interassay imprecision levels were 6.0% and 7.2%, respectively, for prednisolone, 5.8% and 7.2% for prednisone, and 5.6% and 7.9% for cortisol.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,7.9,3295,DB00635,Prednisone
,11294518,recoveries,"Corticosteroid recoveries were 73%, 74%, and 90% for prednisolone, prednisone, and cortisol, respectively.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,73,3296,DB00635,Prednisone
,11294518,recoveries,"Corticosteroid recoveries were 73%, 74%, and 90% for prednisolone, prednisone, and cortisol, respectively.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,74,3297,DB00635,Prednisone
,11294518,recoveries,"Corticosteroid recoveries were 73%, 74%, and 90% for prednisolone, prednisone, and cortisol, respectively.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,90,3298,DB00635,Prednisone
,11856782,AUC(0-12),"There was an association between the risk of acute rejection episodes and MPA-AUC(0-12) values or MPA predose levels; by receiver operating characteristic analysis, an AUC(0-12) of 33.8 mg x h/L in the initial phase posttransplant had a diagnostic sensitivity of 75% and a diagnostic specificity of 64% for discrimination of patients with acute rejections.",The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11856782/),[h·mg] / [l],33.8,5527,DB00635,Prednisone
,15726877,ratio,"The prednisolone/prednisone ratio in urine was 11.1 in group L, 7.3 in group HA and 45.6 in group HC.",Pharmacokinetics of prednisolone in man during acute and chronic exposure to high altitude. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726877/),,11.1,5588,DB00635,Prednisone
,15726877,ratio,"The prednisolone/prednisone ratio in urine was 11.1 in group L, 7.3 in group HA and 45.6 in group HC.",Pharmacokinetics of prednisolone in man during acute and chronic exposure to high altitude. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726877/),,7.3,5589,DB00635,Prednisone
,15726877,ratio,"The prednisolone/prednisone ratio in urine was 11.1 in group L, 7.3 in group HA and 45.6 in group HC.",Pharmacokinetics of prednisolone in man during acute and chronic exposure to high altitude. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726877/),,45.6,5590,DB00635,Prednisone
,7202937,relative bioavailability,The relative bioavailability of prednisone after prednisone-antacid treatments compared to that after prednisone-water treatment was 74% +/- 13% (p less than 0.05) with Melox and 57% +/- 15% (p less than 0.01) with Aldrox in healthy volunteers.,Decreased bioavailability of prednisone due to antacids in patients with chronic active liver disease and in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202937/),%,74,5855,DB00635,Prednisone
,7202937,relative bioavailability,The relative bioavailability of prednisone after prednisone-antacid treatments compared to that after prednisone-water treatment was 74% +/- 13% (p less than 0.05) with Melox and 57% +/- 15% (p less than 0.01) with Aldrox in healthy volunteers.,Decreased bioavailability of prednisone due to antacids in patients with chronic active liver disease and in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202937/),%,57,5856,DB00635,Prednisone
,7202937,bioavailability,"In patients with chronic active liver disease responding to treatment, prednisone bioavailability was 65% +/- 120% (p less than 0.01) and 87% +/- 20%, respectively.",Decreased bioavailability of prednisone due to antacids in patients with chronic active liver disease and in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202937/),%,65,5857,DB00635,Prednisone
,7202937,bioavailability,"In patients with chronic active liver disease responding to treatment, prednisone bioavailability was 65% +/- 120% (p less than 0.01) and 87% +/- 20%, respectively.",Decreased bioavailability of prednisone due to antacids in patients with chronic active liver disease and in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202937/),%,87,5858,DB00635,Prednisone
,25587129,dose,"Among the CYP3A5 expressers, the dose-adjusted trough concentration (C0/D) of tacrolimus in HSD11B1 rs846908 AA homozygous individuals was considerably lower than found in GG+GA carriers [56.2 (23.9-86.6) versus 76.7 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0204]; HSD11B1 rs846910 AA homozygotes had a lower tacrolimus C0/D compared with GG+GA carriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367]; carriers with the HSD11B1 rs4844880 AA genotype had a significantly lower tacrolimus C0/D with respect to carriers of TT+TA genotypes [61.3 (23.9-97.5) versus 77.2 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0002]; the HSD11B1 AA-AA-AA haplotype carriers had a lower tacrolimus C0/D than noncarriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367].",Associations of HSD11B1 polymorphisms with tacrolimus concentrations in Chinese renal transplant recipients with prednisone combined therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25587129/),[ml·ng] / [kg·mg],56.2,6643,DB00635,Prednisone
,25587129,trough concentration (C0/D),"Among the CYP3A5 expressers, the dose-adjusted trough concentration (C0/D) of tacrolimus in HSD11B1 rs846908 AA homozygous individuals was considerably lower than found in GG+GA carriers [56.2 (23.9-86.6) versus 76.7 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0204]; HSD11B1 rs846910 AA homozygotes had a lower tacrolimus C0/D compared with GG+GA carriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367]; carriers with the HSD11B1 rs4844880 AA genotype had a significantly lower tacrolimus C0/D with respect to carriers of TT+TA genotypes [61.3 (23.9-97.5) versus 77.2 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0002]; the HSD11B1 AA-AA-AA haplotype carriers had a lower tacrolimus C0/D than noncarriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367].",Associations of HSD11B1 polymorphisms with tacrolimus concentrations in Chinese renal transplant recipients with prednisone combined therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25587129/),[ml·ng] / [kg·mg],56.2,6644,DB00635,Prednisone
,25587129,trough concentration (C0/D),"Among the CYP3A5 expressers, the dose-adjusted trough concentration (C0/D) of tacrolimus in HSD11B1 rs846908 AA homozygous individuals was considerably lower than found in GG+GA carriers [56.2 (23.9-86.6) versus 76.7 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0204]; HSD11B1 rs846910 AA homozygotes had a lower tacrolimus C0/D compared with GG+GA carriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367]; carriers with the HSD11B1 rs4844880 AA genotype had a significantly lower tacrolimus C0/D with respect to carriers of TT+TA genotypes [61.3 (23.9-97.5) versus 77.2 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0002]; the HSD11B1 AA-AA-AA haplotype carriers had a lower tacrolimus C0/D than noncarriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367].",Associations of HSD11B1 polymorphisms with tacrolimus concentrations in Chinese renal transplant recipients with prednisone combined therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25587129/),[ml·ng] / [kg·mg],76.7,6645,DB00635,Prednisone
,25587129,C0/D,"Among the CYP3A5 expressers, the dose-adjusted trough concentration (C0/D) of tacrolimus in HSD11B1 rs846908 AA homozygous individuals was considerably lower than found in GG+GA carriers [56.2 (23.9-86.6) versus 76.7 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0204]; HSD11B1 rs846910 AA homozygotes had a lower tacrolimus C0/D compared with GG+GA carriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367]; carriers with the HSD11B1 rs4844880 AA genotype had a significantly lower tacrolimus C0/D with respect to carriers of TT+TA genotypes [61.3 (23.9-97.5) versus 77.2 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0002]; the HSD11B1 AA-AA-AA haplotype carriers had a lower tacrolimus C0/D than noncarriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367].",Associations of HSD11B1 polymorphisms with tacrolimus concentrations in Chinese renal transplant recipients with prednisone combined therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25587129/),[ml·ng] / [kg·mg],51.2,6646,DB00635,Prednisone
,25587129,C0/D,"Among the CYP3A5 expressers, the dose-adjusted trough concentration (C0/D) of tacrolimus in HSD11B1 rs846908 AA homozygous individuals was considerably lower than found in GG+GA carriers [56.2 (23.9-86.6) versus 76.7 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0204]; HSD11B1 rs846910 AA homozygotes had a lower tacrolimus C0/D compared with GG+GA carriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367]; carriers with the HSD11B1 rs4844880 AA genotype had a significantly lower tacrolimus C0/D with respect to carriers of TT+TA genotypes [61.3 (23.9-97.5) versus 77.2 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0002]; the HSD11B1 AA-AA-AA haplotype carriers had a lower tacrolimus C0/D than noncarriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367].",Associations of HSD11B1 polymorphisms with tacrolimus concentrations in Chinese renal transplant recipients with prednisone combined therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25587129/),[ml·ng] / [kg·mg],76.3,6647,DB00635,Prednisone
,25587129,C0/D,"Among the CYP3A5 expressers, the dose-adjusted trough concentration (C0/D) of tacrolimus in HSD11B1 rs846908 AA homozygous individuals was considerably lower than found in GG+GA carriers [56.2 (23.9-86.6) versus 76.7 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0204]; HSD11B1 rs846910 AA homozygotes had a lower tacrolimus C0/D compared with GG+GA carriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367]; carriers with the HSD11B1 rs4844880 AA genotype had a significantly lower tacrolimus C0/D with respect to carriers of TT+TA genotypes [61.3 (23.9-97.5) versus 77.2 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0002]; the HSD11B1 AA-AA-AA haplotype carriers had a lower tacrolimus C0/D than noncarriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367].",Associations of HSD11B1 polymorphisms with tacrolimus concentrations in Chinese renal transplant recipients with prednisone combined therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25587129/),,61.3,6648,DB00635,Prednisone
,25587129,C0/D,"Among the CYP3A5 expressers, the dose-adjusted trough concentration (C0/D) of tacrolimus in HSD11B1 rs846908 AA homozygous individuals was considerably lower than found in GG+GA carriers [56.2 (23.9-86.6) versus 76.7 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0204]; HSD11B1 rs846910 AA homozygotes had a lower tacrolimus C0/D compared with GG+GA carriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367]; carriers with the HSD11B1 rs4844880 AA genotype had a significantly lower tacrolimus C0/D with respect to carriers of TT+TA genotypes [61.3 (23.9-97.5) versus 77.2 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0002]; the HSD11B1 AA-AA-AA haplotype carriers had a lower tacrolimus C0/D than noncarriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367].",Associations of HSD11B1 polymorphisms with tacrolimus concentrations in Chinese renal transplant recipients with prednisone combined therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25587129/),,77.2,6649,DB00635,Prednisone
,25111199,time to progression,"A decrease in prostate-specific antigen ≥50% was observed in 82% of 39 evaluable patients, with a median time to progression of 12.3 months.",Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25111199/),month,12.3,7035,DB00635,Prednisone
,25111199,PFS,"Median PFS and OS were 14.9 months (95% CI, 9.2-15.3 months) and 33.3 months (95% CI, 23-35.6 months), respectively.",Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25111199/),month,14,7036,DB00635,Prednisone
,25111199,OS,"Median PFS and OS were 14.9 months (95% CI, 9.2-15.3 months) and 33.3 months (95% CI, 23-35.6 months), respectively.",Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25111199/),month,33,7037,DB00635,Prednisone
,17445553,C(0),"The mean values for C(0) and AUC(0-6h) were 1.8 +/- 1.2 mg/L and 31.1 +/- 14.8 mg*h/L, respectively.",Therapeutic drug monitoring of mycophenolic acid in kidney transplant patients: a abbreviated sampling strategy. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17445553/),[mg] / [l],1.8,9878,DB00635,Prednisone
,17445553,AUC(0-6h),"The mean values for C(0) and AUC(0-6h) were 1.8 +/- 1.2 mg/L and 31.1 +/- 14.8 mg*h/L, respectively.",Therapeutic drug monitoring of mycophenolic acid in kidney transplant patients: a abbreviated sampling strategy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17445553/),[h·mg] / [l],31.1,9879,DB00635,Prednisone
,17445553,dose-corrected AUC(0-6h),The dose-corrected AUC(0-6h) was 35.4 +/- 17.9 mg*h/L.,Therapeutic drug monitoring of mycophenolic acid in kidney transplant patients: a abbreviated sampling strategy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17445553/),[h·mg] / [l],35.4,9880,DB00635,Prednisone
,20920295,AUC₀₋₇,"Mean AUC₀₋₇ (days) was 155.9 versus 152.4 mg*h/mL for Prolastin-C and Prolastin, respectively.",Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20920295/),[h·mg] / [ml],155.9,10708,DB00635,Prednisone
,20920295,AUC₀₋₇,"Mean AUC₀₋₇ (days) was 155.9 versus 152.4 mg*h/mL for Prolastin-C and Prolastin, respectively.",Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20920295/),[h·mg] / [ml],152.4,10709,DB00635,Prednisone
,32539658,CL,"MPA CL, Vc, Vp, Ka and Q were 15.4 L/h, 22.86 L, 768 L, 1.28 h-1 and 20.3 L/h, respectively.",Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32539658/),[l] / [h],15.4,11955,DB00635,Prednisone
,32539658,Vc,"MPA CL, Vc, Vp, Ka and Q were 15.4 L/h, 22.86 L, 768 L, 1.28 h-1 and 20.3 L/h, respectively.",Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32539658/),l,22.86,11956,DB00635,Prednisone
,32539658,Vp,"MPA CL, Vc, Vp, Ka and Q were 15.4 L/h, 22.86 L, 768 L, 1.28 h-1 and 20.3 L/h, respectively.",Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32539658/),l,22.86,11957,DB00635,Prednisone
,32539658,Ka,"MPA CL, Vc, Vp, Ka and Q were 15.4 L/h, 22.86 L, 768 L, 1.28 h-1 and 20.3 L/h, respectively.",Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32539658/),l,22.86,11958,DB00635,Prednisone
,32539658,Q,"MPA CL, Vc, Vp, Ka and Q were 15.4 L/h, 22.86 L, 768 L, 1.28 h-1 and 20.3 L/h, respectively.",Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32539658/),[l] / [h],20.3,11959,DB00635,Prednisone
> or =,15659129,Cmax,A Cmax> or =10 microg/mL was seen in 20 (57%) of the patients.,The need of mycophenolic acid monitoring in long-term renal transplants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15659129/),[μg] / [ml],10,14142,DB00635,Prednisone
,8680052,Cmax,"The Cmax and Tmax for mycophenolic acid (MPA) were 3.6-35.2 micrograms/mL and 0.5-4 h, respectively, and did not significantly change over 6 months.",Mycophenolate mofetil in liver transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8680052/),[μg] / [ml],3.6-35.2,16245,DB00635,Prednisone
,8680052,Tmax,"The Cmax and Tmax for mycophenolic acid (MPA) were 3.6-35.2 micrograms/mL and 0.5-4 h, respectively, and did not significantly change over 6 months.",Mycophenolate mofetil in liver transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8680052/),h,0.5-4,16246,DB00635,Prednisone
,6997330,elimination half-lives,The elimination half-lives were not significantly different in the noncushingoid and cushingoid patients (2.3 vs. 3.3 h).,Prednisolone disposition in cushingoid and noncushingoid kidney transplant patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6997330/),h,2.3,16591,DB00635,Prednisone
,6997330,elimination half-lives,The elimination half-lives were not significantly different in the noncushingoid and cushingoid patients (2.3 vs. 3.3 h).,Prednisolone disposition in cushingoid and noncushingoid kidney transplant patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6997330/),h,3.3,16592,DB00635,Prednisone
,6997330,plasma clearance,"However, other pharmacokinetic parameters were significantly lower in the cushingoid group: plasma clearance (147 vs. 82 ml/min) and volume of distribution (32 vs. 20 liters).",Prednisolone disposition in cushingoid and noncushingoid kidney transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6997330/),[ml] / [min],147,16593,DB00635,Prednisone
,6997330,plasma clearance,"However, other pharmacokinetic parameters were significantly lower in the cushingoid group: plasma clearance (147 vs. 82 ml/min) and volume of distribution (32 vs. 20 liters).",Prednisolone disposition in cushingoid and noncushingoid kidney transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6997330/),[ml] / [min],82,16594,DB00635,Prednisone
,6997330,volume of distribution,"However, other pharmacokinetic parameters were significantly lower in the cushingoid group: plasma clearance (147 vs. 82 ml/min) and volume of distribution (32 vs. 20 liters).",Prednisolone disposition in cushingoid and noncushingoid kidney transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6997330/),l,32,16595,DB00635,Prednisone
,6997330,volume of distribution,"However, other pharmacokinetic parameters were significantly lower in the cushingoid group: plasma clearance (147 vs. 82 ml/min) and volume of distribution (32 vs. 20 liters).",Prednisolone disposition in cushingoid and noncushingoid kidney transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6997330/),l,20,16596,DB00635,Prednisone
,6997330,availability,"In addition, the availability of prednisolone after oral prednisone administration was considerably variable (overall range, 27-108%) and was not significantly different between the two groups.",Prednisolone disposition in cushingoid and noncushingoid kidney transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6997330/),%,27-108,16597,DB00635,Prednisone
,14529944,C(0) MPA level,C(0) MPA level among the tacrolimus group were significantly higher than those in CsA group: 3.18 +/- 2.21 microg/mL versus 1.68 +/- 1.03 microg/mL (P </=.001).,The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14529944/),[μg] / [ml],3.18,17449,DB00635,Prednisone
,14529944,C(0) MPA level,C(0) MPA level among the tacrolimus group were significantly higher than those in CsA group: 3.18 +/- 2.21 microg/mL versus 1.68 +/- 1.03 microg/mL (P </=.001).,The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14529944/),[μg] / [ml],1.68,17450,DB00635,Prednisone
,8926681,retention,"Ara-CTP retention, however, was significantly lower in T-ALL (37 +/- 15%, n = 8) compared to non-T-ALL (67 +/- 25%, n = 33; p < 0.003).",[Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926681/),%,37,18591,DB00635,Prednisone
,8926681,retention,"Ara-CTP retention, however, was significantly lower in T-ALL (37 +/- 15%, n = 8) compared to non-T-ALL (67 +/- 25%, n = 33; p < 0.003).",[Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926681/),%,67,18592,DB00635,Prednisone
,8926681,retention,"Ara-CTP retention was also significantly different in children with and without persistence of peripheral blast cells after one week of prednison treatment (71 +/- 30%, n = 9 and 53 +/- 19%, n = 21; p = 0.031) as well as in children with and without complete bone marrow remission on day 15 of the ALL-BFM treatment protocol (66 +/- 17%, n = 19 and 43 +/- 18%, n = 11; p = 0.018).",[Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926681/),%,71,18593,DB00635,Prednisone
,8926681,retention,"Ara-CTP retention was also significantly different in children with and without persistence of peripheral blast cells after one week of prednison treatment (71 +/- 30%, n = 9 and 53 +/- 19%, n = 21; p = 0.031) as well as in children with and without complete bone marrow remission on day 15 of the ALL-BFM treatment protocol (66 +/- 17%, n = 19 and 43 +/- 18%, n = 11; p = 0.018).",[Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926681/),%,53,18594,DB00635,Prednisone
,8926681,retention,"Ara-CTP retention was also significantly different in children with and without persistence of peripheral blast cells after one week of prednison treatment (71 +/- 30%, n = 9 and 53 +/- 19%, n = 21; p = 0.031) as well as in children with and without complete bone marrow remission on day 15 of the ALL-BFM treatment protocol (66 +/- 17%, n = 19 and 43 +/- 18%, n = 11; p = 0.018).",[Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926681/),%,66,18595,DB00635,Prednisone
,8926681,retention,"Ara-CTP retention was also significantly different in children with and without persistence of peripheral blast cells after one week of prednison treatment (71 +/- 30%, n = 9 and 53 +/- 19%, n = 21; p = 0.031) as well as in children with and without complete bone marrow remission on day 15 of the ALL-BFM treatment protocol (66 +/- 17%, n = 19 and 43 +/- 18%, n = 11; p = 0.018).",[Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926681/),%,43,18596,DB00635,Prednisone
,8926681,retention,"Ara-CTP retention was inversely correlated with the risk groups defined by the ALL-BFM treatment protocols (standard 79 +/- 29, intermediate 59 +/- 25, high risk 47 +/- 21%).",[Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926681/),,79,18597,DB00635,Prednisone
,8926681,retention,"Ara-CTP retention was inversely correlated with the risk groups defined by the ALL-BFM treatment protocols (standard 79 +/- 29, intermediate 59 +/- 25, high risk 47 +/- 21%).",[Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926681/),,59,18598,DB00635,Prednisone
,8926681,retention,"Ara-CTP retention was inversely correlated with the risk groups defined by the ALL-BFM treatment protocols (standard 79 +/- 29, intermediate 59 +/- 25, high risk 47 +/- 21%).",[Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8926681/),,47,18599,DB00635,Prednisone
,10850396,elimination half-life,The Rituximab elimination half-life of approximately 20 days accounts for the demonstrated accumulation of MAb in serum samples.,Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850396/),d,20,19743,DB00635,Prednisone
,2967477,Peak serum concentrations,Peak serum concentrations of prednisolone obtained after dosing with prednisone occurred earlier and were higher (473 +/- 106 ng/ml) than those obtained after dosing with prednisolone methylsulfobenzoate (232 +/- 70 ng/ml; P less than 0.01).,[Comparative serum pharmacokinetics of prednisone and prednisolone methylsulfobenzoate after oral administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967477/),[ng] / [ml],473,20095,DB00635,Prednisone
,2967477,Peak serum concentrations,Peak serum concentrations of prednisolone obtained after dosing with prednisone occurred earlier and were higher (473 +/- 106 ng/ml) than those obtained after dosing with prednisolone methylsulfobenzoate (232 +/- 70 ng/ml; P less than 0.01).,[Comparative serum pharmacokinetics of prednisone and prednisolone methylsulfobenzoate after oral administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967477/),[ng] / [ml],232,20096,DB00635,Prednisone
,11523724,trough concentration,"Target trough concentration ranges depend on the concomitant immunosuppressive regimen, but a range of 5 to 15 microg/L is appropriate if cyclosporin is being used at trough concentrations of 75 to 150 microg/L.",Clinical pharmacokinetics of sirolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11523724/),[μg] / [l],5 to 15,20590,DB00635,Prednisone
,11523724,trough concentrations,"Target trough concentration ranges depend on the concomitant immunosuppressive regimen, but a range of 5 to 15 microg/L is appropriate if cyclosporin is being used at trough concentrations of 75 to 150 microg/L.",Clinical pharmacokinetics of sirolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11523724/),[μg] / [l],75 to 150,20591,DB00635,Prednisone
,12644921,C(0),"Mean C(0), C(max), AUC (0-12), and T(max )were 3.46+/-1.32, 13.5+/-0.58 microg/ml, 63.2+/-24.4 microg x h/ml, and 1.3+/-0.6 h, respectively.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[μg] / [ml],3.46,21628,DB00635,Prednisone
,12644921,C(max),"Mean C(0), C(max), AUC (0-12), and T(max )were 3.46+/-1.32, 13.5+/-0.58 microg/ml, 63.2+/-24.4 microg x h/ml, and 1.3+/-0.6 h, respectively.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[μg] / [ml],13.5,21629,DB00635,Prednisone
,12644921,C(max),"Mean C(0), C(max), AUC (0-12), and T(max )were 3.46+/-1.32, 13.5+/-0.58 microg/ml, 63.2+/-24.4 microg x h/ml, and 1.3+/-0.6 h, respectively.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[h·μg] / [ml],63.2,21630,DB00635,Prednisone
,12644921,AUC (0-12),"Mean C(0), C(max), AUC (0-12), and T(max )were 3.46+/-1.32, 13.5+/-0.58 microg/ml, 63.2+/-24.4 microg x h/ml, and 1.3+/-0.6 h, respectively.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[μg] / [ml],13.5,21631,DB00635,Prednisone
,12644921,AUC (0-12),"Mean C(0), C(max), AUC (0-12), and T(max )were 3.46+/-1.32, 13.5+/-0.58 microg/ml, 63.2+/-24.4 microg x h/ml, and 1.3+/-0.6 h, respectively.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[h·μg] / [ml],63.2,21632,DB00635,Prednisone
,12644921,T(max ),"Mean C(0), C(max), AUC (0-12), and T(max )were 3.46+/-1.32, 13.5+/-0.58 microg/ml, 63.2+/-24.4 microg x h/ml, and 1.3+/-0.6 h, respectively.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),h,1.3,21633,DB00635,Prednisone
>,12644921,AUC(0-12 ),"Six (30%) children were considered to have an adequate exposure (36-54 microg x h/ml) to MPA, 11 (55%) showed an AUC(0-12 )>54 microg.h/ml, and 3 (15%) showed an AUC(0-12 )<36 microg x h/ml.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[h·μg] / [ml],54,21634,DB00635,Prednisone
<,12644921,AUC(0-12 ),"Six (30%) children were considered to have an adequate exposure (36-54 microg x h/ml) to MPA, 11 (55%) showed an AUC(0-12 )>54 microg.h/ml, and 3 (15%) showed an AUC(0-12 )<36 microg x h/ml.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[h·μg] / [ml],36,21635,DB00635,Prednisone
>/=,12644921,C(max ),A C(max )>/=10 microg/ml was seen in 13 (65%) children.,Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[μg] / [ml],10,21636,DB00635,Prednisone
,3235500,Peak serum methylprednisone concentrations,Peak serum methylprednisone concentrations of ca. 250 ng/ml occurred within 5 min of methylprednisolone administration and the average area under the curve ratio (methylprednisolone/methylprednisone) was 9.3.,"Analysis of methylprednisolone, methylprednisone and corticosterone for assessment of methylprednisolone disposition in the rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3235500/),[ng] / [ml],250,24265,DB00635,Prednisone
,3235500,area under the curve ratio,Peak serum methylprednisone concentrations of ca. 250 ng/ml occurred within 5 min of methylprednisolone administration and the average area under the curve ratio (methylprednisolone/methylprednisone) was 9.3.,"Analysis of methylprednisolone, methylprednisone and corticosterone for assessment of methylprednisolone disposition in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3235500/),,9.3,24266,DB00635,Prednisone
,10440399,AUC,"A total of 154 adult recipients of a primary or secondary cadaveric kidney graft were randomly allocated, in this double-blind trial, to receive MMF treatment aimed at three predefined target MPA AUC values (16.1, 32.2, and 60.6 microg x hr/ml).","A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440399/),[h·μg] / [ml],16.1,24351,DB00635,Prednisone
,10440399,AUC,"A total of 154 adult recipients of a primary or secondary cadaveric kidney graft were randomly allocated, in this double-blind trial, to receive MMF treatment aimed at three predefined target MPA AUC values (16.1, 32.2, and 60.6 microg x hr/ml).","A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440399/),[h·μg] / [ml],32.2,24352,DB00635,Prednisone
,10440399,AUC,"A total of 154 adult recipients of a primary or secondary cadaveric kidney graft were randomly allocated, in this double-blind trial, to receive MMF treatment aimed at three predefined target MPA AUC values (16.1, 32.2, and 60.6 microg x hr/ml).","A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440399/),[h·μg] / [ml],60.6,24353,DB00635,Prednisone
,7462536,apparent half-life,The mean (+/-SD) apparent half-life of prednisolone in these children was 2.5 +/- 0.5 hr.,Prednisolone disposition in steroid-dependent asthmatic children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7462536/),h,2.5,24808,DB00635,Prednisone
,7462536,total volume of distribution,The mean total volume of distribution was 52.8 +/- 14.5 L/1.73 m2 and mean plasma clearance was 246 +/- 62 ml/min/1.73 m2.,Prednisolone disposition in steroid-dependent asthmatic children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7462536/),[l] / [1.73·m2],52.8,24809,DB00635,Prednisone
,7462536,plasma clearance,The mean total volume of distribution was 52.8 +/- 14.5 L/1.73 m2 and mean plasma clearance was 246 +/- 62 ml/min/1.73 m2.,Prednisolone disposition in steroid-dependent asthmatic children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7462536/),[ml] / [1.73·m2·min],246,24810,DB00635,Prednisone
,22752248,overall survival,Median overall survival was 25.2 months.,Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22752248/),month,25.2,27315,DB00635,Prednisone
,9421103,alpha,"The mean (SEM) values of alpha, beta, k12, k21, k10, Vc, Vss, AUC, total clearance, and mean residence time observed in Group-1 were 4.06 (0.96) hr(-1), 0.0395 (0.0068) hr(-1), 3.13 (0.79) hr(-1), 0.264 (0.052) hr(-1), 0.708 (0.19) hr(-1), 525 (156) l/m2, 1060 (163) l/m2, 1145 (234) microg x hr/l, 49.3 (8.5) l/hr x m2, and 26.8 (6.6) hours, respectively.",Effect of tamoxifen on the pharmacokinetics of doxorubicin in patients with non-Hodgkin's lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9421103/),1/[hr],4.06,27469,DB00635,Prednisone
,9421103,mean residence time,"The mean (SEM) values of alpha, beta, k12, k21, k10, Vc, Vss, AUC, total clearance, and mean residence time observed in Group-1 were 4.06 (0.96) hr(-1), 0.0395 (0.0068) hr(-1), 3.13 (0.79) hr(-1), 0.264 (0.052) hr(-1), 0.708 (0.19) hr(-1), 525 (156) l/m2, 1060 (163) l/m2, 1145 (234) microg x hr/l, 49.3 (8.5) l/hr x m2, and 26.8 (6.6) hours, respectively.",Effect of tamoxifen on the pharmacokinetics of doxorubicin in patients with non-Hodgkin's lymphoma. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9421103/),[h·μg] / [l],1145,27470,DB00635,Prednisone
,9421103,mean residence time,"The mean (SEM) values of alpha, beta, k12, k21, k10, Vc, Vss, AUC, total clearance, and mean residence time observed in Group-1 were 4.06 (0.96) hr(-1), 0.0395 (0.0068) hr(-1), 3.13 (0.79) hr(-1), 0.264 (0.052) hr(-1), 0.708 (0.19) hr(-1), 525 (156) l/m2, 1060 (163) l/m2, 1145 (234) microg x hr/l, 49.3 (8.5) l/hr x m2, and 26.8 (6.6) hours, respectively.",Effect of tamoxifen on the pharmacokinetics of doxorubicin in patients with non-Hodgkin's lymphoma. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9421103/),[l] / [h·m2],49.3,27471,DB00635,Prednisone
,9421103,mean residence time,"The mean (SEM) values of alpha, beta, k12, k21, k10, Vc, Vss, AUC, total clearance, and mean residence time observed in Group-1 were 4.06 (0.96) hr(-1), 0.0395 (0.0068) hr(-1), 3.13 (0.79) hr(-1), 0.264 (0.052) hr(-1), 0.708 (0.19) hr(-1), 525 (156) l/m2, 1060 (163) l/m2, 1145 (234) microg x hr/l, 49.3 (8.5) l/hr x m2, and 26.8 (6.6) hours, respectively.",Effect of tamoxifen on the pharmacokinetics of doxorubicin in patients with non-Hodgkin's lymphoma. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9421103/),h,26.8,27472,DB00635,Prednisone
,3315280,plasma elimination half-lives,"Cyclophosphamide plasma elimination half-lives ranged between 152 and 984 min (mean 457 min), the apparent volume of distribution between 19.1 and 62.3 1 (mean 36.1 1), and plasma clearance between 25.9 and 166.6 ml/min (mean 69.5 ml/min).",Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3315280/),min,457,28030,DB00635,Prednisone
,3315280,apparent volume of distribution,"Cyclophosphamide plasma elimination half-lives ranged between 152 and 984 min (mean 457 min), the apparent volume of distribution between 19.1 and 62.3 1 (mean 36.1 1), and plasma clearance between 25.9 and 166.6 ml/min (mean 69.5 ml/min).",Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3315280/),1,36.1,28031,DB00635,Prednisone
,3315280,plasma clearance,"Cyclophosphamide plasma elimination half-lives ranged between 152 and 984 min (mean 457 min), the apparent volume of distribution between 19.1 and 62.3 1 (mean 36.1 1), and plasma clearance between 25.9 and 166.6 ml/min (mean 69.5 ml/min).",Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3315280/),[ml] / [min],25.9 and 166.6,28032,DB00635,Prednisone
,3315280,plasma clearance,"Cyclophosphamide plasma elimination half-lives ranged between 152 and 984 min (mean 457 min), the apparent volume of distribution between 19.1 and 62.3 1 (mean 36.1 1), and plasma clearance between 25.9 and 166.6 ml/min (mean 69.5 ml/min).",Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3315280/),[ml] / [min],69.5,28033,DB00635,Prednisone
,31625621,CLU /F,"Free prednisolone CLU /F and VU /F, scaled allometrically on lean body weight, were, respectively, 26.7 L/h and 94.3 L for 50 kg LBW.",Free prednisolone pharmacokinetics predicted from total concentrations in patients with inflammatory - immunonologic conditions. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31625621/),[l] / [h],26.7,29404,DB00635,Prednisone
,31625621,VU /F,"Free prednisolone CLU /F and VU /F, scaled allometrically on lean body weight, were, respectively, 26.7 L/h and 94.3 L for 50 kg LBW.",Free prednisolone pharmacokinetics predicted from total concentrations in patients with inflammatory - immunonologic conditions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31625621/),l,94.3,29405,DB00635,Prednisone
,31625621,CLU /F,CLU /F interindividual variability was 0.20.,Free prednisolone pharmacokinetics predicted from total concentrations in patients with inflammatory - immunonologic conditions. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31625621/),,0.20,29406,DB00635,Prednisone
,15602664,blood concentration,"The mean CsA dose and the mean CsA blood concentration were 4.4 mg/kg per day (range 3.6-5.8) and 276.6 ng/ml (range 162-346), respectively.",Cyclosporine therapy monitored with abbreviated area under curve in nephrotic syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15602664/),[ng] / [ml],276.6,29528,DB00635,Prednisone
,18829508,maximum tolerated dose,The maximum tolerated dose of docetaxel was 70 to 75 mg/m(2).,A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18829508/),[mg] / [m],70 to 75,30053,DB00635,Prednisone
,18829508,overall survival,"Median overall survival was 17.6 months (95% CI, 13.0-23.2) and median progression-free survival was 4.2 months (95% CI, 2.3-5.8).",A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18829508/),month,17.6,30054,DB00635,Prednisone
,18829508,progression-free survival,"Median overall survival was 17.6 months (95% CI, 13.0-23.2) and median progression-free survival was 4.2 months (95% CI, 2.3-5.8).",A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18829508/),month,4.2,30055,DB00635,Prednisone
,18829508,maximum tolerated dose,The maximum tolerated dose of every-3-week docetaxel with 10 mg atrasentan is 70 to 75 mg/m(2).,A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18829508/),,70 to 75,30056,DB00635,Prednisone
,27445161,area under the concentration-time curve,The findings indicate individual dose adaptation in 53 patients (38%) to achieve an area under the concentration-time curve target of 30-60 mg·h/L.,Mycophenolic Acid Pharmacokinetics and Relapse in Children with Steroid-Dependent Idiopathic Nephrotic Syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27445161/),[h·mg] / [l],30-60,31092,DB00635,Prednisone
>,27445161,area under the concentration-time curve,"In a multivariable negative binomial model including sex, age at disease onset, time to start of mycophenolate mofetil, previous immunomodulatory treatment, and concomitant prednisone dose, a level of area under the concentration-time curve of mycophenolic acid >45 mg·h/L was significantly associated with a lower relapse rate (rate ratio, 0.65; 95% confidence interval, 0.46 to 0.89; P=0.01).",Mycophenolic Acid Pharmacokinetics and Relapse in Children with Steroid-Dependent Idiopathic Nephrotic Syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27445161/),[h·mg] / [l],45,31093,DB00635,Prednisone
,3665340,Plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],302.7,31407,DB00635,Prednisone
,3665340,Plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],383.2,31408,DB00635,Prednisone
,3665340,Plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],378.9,31409,DB00635,Prednisone
,3665340,Plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],214.0,31410,DB00635,Prednisone
,3665340,plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],1179.1,31411,DB00635,Prednisone
,3665340,plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],1687.0,31412,DB00635,Prednisone
,3665340,plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],2209.5,31413,DB00635,Prednisone
,3665340,plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],381.7,31414,DB00635,Prednisone
,3665340,Bioavailability,Bioavailability of prednisolone after the oral administration of prednisone and methylprednisolone ranged from 86% to 104% during anticonvulsant therapy.,Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),%,86,31415,DB00635,Prednisone
,3665340,Bioavailability,Bioavailability of prednisolone after the oral administration of prednisone and methylprednisolone ranged from 86% to 104% during anticonvulsant therapy.,Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),%,104,31416,DB00635,Prednisone
,23813218,trough level,"We conducted a randomized, multicenter, open-label, crossover study comparing the efficacy and safety of a 1-year treatment with mycophenolate mofetil (MMF; target plasma mycophenolic acid trough level of 1.5-2.5 µg/ml) or CsA (target trough level of 80-100 ng/ml) in 60 pediatric patients with FR-SSNS.",Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23813218/),[μg] / [ml],1.5-2.5,31840,DB00635,Prednisone
,23813218,trough level,"We conducted a randomized, multicenter, open-label, crossover study comparing the efficacy and safety of a 1-year treatment with mycophenolate mofetil (MMF; target plasma mycophenolic acid trough level of 1.5-2.5 µg/ml) or CsA (target trough level of 80-100 ng/ml) in 60 pediatric patients with FR-SSNS.",Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23813218/),[ng] / [ml],80-100,31841,DB00635,Prednisone
<,23813218,AUC,"In post hoc analysis, patients with low mycophenolic acid exposure (AUC <50 µg⋅h/ml) experienced 1.4 relapses per year compared with 0.27 relapses per year in those with high exposure (AUC>50 µg⋅h/ml; P<0.05).",Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23813218/),[h·μg] / [ml],50,31842,DB00635,Prednisone
>,23813218,AUC,"In post hoc analysis, patients with low mycophenolic acid exposure (AUC <50 µg⋅h/ml) experienced 1.4 relapses per year compared with 0.27 relapses per year in those with high exposure (AUC>50 µg⋅h/ml; P<0.05).",Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23813218/),[h·μg] / [ml],50,31843,DB00635,Prednisone
,11897977,free fraction,"The average MPA free fraction in healthy adult individuals, stable renal transplant recipients, and heart transplant recipients is approximately 2 to 3%.",Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897977/),%,2 to 3,32179,DB00635,Prednisone
,11897977,AUC,"Mean (+/- SD) AUC was 45.78 +/- 18.35 microg.h/mL (range, 16.56-74.22 microg.h/mL), Cmax was 17.37 +/- 7.69 microg/mL (range, 4.92-26.63 microg/mL), Tmax was 1.2 +/- 0.4 hours (range, 1.0-2.0 h), Cmin was 3.12 +/- 1.41 microg/mL (range, 1.47-4.82 microg/mL), f was 2.90 +/- 0.56% (range, 2.00-3.40%), and free MPA AUC was 1.29 +/- 0.50 microg.h/mL (range, 0.54-1.88 microg.h/mL).",Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897977/),[h·μg] / [ml],45.78,32180,DB00635,Prednisone
,11897977,Cmax,"Mean (+/- SD) AUC was 45.78 +/- 18.35 microg.h/mL (range, 16.56-74.22 microg.h/mL), Cmax was 17.37 +/- 7.69 microg/mL (range, 4.92-26.63 microg/mL), Tmax was 1.2 +/- 0.4 hours (range, 1.0-2.0 h), Cmin was 3.12 +/- 1.41 microg/mL (range, 1.47-4.82 microg/mL), f was 2.90 +/- 0.56% (range, 2.00-3.40%), and free MPA AUC was 1.29 +/- 0.50 microg.h/mL (range, 0.54-1.88 microg.h/mL).",Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897977/),[μg] / [ml],17.37,32181,DB00635,Prednisone
,11897977,Tmax,"Mean (+/- SD) AUC was 45.78 +/- 18.35 microg.h/mL (range, 16.56-74.22 microg.h/mL), Cmax was 17.37 +/- 7.69 microg/mL (range, 4.92-26.63 microg/mL), Tmax was 1.2 +/- 0.4 hours (range, 1.0-2.0 h), Cmin was 3.12 +/- 1.41 microg/mL (range, 1.47-4.82 microg/mL), f was 2.90 +/- 0.56% (range, 2.00-3.40%), and free MPA AUC was 1.29 +/- 0.50 microg.h/mL (range, 0.54-1.88 microg.h/mL).",Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897977/),h,1.2,32182,DB00635,Prednisone
,11897977,Cmin,"Mean (+/- SD) AUC was 45.78 +/- 18.35 microg.h/mL (range, 16.56-74.22 microg.h/mL), Cmax was 17.37 +/- 7.69 microg/mL (range, 4.92-26.63 microg/mL), Tmax was 1.2 +/- 0.4 hours (range, 1.0-2.0 h), Cmin was 3.12 +/- 1.41 microg/mL (range, 1.47-4.82 microg/mL), f was 2.90 +/- 0.56% (range, 2.00-3.40%), and free MPA AUC was 1.29 +/- 0.50 microg.h/mL (range, 0.54-1.88 microg.h/mL).",Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897977/),[μg] / [ml],3.12,32183,DB00635,Prednisone
,11897977,f,"Mean (+/- SD) AUC was 45.78 +/- 18.35 microg.h/mL (range, 16.56-74.22 microg.h/mL), Cmax was 17.37 +/- 7.69 microg/mL (range, 4.92-26.63 microg/mL), Tmax was 1.2 +/- 0.4 hours (range, 1.0-2.0 h), Cmin was 3.12 +/- 1.41 microg/mL (range, 1.47-4.82 microg/mL), f was 2.90 +/- 0.56% (range, 2.00-3.40%), and free MPA AUC was 1.29 +/- 0.50 microg.h/mL (range, 0.54-1.88 microg.h/mL).",Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897977/),%,2.90,32184,DB00635,Prednisone
,11897977,AUC,"Mean (+/- SD) AUC was 45.78 +/- 18.35 microg.h/mL (range, 16.56-74.22 microg.h/mL), Cmax was 17.37 +/- 7.69 microg/mL (range, 4.92-26.63 microg/mL), Tmax was 1.2 +/- 0.4 hours (range, 1.0-2.0 h), Cmin was 3.12 +/- 1.41 microg/mL (range, 1.47-4.82 microg/mL), f was 2.90 +/- 0.56% (range, 2.00-3.40%), and free MPA AUC was 1.29 +/- 0.50 microg.h/mL (range, 0.54-1.88 microg.h/mL).",Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897977/),[h·μg] / [ml],1.29,32185,DB00635,Prednisone
,9190003,Total plasma prednisolone levels,Total plasma prednisolone levels declined over time from 597 +/- 174 ng/ml two hours post-dose to 422 +/- 106 ng/ml four hours post-dose and 250 +/- 85 ng/ml six hours post-dose.,Prednisolone concentrations in cerebrospinal fluid after oral prednisone. Preliminary data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190003/),[ng] / [ml],597,32364,DB00635,Prednisone
,9190003,Total plasma prednisolone levels,Total plasma prednisolone levels declined over time from 597 +/- 174 ng/ml two hours post-dose to 422 +/- 106 ng/ml four hours post-dose and 250 +/- 85 ng/ml six hours post-dose.,Prednisolone concentrations in cerebrospinal fluid after oral prednisone. Preliminary data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190003/),[ng] / [ml],422,32365,DB00635,Prednisone
,9190003,Total plasma prednisolone levels,Total plasma prednisolone levels declined over time from 597 +/- 174 ng/ml two hours post-dose to 422 +/- 106 ng/ml four hours post-dose and 250 +/- 85 ng/ml six hours post-dose.,Prednisolone concentrations in cerebrospinal fluid after oral prednisone. Preliminary data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190003/),[ng] / [ml],250,32366,DB00635,Prednisone
,9190003,Plasma levels,"Plasma levels of free prednisolone were 95 +/- 21 ng/ml, 59 +/- 17 ng/ml, and 18 +/- 14 ng/ml, respectively, at the same time points.",Prednisolone concentrations in cerebrospinal fluid after oral prednisone. Preliminary data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190003/),[ng] / [ml],95,32367,DB00635,Prednisone
,9190003,Plasma levels,"Plasma levels of free prednisolone were 95 +/- 21 ng/ml, 59 +/- 17 ng/ml, and 18 +/- 14 ng/ml, respectively, at the same time points.",Prednisolone concentrations in cerebrospinal fluid after oral prednisone. Preliminary data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190003/),[ng] / [ml],59,32368,DB00635,Prednisone
,9190003,Plasma levels,"Plasma levels of free prednisolone were 95 +/- 21 ng/ml, 59 +/- 17 ng/ml, and 18 +/- 14 ng/ml, respectively, at the same time points.",Prednisolone concentrations in cerebrospinal fluid after oral prednisone. Preliminary data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190003/),[ng] / [ml],18,32369,DB00635,Prednisone
,1578318,Bioavailability,Bioavailability averaged 88.4% +/- 20.1% of the administered dose.,Altered prednisolone pharmacokinetics in patients with cystic fibrosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1578318/),%,88.4,32850,DB00635,Prednisone
,14749551,area under the curve (AUC),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[h·ng] / [ml],4019,34870,DB00635,Prednisone
,14749551,maximum concentration (C(max)),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[h·ng] / [ml],3971,34871,DB00635,Prednisone
,14749551,maximum concentration (C(max)),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[ng] / [ml],998,34872,DB00635,Prednisone
,14749551,maximum concentration (C(max)),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[ng] / [ml],1021,34873,DB00635,Prednisone
,14749551,concentration at the second hour (C2),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[ng] / [ml],1021,34874,DB00635,Prednisone
,14749551,concentration at the second hour (C2),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[ng] / [ml],707,34875,DB00635,Prednisone
,14749551,concentration at the second hour (C2),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[ng] / [ml],734,34876,DB00635,Prednisone
,2595785,total clearance,The mean total clearance of methylprednisolone was 379 ml/hr/kg (range 105-672) and the volume of distribution was 1.4 +/- 0.5 L/kg.,Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595785/),[ml] / [h·kg],379,35683,DB00635,Prednisone
,2595785,volume of distribution,The mean total clearance of methylprednisolone was 379 ml/hr/kg (range 105-672) and the volume of distribution was 1.4 +/- 0.5 L/kg.,Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595785/),[l] / [kg],1.4,35684,DB00635,Prednisone
,2595785,plasma half-life,The mean plasma half-life was 2.7 +/- 1.1 hr.,Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595785/),h,2.7,35685,DB00635,Prednisone
,2595785,peak concentration,"When normalized to a 1 mg dose of methylprednisolone, the mean peak concentration at 1 hr was 10.0 +/- 3.5 ng/ml with an 8 hr concentration ranging from 0.3 to 5.5 ng/ml.",Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595785/),[ng] / [ml],10.0,35686,DB00635,Prednisone
,26096139,area under plasma concentration-time curve (AUC),"In healthy subjects, geometric mean (GM) abiraterone area under plasma concentration-time curve (AUC) increased ∼5- and ∼10-fold, respectively, with low-fat and high-fat meals versus fasted state (GM [coefficient of variation], 1942 [48] and 4077 [37] ng · h/mL vs 421 [67] ng · h/mL, respectively).",Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26096139/),[h·ng] / [ml],1942,35842,DB00635,Prednisone
,26096139,area under plasma concentration-time curve (AUC),"In healthy subjects, geometric mean (GM) abiraterone area under plasma concentration-time curve (AUC) increased ∼5- and ∼10-fold, respectively, with low-fat and high-fat meals versus fasted state (GM [coefficient of variation], 1942 [48] and 4077 [37] ng · h/mL vs 421 [67] ng · h/mL, respectively).",Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26096139/),[h·ng] / [ml],4077,35843,DB00635,Prednisone
,26096139,area under plasma concentration-time curve (AUC),"In healthy subjects, geometric mean (GM) abiraterone area under plasma concentration-time curve (AUC) increased ∼5- and ∼10-fold, respectively, with low-fat and high-fat meals versus fasted state (GM [coefficient of variation], 1942 [48] and 4077 [37] ng · h/mL vs 421 [67] ng · h/mL, respectively).",Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26096139/),[h·ng] / [ml],421,35844,DB00635,Prednisone
,26096139,AUC,"In mCRPC patients, abiraterone AUC was ∼2-fold higher with a high-fat meal and similar with a low-fat meal versus modified fasting state (GM [coefficient of variation]: 1992 [34] vs 973 [58] ng · h/mL and 1264 [65] vs 1185 [90] ng · h/mL, respectively).",Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26096139/),[h·ng] / [ml],1992,35845,DB00635,Prednisone
,26096139,AUC,"In mCRPC patients, abiraterone AUC was ∼2-fold higher with a high-fat meal and similar with a low-fat meal versus modified fasting state (GM [coefficient of variation]: 1992 [34] vs 973 [58] ng · h/mL and 1264 [65] vs 1185 [90] ng · h/mL, respectively).",Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26096139/),[h·ng] / [ml],973,35846,DB00635,Prednisone
,26096139,AUC,"In mCRPC patients, abiraterone AUC was ∼2-fold higher with a high-fat meal and similar with a low-fat meal versus modified fasting state (GM [coefficient of variation]: 1992 [34] vs 973 [58] ng · h/mL and 1264 [65] vs 1185 [90] ng · h/mL, respectively).",Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26096139/),[h·ng] / [ml],1264,35847,DB00635,Prednisone
,26096139,AUC,"In mCRPC patients, abiraterone AUC was ∼2-fold higher with a high-fat meal and similar with a low-fat meal versus modified fasting state (GM [coefficient of variation]: 1992 [34] vs 973 [58] ng · h/mL and 1264 [65] vs 1185 [90] ng · h/mL, respectively).",Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26096139/),[h·ng] / [ml],1185,35848,DB00635,Prednisone
,26518936,concentration-,"(3) However, from the first month after transplantation, patients with grafts from donor carriers of minor allele*1 had lower concentration-dose ratios compared with patients with grafts from donor non-carriers of that allele (71.1 versus 119.3 and 90.5 versus 126.3, for 30 and 90 days after transplantation, respectively; P < .05).",Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26518936/),,119,39213,DB00635,Prednisone
,26518936,concentration-,"(3) However, from the first month after transplantation, patients with grafts from donor carriers of minor allele*1 had lower concentration-dose ratios compared with patients with grafts from donor non-carriers of that allele (71.1 versus 119.3 and 90.5 versus 126.3, for 30 and 90 days after transplantation, respectively; P < .05).",Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26518936/),,90,39214,DB00635,Prednisone
,26518936,concentration-,"(3) However, from the first month after transplantation, patients with grafts from donor carriers of minor allele*1 had lower concentration-dose ratios compared with patients with grafts from donor non-carriers of that allele (71.1 versus 119.3 and 90.5 versus 126.3, for 30 and 90 days after transplantation, respectively; P < .05).",Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26518936/),,126,39215,DB00635,Prednisone
,17437161,distribution volume,"The means of distribution volume and elimination half-life (t (1/2)) during the first 2 weeks were 0.05 l/kg and 9.5 days, respectively.",A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17437161/),[l] / [kg],0.05,39821,DB00635,Prednisone
,17437161,elimination half-life (t (1/2)),"The means of distribution volume and elimination half-life (t (1/2)) during the first 2 weeks were 0.05 l/kg and 9.5 days, respectively.",A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17437161/),d,9.5,39822,DB00635,Prednisone
,12372043,AUC0-12,"Morning and evening doses were independently adjusted to reach an AUC0-12 of 6600-7200 ng h/mL and a C0 of 250-325 ng/mL, respectively.",Can a pharmacokinetic approach to immunosuppression eliminate ethnic disparities in renal allograft outcome? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12372043/),[h·ng] / [ml],6600-7200,41559,DB00635,Prednisone
,12372043,C0,"Morning and evening doses were independently adjusted to reach an AUC0-12 of 6600-7200 ng h/mL and a C0 of 250-325 ng/mL, respectively.",Can a pharmacokinetic approach to immunosuppression eliminate ethnic disparities in renal allograft outcome? ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12372043/),[ng] / [ml],250-325,41560,DB00635,Prednisone
,12372043,AUCs,An average of 8 AUCs (range 5-13) were measured in the first 3 months.,Can a pharmacokinetic approach to immunosuppression eliminate ethnic disparities in renal allograft outcome? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12372043/),,8,41561,DB00635,Prednisone
,34080039,area under the concentration-time curve [AUC] ratio,"Extrapolation of the vincristine mechanistic PBPK model to other P-gp substrates further suggested DDI risk when ibrutinib (area under the concentration-time curve [AUC] ratio: 1.8), but not acalabrutinib (AUC ratio: 0.92), was given orally with venetoclax or digoxin.",Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34080039/),,1.8,41785,DB00635,Prednisone
,34080039,AUC ratio,"Extrapolation of the vincristine mechanistic PBPK model to other P-gp substrates further suggested DDI risk when ibrutinib (area under the concentration-time curve [AUC] ratio: 1.8), but not acalabrutinib (AUC ratio: 0.92), was given orally with venetoclax or digoxin.",Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34080039/),,0.92,41786,DB00635,Prednisone
,8620666,half-life (t1/2),"A slight but statistically significant increase in the mean half-life (t1/2) of prednisolone was detected with zileuton + prednisone administration compared with prednisone + placebo (from 2.8 to 2.9 hours); however, this change was of no clinical relevance.",Pharmacokinetic interactions between zileuton and prednisone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620666/),h,2.8,45223,DB00635,Prednisone
,8620666,half-life (t1/2),"A slight but statistically significant increase in the mean half-life (t1/2) of prednisolone was detected with zileuton + prednisone administration compared with prednisone + placebo (from 2.8 to 2.9 hours); however, this change was of no clinical relevance.",Pharmacokinetic interactions between zileuton and prednisone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620666/),h,2.9,45224,DB00635,Prednisone
,8620666,0 to 6 hours (AUC0-6),"While the single 40mg dose of prednisone resulted in a slight but statistically significant decrease in the mean zileuton AUC value from 0 to 6 hours (AUC0-6) [from 23 to 20 mg/L/h] and a reduction in tMAX (from 2.3 to 1.7 hours), these results were not considered to be clinically significant.",Pharmacokinetic interactions between zileuton and prednisone. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620666/),[mg] / [h·l],23,45225,DB00635,Prednisone
,8620666,0 to 6 hours (AUC0-6),"While the single 40mg dose of prednisone resulted in a slight but statistically significant decrease in the mean zileuton AUC value from 0 to 6 hours (AUC0-6) [from 23 to 20 mg/L/h] and a reduction in tMAX (from 2.3 to 1.7 hours), these results were not considered to be clinically significant.",Pharmacokinetic interactions between zileuton and prednisone. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620666/),[mg] / [h·l],20,45226,DB00635,Prednisone
,7656504,plasma elimination half-life (t1/2),Mean plasma elimination half-life (t1/2) is between 1.3 and 2.1 hours in healthy volunteers.,Clinical pharmacokinetics of lansoprazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7656504/),h,1.3 and 2.1,47682,DB00635,Prednisone
,11557912,absorption rate constant,"For a reference 44-year-old, 71-kg Caucasian kidney allograft recipient receiving everolimus as part of a cyclosporine (INN, ciclosporin)-prednisone immunosuppressive regimen, the absorption rate constant was 6.07 h(-1) (standard error [SE], 0.70 h(-1)), the apparent clearance was 8.8 L/h (SE, 0.2 L/h), and the apparent central distribution volume was 110 L (SE, 5 L).",Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557912/),1/[h],6.07,52477,DB00635,Prednisone
,11557912,apparent clearance,"For a reference 44-year-old, 71-kg Caucasian kidney allograft recipient receiving everolimus as part of a cyclosporine (INN, ciclosporin)-prednisone immunosuppressive regimen, the absorption rate constant was 6.07 h(-1) (standard error [SE], 0.70 h(-1)), the apparent clearance was 8.8 L/h (SE, 0.2 L/h), and the apparent central distribution volume was 110 L (SE, 5 L).",Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557912/),[l] / [h],8.8,52478,DB00635,Prednisone
,11557912,apparent central distribution volume,"For a reference 44-year-old, 71-kg Caucasian kidney allograft recipient receiving everolimus as part of a cyclosporine (INN, ciclosporin)-prednisone immunosuppressive regimen, the absorption rate constant was 6.07 h(-1) (standard error [SE], 0.70 h(-1)), the apparent clearance was 8.8 L/h (SE, 0.2 L/h), and the apparent central distribution volume was 110 L (SE, 5 L).",Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557912/),l,110,52479,DB00635,Prednisone
,26711181,overall,"The overall and complete response rates were 68% and 37%, respectively.",Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26711181/),%,68,56026,DB00635,Prednisone
,26711181,complete response rates,"The overall and complete response rates were 68% and 37%, respectively.",Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26711181/),%,37,56027,DB00635,Prednisone
,26711181,trough levels,"Highest day 1 alemtuzumab trough levels were achieved at 60 mg (1973 ng/mL), but with significant inter- and intradose variability.",Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26711181/),[ng] / [ml],1973,56028,DB00635,Prednisone
,30210349,maximum concentration (Cmax,"VCR elimination from the circulation after injection of VSLI was characterized by a significantly increased maximum concentration (Cmax, 86.6 ng/mL) and plasma area under the plasma concentration-time curve from zero to infinity (AUC0-Inf, 222.1 ng/mL h), markedly decreased distribution volume (Vz, 224.1 L) and plasma clearance (CL, 8.9 L/h) compared to lower Cmax (26.6 ng/mL) and AUC0-Inf (95.1 ng/mL h), larger Vz (688.8 L) and CL (22.1 L/h) for VSI.",Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30210349/),[ng] / [ml],86.6,57819,DB00635,Prednisone
,30210349,distribution volume (Vz,"VCR elimination from the circulation after injection of VSLI was characterized by a significantly increased maximum concentration (Cmax, 86.6 ng/mL) and plasma area under the plasma concentration-time curve from zero to infinity (AUC0-Inf, 222.1 ng/mL h), markedly decreased distribution volume (Vz, 224.1 L) and plasma clearance (CL, 8.9 L/h) compared to lower Cmax (26.6 ng/mL) and AUC0-Inf (95.1 ng/mL h), larger Vz (688.8 L) and CL (22.1 L/h) for VSI.",Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30210349/),l,224.1,57820,DB00635,Prednisone
,30210349,plasma clearance (CL,"VCR elimination from the circulation after injection of VSLI was characterized by a significantly increased maximum concentration (Cmax, 86.6 ng/mL) and plasma area under the plasma concentration-time curve from zero to infinity (AUC0-Inf, 222.1 ng/mL h), markedly decreased distribution volume (Vz, 224.1 L) and plasma clearance (CL, 8.9 L/h) compared to lower Cmax (26.6 ng/mL) and AUC0-Inf (95.1 ng/mL h), larger Vz (688.8 L) and CL (22.1 L/h) for VSI.",Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30210349/),[l] / [h],8.9,57821,DB00635,Prednisone
,30210349,Cmax,"VCR elimination from the circulation after injection of VSLI was characterized by a significantly increased maximum concentration (Cmax, 86.6 ng/mL) and plasma area under the plasma concentration-time curve from zero to infinity (AUC0-Inf, 222.1 ng/mL h), markedly decreased distribution volume (Vz, 224.1 L) and plasma clearance (CL, 8.9 L/h) compared to lower Cmax (26.6 ng/mL) and AUC0-Inf (95.1 ng/mL h), larger Vz (688.8 L) and CL (22.1 L/h) for VSI.",Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30210349/),[ng] / [ml],26.6,57822,DB00635,Prednisone
,30210349,AUC0-Inf,"VCR elimination from the circulation after injection of VSLI was characterized by a significantly increased maximum concentration (Cmax, 86.6 ng/mL) and plasma area under the plasma concentration-time curve from zero to infinity (AUC0-Inf, 222.1 ng/mL h), markedly decreased distribution volume (Vz, 224.1 L) and plasma clearance (CL, 8.9 L/h) compared to lower Cmax (26.6 ng/mL) and AUC0-Inf (95.1 ng/mL h), larger Vz (688.8 L) and CL (22.1 L/h) for VSI.",Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30210349/),[ng] / [h·ml],95.1,57823,DB00635,Prednisone
,30210349,Vz,"VCR elimination from the circulation after injection of VSLI was characterized by a significantly increased maximum concentration (Cmax, 86.6 ng/mL) and plasma area under the plasma concentration-time curve from zero to infinity (AUC0-Inf, 222.1 ng/mL h), markedly decreased distribution volume (Vz, 224.1 L) and plasma clearance (CL, 8.9 L/h) compared to lower Cmax (26.6 ng/mL) and AUC0-Inf (95.1 ng/mL h), larger Vz (688.8 L) and CL (22.1 L/h) for VSI.",Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30210349/),l,688.8,57824,DB00635,Prednisone
,30210349,CL,"VCR elimination from the circulation after injection of VSLI was characterized by a significantly increased maximum concentration (Cmax, 86.6 ng/mL) and plasma area under the plasma concentration-time curve from zero to infinity (AUC0-Inf, 222.1 ng/mL h), markedly decreased distribution volume (Vz, 224.1 L) and plasma clearance (CL, 8.9 L/h) compared to lower Cmax (26.6 ng/mL) and AUC0-Inf (95.1 ng/mL h), larger Vz (688.8 L) and CL (22.1 L/h) for VSI.",Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30210349/),[l] / [h],22.1,57825,DB00635,Prednisone
,30210349,Cmax,The small proportion of F-VCR following infusion of VSLI in circulation was reflected by very low Cmax (1.8 ng/mL) and AUC0-Inf (50.5 ng/mL h).,Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30210349/),[ng] / [ml],1.8,57826,DB00635,Prednisone
,30210349,AUC0-Inf,The small proportion of F-VCR following infusion of VSLI in circulation was reflected by very low Cmax (1.8 ng/mL) and AUC0-Inf (50.5 ng/mL h).,Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30210349/),[ng] / [h·ml],50.5,57827,DB00635,Prednisone
,30210349,elimination percentage,"The elimination percentage of 40-21-14% for VSI changed to 6.2-24-39% for VSLI at intervals of 0-5, 5-13 and 13-25 h, respectively.",Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30210349/),%,40-21-14,57828,DB00635,Prednisone
,30210349,elimination percentage,"The elimination percentage of 40-21-14% for VSI changed to 6.2-24-39% for VSLI at intervals of 0-5, 5-13 and 13-25 h, respectively.",Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30210349/),%,6,57829,DB00635,Prednisone
,25537545,Area under the concentration time curve (AUC48-∝),"Area under the concentration time curve (AUC48-∝) of MTX significantly increased in variant group [(23.18±19.91) vs.(5.66±2.01) h·µmol/L] (t=4.025, P=0.001).",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),[h·μM] / [l],23.18,57930,DB00635,Prednisone
,25537545,Area under the concentration time curve (AUC48-∝),"Area under the concentration time curve (AUC48-∝) of MTX significantly increased in variant group [(23.18±19.91) vs.(5.66±2.01) h·µmol/L] (t=4.025, P=0.001).",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),[h·μM] / [l],5.66,57931,DB00635,Prednisone
>,25537545,Time above the,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),[μM] / [l],0.1,57932,DB00635,Prednisone
,25537545,Time above the,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,95.3,57933,DB00635,Prednisone
,25537545,Time above the,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,67.1,57934,DB00635,Prednisone
>,25537545,safety threshold (,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),[μM] / [l],0.1,57935,DB00635,Prednisone
,25537545,safety threshold (,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,95.3,57936,DB00635,Prednisone
,25537545,safety threshold (,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,67.1,57937,DB00635,Prednisone
>,25537545,TC,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),[μM] / [l],0.1,57938,DB00635,Prednisone
,25537545,TC,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,95.3,57939,DB00635,Prednisone
,25537545,TC,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,67.1,57940,DB00635,Prednisone
,25537545,Hospital stay,"Hospital stay of variant group was significantly longer than that of wild-type [(4.95±1.43) vs. (4.05±0.22) d, t=2.881, P=0.009].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),d,4.95,57941,DB00635,Prednisone
,25537545,Hospital stay,"Hospital stay of variant group was significantly longer than that of wild-type [(4.95±1.43) vs. (4.05±0.22) d, t=2.881, P=0.009].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),d,4.05,57942,DB00635,Prednisone
,9808549,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) of methotrexate ranged from 0.63 to 12 micromol*h/L, and the AUC of mercaptopurine ranged from 0.11 to 8 micromol*h/L.",Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808549/),[h·μM] / [l],0.63 to 12,59168,DB00635,Prednisone
,9808549,AUC,"The area under the plasma concentration-time curve (AUC) of methotrexate ranged from 0.63 to 12 micromol*h/L, and the AUC of mercaptopurine ranged from 0.11 to 8 micromol*h/L.",Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808549/),[h·μM] / [l],0.11 to 8,59169,DB00635,Prednisone
,19834427,clearance,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),[l] / [h],23.1,59323,DB00635,Prednisone
,19834427,central,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),l,35.4,59324,DB00635,Prednisone
,19834427,peripheral volume of distribution,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),l,35.4,59325,DB00635,Prednisone
,19834427,peripheral volume of distribution,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),l,1090,59326,DB00635,Prednisone
,19834427,intercompartmental clearance,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),l,27.3,59327,DB00635,Prednisone
,19834427,mean transit time (tau),"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),d,3.8,59328,DB00635,Prednisone
,19834427,tau,"When patients had an early decrease in bilirubin at day 7, tau increased to 28.2 days.",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),d,28.2,59329,DB00635,Prednisone
,20970603,AUC0-24,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[h·ng] / [ml],300.8,59514,DB00635,Prednisone
,20970603,AUC0-24,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[h·ng] / [ml],287.7,59515,DB00635,Prednisone
,20970603,AUC0-24,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[h·ng] / [ml],303.05,59516,DB00635,Prednisone
,20970603,AUC0-24,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[h·ng] / [ml],275.26,59517,DB00635,Prednisone
,20970603,blood levels,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[ng] / [ml],8.76,59518,DB00635,Prednisone
,20970603,blood levels,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[ng] / [ml],8.8,59519,DB00635,Prednisone
,20970603,blood levels,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[ng] / [ml],7.30,59520,DB00635,Prednisone
,20970603,blood levels,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[ng] / [ml],8.80,59521,DB00635,Prednisone
,20970603,blood levels,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[ng] / [ml],7.19,59522,DB00635,Prednisone
,20970603,blood levels,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[ng] / [ml],6.60,59523,DB00635,Prednisone
,28967708,half-life,CORT125134 was absorbed rapidly and eliminated with a mean half-life ranging from 11 to 19 hours.,"Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacological Effect of Orally Administered CORT125134: An Adaptive, Double-Blind, Randomized, Placebo-Controlled Phase 1 Clinical Study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28967708/),h,11 to 19,59738,DB00635,Prednisone
excess of,9133469,peak CD4 saturations,Ninety-three percent of patients treated at 0.5 mg/kg OKT4A and all patients at higher doses had mean peak CD4 saturations in excess of 90%.,Murine OKT4A immunosuppression in cadaver donor renal allograft recipients: a Cooperative Clinical Trials in Transplantation pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9133469/),%,90,60628,DB00635,Prednisone
,3987177,ratio,"Cimetidine reduced the mean (+/- SD) ratio of prednisone dose to the plasma prednisolone AUC (16.6 +/- 2.9 L/hr) below that ratio after ranitidine (19.2 +/- 4.2 L/hr) and placebo (19.3 +/- 2.8 L/hr), and resulted in the lowest fractional excretion of prednisolone in the urine (5.2% +/- 2.2%, 9.8% +/- 4.5%, and 12.4% +/- 4.9%, respectively).",Effects of cimetidine and ranitidine on the conversion of prednisone to prednisolone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987177/),[l] / [h],16.6,62253,DB00635,Prednisone
,3987177,ratio,"Cimetidine reduced the mean (+/- SD) ratio of prednisone dose to the plasma prednisolone AUC (16.6 +/- 2.9 L/hr) below that ratio after ranitidine (19.2 +/- 4.2 L/hr) and placebo (19.3 +/- 2.8 L/hr), and resulted in the lowest fractional excretion of prednisolone in the urine (5.2% +/- 2.2%, 9.8% +/- 4.5%, and 12.4% +/- 4.9%, respectively).",Effects of cimetidine and ranitidine on the conversion of prednisone to prednisolone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987177/),[l] / [h],19.2,62254,DB00635,Prednisone
,7636539,MTD,"The MTD of dexverapamil was 150 mg/m2 every 4 hours (900 mg/m2/d), and hypotension was the principal dose-limiting toxicity.",Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636539/),[mg] / [m2],150,64149,DB00635,Prednisone
,9013365,peak plasma concentration (Cmax),Mean pharmacokinetic values of prednisolone found before sirolimus administration were as follows: peak plasma concentration (Cmax) was 187 ng/mL; time to peak plasma concentration (tmax) was 2.03 hours; rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]) was 0.149 hour-1; terminal half-life (t1/2) was 3.60 hours; AUC was 1206 ng.hour/mL; and apparent clearance (Cl/F) was 0.094 L/hour/kg.,Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013365/),[ng] / [ml],187,64277,DB00635,Prednisone
,9013365,time to peak plasma concentration (tmax),Mean pharmacokinetic values of prednisolone found before sirolimus administration were as follows: peak plasma concentration (Cmax) was 187 ng/mL; time to peak plasma concentration (tmax) was 2.03 hours; rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]) was 0.149 hour-1; terminal half-life (t1/2) was 3.60 hours; AUC was 1206 ng.hour/mL; and apparent clearance (Cl/F) was 0.094 L/hour/kg.,Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013365/),h,2.03,64278,DB00635,Prednisone
,9013365,rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]),Mean pharmacokinetic values of prednisolone found before sirolimus administration were as follows: peak plasma concentration (Cmax) was 187 ng/mL; time to peak plasma concentration (tmax) was 2.03 hours; rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]) was 0.149 hour-1; terminal half-life (t1/2) was 3.60 hours; AUC was 1206 ng.hour/mL; and apparent clearance (Cl/F) was 0.094 L/hour/kg.,Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013365/),1/[h],0.149,64279,DB00635,Prednisone
,9013365,terminal half-life (t1/2),Mean pharmacokinetic values of prednisolone found before sirolimus administration were as follows: peak plasma concentration (Cmax) was 187 ng/mL; time to peak plasma concentration (tmax) was 2.03 hours; rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]) was 0.149 hour-1; terminal half-life (t1/2) was 3.60 hours; AUC was 1206 ng.hour/mL; and apparent clearance (Cl/F) was 0.094 L/hour/kg.,Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013365/),h,3.60,64280,DB00635,Prednisone
,9013365,AUC,Mean pharmacokinetic values of prednisolone found before sirolimus administration were as follows: peak plasma concentration (Cmax) was 187 ng/mL; time to peak plasma concentration (tmax) was 2.03 hours; rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]) was 0.149 hour-1; terminal half-life (t1/2) was 3.60 hours; AUC was 1206 ng.hour/mL; and apparent clearance (Cl/F) was 0.094 L/hour/kg.,Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013365/),[h·ng] / [ml],1206,64281,DB00635,Prednisone
,9013365,apparent clearance (Cl/F),Mean pharmacokinetic values of prednisolone found before sirolimus administration were as follows: peak plasma concentration (Cmax) was 187 ng/mL; time to peak plasma concentration (tmax) was 2.03 hours; rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]) was 0.149 hour-1; terminal half-life (t1/2) was 3.60 hours; AUC was 1206 ng.hour/mL; and apparent clearance (Cl/F) was 0.094 L/hour/kg.,Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013365/),[l] / [h·kg],0.094,64282,DB00635,Prednisone
,7026594,areas under the plasma concentration time curve,"Patients with cushingoid habitus more frequently exhibited peak hydrocortisone levels within the normal range (6 of 14 vs. 1 of 13) and had higher areas under the plasma concentration time curve of hydrocortisone (median, range), i.e. 2672 ng/ml.min (0-21, 637 ng/ml.min) vs. 308 ng/ml.min (0-12, 495 ng/ml.min) compared to those without cushingoid appearance (P less than 0.05).","Endogenous hydrocortisone, a possible factor contributing to the genesis of cushingoid habitus in patients on prednisone. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7026594/),[ng] / [min·ml],2672,65833,DB00635,Prednisone
,7026594,areas under the plasma concentration time curve,"Patients with cushingoid habitus more frequently exhibited peak hydrocortisone levels within the normal range (6 of 14 vs. 1 of 13) and had higher areas under the plasma concentration time curve of hydrocortisone (median, range), i.e. 2672 ng/ml.min (0-21, 637 ng/ml.min) vs. 308 ng/ml.min (0-12, 495 ng/ml.min) compared to those without cushingoid appearance (P less than 0.05).","Endogenous hydrocortisone, a possible factor contributing to the genesis of cushingoid habitus in patients on prednisone. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7026594/),[ng] / [min·ml],308,65834,DB00635,Prednisone
,12721757,blood concentration,VX-710 blood concentration at the time of mitoxantrone administration averaged 4.52 microg/ml.,"Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12721757/),[μg] / [ml],4.52,67381,DB00635,Prednisone
,12721757,time to PSA progression,The median time to PSA progression was 41 weeks (95% CI 34-68 weeks).,"Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12721757/),weeks,41,67382,DB00635,Prednisone
,26375845,AUC,Grade 3 or 4 thrombocytopenia or neutropenia in 4 of 6 initial patients required dose adjustment of carboplatin to AUC of 4 for subsequent patients.,"Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26375845/),,4,67934,DB00635,Prednisone
,26375845,time to progression,"The median time to progression was 2.5 months (90% confidence interval [CI], 1.8-4.3 months), and median overall survival was 12.5 months (90% CI, 7.7-18.7 months).","Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26375845/),month,2.5,67935,DB00635,Prednisone
,26375845,overall survival,"The median time to progression was 2.5 months (90% confidence interval [CI], 1.8-4.3 months), and median overall survival was 12.5 months (90% CI, 7.7-18.7 months).","Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26375845/),month,12.5,67936,DB00635,Prednisone
,671172,half-life,Peak prednisolone levels occurred one to two hours after ingestion; half-life studies gave a mean value of 132 minutes in most children.,"Plasma levels, half-life values, and correlation with physiologic assays for growth and immunity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/671172/),min,132,69593,DB00635,Prednisone
,2596127,clearance,Prednisolone clearance before and after ketoconazole therapy was not significantly different (160 +/- 38 vs. 148 +/- 23 mL/h/kg).,Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),[ml] / [h·kg],160,69779,DB00635,Prednisone
,2596127,clearance,Prednisolone clearance before and after ketoconazole therapy was not significantly different (160 +/- 38 vs. 148 +/- 23 mL/h/kg).,Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),[ml] / [h·kg],148,69780,DB00635,Prednisone
,2596127,mean residence time,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),h,5.03,69781,DB00635,Prednisone
,2596127,mean residence time,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),h,6.18,69782,DB00635,Prednisone
,2596127,terminal slope,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),1/[h],0.23,69783,DB00635,Prednisone
,2596127,terminal slope,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),1/[h],0.19,69784,DB00635,Prednisone
,2596127,volume of distribution,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),[l] / [kg],0.79,69785,DB00635,Prednisone
,2596127,volume of distribution,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),[l] / [kg],0.84,69786,DB00635,Prednisone
,23136195,OS,"Median OS was 12.2 versus 11.1 months [HR, 1.10; 80% confidence interval (CI), 0.82-1.48] in the combined rilotumumab versus control arms.",Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136195/),month,12.2,70846,DB00635,Prednisone
,23136195,OS,"Median OS was 12.2 versus 11.1 months [HR, 1.10; 80% confidence interval (CI), 0.82-1.48] in the combined rilotumumab versus control arms.",Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136195/),month,11.1,70847,DB00635,Prednisone
,23136195,progression-free survival,"Median progression-free survival was 3.0 versus 2.9 months (HR, 1.02; 80% CI, 0.79-1.31).",Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136195/),month,3.0,70848,DB00635,Prednisone
,23136195,progression-free survival,"Median progression-free survival was 3.0 versus 2.9 months (HR, 1.02; 80% CI, 0.79-1.31).",Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23136195/),month,2.9,70849,DB00635,Prednisone
,2285202,Maximum prednisolone concentrations,Maximum prednisolone concentrations measured after ingestion of prednisone are higher (535 +/- 32 ng/ml) and occur earlier than after taking prednisolone sodium metasulfobenzoate (198 +/- 114 ng/ml) (p less than 0.001).,[Pharmacokinetic parameters of prednisone and prednisolone in healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2285202/),[ng] / [ml],535,71110,DB00635,Prednisone
,2285202,Maximum prednisolone concentrations,Maximum prednisolone concentrations measured after ingestion of prednisone are higher (535 +/- 32 ng/ml) and occur earlier than after taking prednisolone sodium metasulfobenzoate (198 +/- 114 ng/ml) (p less than 0.001).,[Pharmacokinetic parameters of prednisone and prednisolone in healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2285202/),[ng] / [ml],198,71111,DB00635,Prednisone
,25556680,time to PSA progression,"Median time to PSA progression and radiographic disease progression was 6.7 and 12.9 months, respectively.","Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25556680/),month,6.7,72965,DB00635,Prednisone
,8583374,Area under the curves (AUC),"Area under the curves (AUC) of prednisolone before and after the treatment decreased from 0.94 to 0.78 mg h L-1 (P < 0.05) in the Sho-saiko-To group, increased from 0.92 to 1.06 mg h L-1 (P < 0.01) in the Saiboku-To group, and did not change in the Sairei-To group.",Different effects of traditional Chinese medicines containing similar herbal constituents on prednisolone pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583374/),[h·mg] / [l],0.94,73046,DB00635,Prednisone
,8583374,Area under the curves (AUC),"Area under the curves (AUC) of prednisolone before and after the treatment decreased from 0.94 to 0.78 mg h L-1 (P < 0.05) in the Sho-saiko-To group, increased from 0.92 to 1.06 mg h L-1 (P < 0.01) in the Saiboku-To group, and did not change in the Sairei-To group.",Different effects of traditional Chinese medicines containing similar herbal constituents on prednisolone pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583374/),[h·mg] / [l],0,73047,DB00635,Prednisone
,8583374,Area under the curves (AUC),"Area under the curves (AUC) of prednisolone before and after the treatment decreased from 0.94 to 0.78 mg h L-1 (P < 0.05) in the Sho-saiko-To group, increased from 0.92 to 1.06 mg h L-1 (P < 0.01) in the Saiboku-To group, and did not change in the Sairei-To group.",Different effects of traditional Chinese medicines containing similar herbal constituents on prednisolone pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583374/),[h·mg] / [l],0.92,73048,DB00635,Prednisone
,8583374,Area under the curves (AUC),"Area under the curves (AUC) of prednisolone before and after the treatment decreased from 0.94 to 0.78 mg h L-1 (P < 0.05) in the Sho-saiko-To group, increased from 0.92 to 1.06 mg h L-1 (P < 0.01) in the Saiboku-To group, and did not change in the Sairei-To group.",Different effects of traditional Chinese medicines containing similar herbal constituents on prednisolone pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583374/),[h·mg] / [l],1,73049,DB00635,Prednisone
,3691616,rate constant,"For distribution between plasma and CSF a rate constant of 4.9 h-1 for free PZQ, corresponding to a t1/2 of 8 min or less for the non-protein bound fraction was calculated for Patient 1.",Penetration of praziquantel into cerebrospinal fluid and cysticerci in human cysticercosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691616/),1/[h],4.9,74307,DB00635,Prednisone
,3691616,t1/2,"For distribution between plasma and CSF a rate constant of 4.9 h-1 for free PZQ, corresponding to a t1/2 of 8 min or less for the non-protein bound fraction was calculated for Patient 1.",Penetration of praziquantel into cerebrospinal fluid and cysticerci in human cysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691616/),min,8,74308,DB00635,Prednisone
,3691616,rate,"The rate constant for distribution of the drug between plasma and parasites was 1.4 h-1, corresponding to a t1/2 of 30 min or less.",Penetration of praziquantel into cerebrospinal fluid and cysticerci in human cysticercosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691616/),1/[h],1.4,74309,DB00635,Prednisone
,3691616,t1/2,"The rate constant for distribution of the drug between plasma and parasites was 1.4 h-1, corresponding to a t1/2 of 30 min or less.",Penetration of praziquantel into cerebrospinal fluid and cysticerci in human cysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691616/),min,30,74310,DB00635,Prednisone
,3691616,plasma half-life,"It enters the parasite more slowly, although still more rapidly than the plasma half-life of PZQ (1-1 1/2 h).",Penetration of praziquantel into cerebrospinal fluid and cysticerci in human cysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691616/),h,1-1 1/2,74311,DB00635,Prednisone
,10051048,oral clearance (CL/F),The mean oral clearance (CL/F) and apparent volume of distribution (Vd/F) averaged 0.21+/-0.08 L/hour/kg and 2.4+/-0.8 L/kg while the half-life averaged 8.7+/-3.5 hours.,Clinical pharmacokinetics of tacrolimus in heart transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051048/),[l] / [h·kg],0.21,76612,DB00635,Prednisone
,10051048,apparent volume of distribution (Vd/F),The mean oral clearance (CL/F) and apparent volume of distribution (Vd/F) averaged 0.21+/-0.08 L/hour/kg and 2.4+/-0.8 L/kg while the half-life averaged 8.7+/-3.5 hours.,Clinical pharmacokinetics of tacrolimus in heart transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051048/),[l] / [kg],2.4,76613,DB00635,Prednisone
,10051048,half-life,The mean oral clearance (CL/F) and apparent volume of distribution (Vd/F) averaged 0.21+/-0.08 L/hour/kg and 2.4+/-0.8 L/kg while the half-life averaged 8.7+/-3.5 hours.,Clinical pharmacokinetics of tacrolimus in heart transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051048/),h,8.7,76614,DB00635,Prednisone
,10051048,accumulation,Tacrolimus accumulation index during chronic therapy (Rac = Cmin(steady state)/Cmin(first dose) normalized to the same dose) averaged 1.3.,Clinical pharmacokinetics of tacrolimus in heart transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051048/),,1.3,76615,DB00635,Prednisone
,10051048,trough blood levels,Eighty-eight percent of the trough blood levels measured in our patients were within 5 and 20 ng/ml.,Clinical pharmacokinetics of tacrolimus in heart transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051048/),[ng] / [ml],5,76616,DB00635,Prednisone
,10051048,trough blood levels,Eighty-eight percent of the trough blood levels measured in our patients were within 5 and 20 ng/ml.,Clinical pharmacokinetics of tacrolimus in heart transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051048/),[ng] / [ml],20,76617,DB00635,Prednisone
,10051048,trough blood concentrations,Pharmacokinetic data suggest that maintenance tacrolimus daily dose should be equal to 0.1 mg/kg/day to obtain trough blood concentrations of approximately 10 ng/ml.,Clinical pharmacokinetics of tacrolimus in heart transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051048/),[ng] / [ml],10,76618,DB00635,Prednisone
,7119300,time-to-peak concentration,"Tablet data demonstrated a time-to-peak concentration of 1.23 +/- 0.68 hr (SD), mean residence time of 5.1 +/- 0.49 hr, and absolute bioavailability (tablet/i.v.) of 97.5% +/-- 17.5%.",Bioavailability assessment of a liquid prednisone preparation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7119300/),h,1.23,78781,DB00635,Prednisone
,7119300,mean residence time,"Tablet data demonstrated a time-to-peak concentration of 1.23 +/- 0.68 hr (SD), mean residence time of 5.1 +/- 0.49 hr, and absolute bioavailability (tablet/i.v.) of 97.5% +/-- 17.5%.",Bioavailability assessment of a liquid prednisone preparation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7119300/),h,5.1,78782,DB00635,Prednisone
,7119300,absolute bioavailability,"Tablet data demonstrated a time-to-peak concentration of 1.23 +/- 0.68 hr (SD), mean residence time of 5.1 +/- 0.49 hr, and absolute bioavailability (tablet/i.v.) of 97.5% +/-- 17.5%.",Bioavailability assessment of a liquid prednisone preparation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7119300/),%,97.5,78783,DB00635,Prednisone
,7119300,time-to-peak concentration,"Liquid data demonstrated a significantly (p less than 0.01) shorter time-to-peak concentration, 0.54 +/- 0.20 hr, and mean residence time 4.6 +/- 0.34 hr, with no significant difference in absolute bioavailability (liquid/i.v.), 88.2% +/- 15.8%.",Bioavailability assessment of a liquid prednisone preparation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7119300/),h,0.54,78784,DB00635,Prednisone
,7119300,mean residence time,"Liquid data demonstrated a significantly (p less than 0.01) shorter time-to-peak concentration, 0.54 +/- 0.20 hr, and mean residence time 4.6 +/- 0.34 hr, with no significant difference in absolute bioavailability (liquid/i.v.), 88.2% +/- 15.8%.",Bioavailability assessment of a liquid prednisone preparation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7119300/),h,4.6,78785,DB00635,Prednisone
,7119300,absolute bioavailability,"Liquid data demonstrated a significantly (p less than 0.01) shorter time-to-peak concentration, 0.54 +/- 0.20 hr, and mean residence time 4.6 +/- 0.34 hr, with no significant difference in absolute bioavailability (liquid/i.v.), 88.2% +/- 15.8%.",Bioavailability assessment of a liquid prednisone preparation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7119300/),%,88.2,78786,DB00635,Prednisone
,26103520,maximum dose,"The median maximum dose of MMF was 60 mg/kg/day (range, 34-107).",Mycophenolate mofetil for treatment of steroid-refractory acute graft-versus-host disease after pediatric hematopoietic stem cell transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26103520/),[mg] / [d·kg],60,80473,DB00635,Prednisone
excess of,9158016,peak CD4 saturations,Ninety-three percent of patients treated at 0.5 mg/kg OKT4A and all patients at higher doses had mean peak CD4 saturations in excess of 90%.,Murine OKT4A immunosuppression in cadaver donor renal allograft recipients: a cooperative clinical trials in transplantation pilot study. Cooperative Clinical Trials in Transplantation Research Group. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9158016/),%,90,82201,DB00635,Prednisone
,14748618,trough concentration,The target trough concentration of everolimus should range between 3 and 15 microg/L in combination therapy with ciclosporin (trough concentration 100-300 microg/L) and prednisone.,Clinical pharmacokinetics of everolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748618/),[μg] / [l],3 and 15,83849,DB00635,Prednisone
,14748618,trough concentration,The target trough concentration of everolimus should range between 3 and 15 microg/L in combination therapy with ciclosporin (trough concentration 100-300 microg/L) and prednisone.,Clinical pharmacokinetics of everolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748618/),[μg] / [l],100-300,83850,DB00635,Prednisone
,3806166,CSF to plasma ratios,"The CSF to plasma ratios of dexamethasone and prednisolone following IV bolus administration were 0.15 +/- 0.02 and 0.08 +/- 0.03, respectively.",Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806166/),,0.15,83936,DB00635,Prednisone
,3806166,CSF to plasma ratios,"The CSF to plasma ratios of dexamethasone and prednisolone following IV bolus administration were 0.15 +/- 0.02 and 0.08 +/- 0.03, respectively.",Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806166/),,0.08,83937,DB00635,Prednisone
,3806166,protein binding,"Dexamethasone was 70% protein bound over a wide concentration range, while the protein binding of prednisolone was concentration dependent, ranging from 60% at 10 mumol/L to 95% at 0.5 mumol/L and below.",Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806166/),%,60,83938,DB00635,Prednisone
,3806166,protein binding,"Dexamethasone was 70% protein bound over a wide concentration range, while the protein binding of prednisolone was concentration dependent, ranging from 60% at 10 mumol/L to 95% at 0.5 mumol/L and below.",Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806166/),%,95,83939,DB00635,Prednisone
,19552842,C(0),No side effect or acute rejection episode occurred with the median MPA-C(0) value of 0.74 mg/L.,[Correlation of mycophenolic acid pharmacokinetic parameters with clinical events in kidney transplant patients treated with mycophenolate mofetil]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19552842/),[mg] / [l],0.74,84570,DB00635,Prednisone
,19552842,C(0),Side effects occurred with the median MPA-C(0) value of 1.32 mg/L.,[Correlation of mycophenolic acid pharmacokinetic parameters with clinical events in kidney transplant patients treated with mycophenolate mofetil]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19552842/),[mg] / [l],1.32,84571,DB00635,Prednisone
,19552842,C(0),Sixteen case-times demonstrated acute rejection episode with the median MPA-C(0) value of 0.39 mg/L.,[Correlation of mycophenolic acid pharmacokinetic parameters with clinical events in kidney transplant patients treated with mycophenolate mofetil]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19552842/),[mg] / [l],0.39,84572,DB00635,Prednisone
,21982386,AUC(0-9),"Mean total prednisolone AUC(0-9), prednisone CL/F at steady state, and half-life were 1094 (range, 467-2404) ng/h/mL, 11 (range, 6.7-13.7) L/hr, and 2.6 (range, 1.3-3.9) hours.","Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21982386/),[ng] / [h·ml],1094,85858,DB00635,Prednisone
,21982386,CL/F at steady state,"Mean total prednisolone AUC(0-9), prednisone CL/F at steady state, and half-life were 1094 (range, 467-2404) ng/h/mL, 11 (range, 6.7-13.7) L/hr, and 2.6 (range, 1.3-3.9) hours.","Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21982386/),[l] / [h],11,85859,DB00635,Prednisone
,21982386,half-life,"Mean total prednisolone AUC(0-9), prednisone CL/F at steady state, and half-life were 1094 (range, 467-2404) ng/h/mL, 11 (range, 6.7-13.7) L/hr, and 2.6 (range, 1.3-3.9) hours.","Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21982386/),h,2.6,85860,DB00635,Prednisone
,21982386,AUC(0-9),"Mean total prednisolone AUC(0-9) normalized to prednisone dose by weight was 4361 (range, 1136-9580) ng/h/mL/mg/kg.","Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21982386/),[ng] / [h·kg·mg·ml],4361,85861,DB00635,Prednisone
,21982386,C(max),"Mean total prednisolone C(max) normalized to prednisone dose by weight was 1097 (range, 301-2211) ng/mL/mg/kg at 1.84 (range, 0.48-4) hours (T(max)).","Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21982386/),[ng] / [kg·mg·ml],1097,85862,DB00635,Prednisone
,11304769,complete response rates,"The complete response rates were 30% and 48% among patients who received mCHOP and full-dose CHOP combined with HAART, respectively.",Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304769/),%,30,86057,DB00635,Prednisone
,11304769,complete response rates,"The complete response rates were 30% and 48% among patients who received mCHOP and full-dose CHOP combined with HAART, respectively.",Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304769/),%,48,86058,DB00635,Prednisone
,3909980,elimination half life,Results show important variability between patients: the elimination half life was 2.70 +/- 0.78 hr.; Tmax time to reach Cmax was 2.10 +/- 1.08 hr.; Maximal concentration (Cmax) was 474 +/- 153 ng/ml.,[Pharmacokinetics of prednisone after oral administration in children with renal grafts. Changes induced by phenobarbital and renal insufficiency]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3909980/),h,2.70,86144,DB00635,Prednisone
,3909980,Tmax time to reach Cmax,Results show important variability between patients: the elimination half life was 2.70 +/- 0.78 hr.; Tmax time to reach Cmax was 2.10 +/- 1.08 hr.; Maximal concentration (Cmax) was 474 +/- 153 ng/ml.,[Pharmacokinetics of prednisone after oral administration in children with renal grafts. Changes induced by phenobarbital and renal insufficiency]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3909980/),h,2.10,86145,DB00635,Prednisone
,3909980,Maximal concentration (Cmax),Results show important variability between patients: the elimination half life was 2.70 +/- 0.78 hr.; Tmax time to reach Cmax was 2.10 +/- 1.08 hr.; Maximal concentration (Cmax) was 474 +/- 153 ng/ml.,[Pharmacokinetics of prednisone after oral administration in children with renal grafts. Changes induced by phenobarbital and renal insufficiency]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3909980/),[ng] / [ml],474,86146,DB00635,Prednisone
,3909980,urinary excretion,"With respect to the dose of steroid administered, the urinary excretion of corticosteroids: 17-hydroxycorticosteroids was 12.9 +/- 7.4% and that of unchanged prednisolone 2.8 +/- 3.1%.",[Pharmacokinetics of prednisone after oral administration in children with renal grafts. Changes induced by phenobarbital and renal insufficiency]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3909980/),%,12.9,86147,DB00635,Prednisone
,3909980,urinary excretion,"With respect to the dose of steroid administered, the urinary excretion of corticosteroids: 17-hydroxycorticosteroids was 12.9 +/- 7.4% and that of unchanged prednisolone 2.8 +/- 3.1%.",[Pharmacokinetics of prednisone after oral administration in children with renal grafts. Changes induced by phenobarbital and renal insufficiency]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3909980/),%,2.8,86148,DB00635,Prednisone
,32737470,minimum optimal C1-trough,"The first cycle trough concentration (C1-trough) of rituximab was a significant independent risk factor for achieving CR in matched-pair logistic regression analysis, rather than the concentrations in later cycles; the recommendatory minimum optimal C1-trough was 13.60 μg/mL.",Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32737470/),[μg] / [ml],13.60,88213,DB00635,Prednisone
,32737470,C1-trough,"Patients with grade 1/2 had significantly lower C1-trough compared with grade 3 (12.21 μg/mL vs. 23.45 μg/mL, P < 0.001), only 30% patients with grade 1/2 could reach 13.60 μg/mL, compared with 91.67% in patients with grade 3, which was in accord with its unsatisfactory CR rates (43.33% vs. 76.32%).",Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32737470/),[μg] / [ml],12.21,88214,DB00635,Prednisone
,32737470,C1-trough,"Patients with grade 1/2 had significantly lower C1-trough compared with grade 3 (12.21 μg/mL vs. 23.45 μg/mL, P < 0.001), only 30% patients with grade 1/2 could reach 13.60 μg/mL, compared with 91.67% in patients with grade 3, which was in accord with its unsatisfactory CR rates (43.33% vs. 76.32%).",Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32737470/),[μg] / [ml],23.45,88215,DB00635,Prednisone
,22263871,heart rate,He was found to be bradycardic with a heart rate of 42/min.,"Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22263871/),1/[min],42,90698,DB00635,Prednisone
,22263871,trough,"The tacrolimus trough was elevated at 14 ng/mL, which decreased after stopping ranolazine, reaching 7 ng/mL after 3 days, while continuing the same dose of tacrolimus.","Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22263871/),[ng] / [ml],14,90699,DB00635,Prednisone
,22263871,trough,"The tacrolimus trough was elevated at 14 ng/mL, which decreased after stopping ranolazine, reaching 7 ng/mL after 3 days, while continuing the same dose of tacrolimus.","Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22263871/),[ng] / [ml],7,90700,DB00635,Prednisone
,16213292,area under the curve,"In the study group, the mean area under the curve was significantly below the average therapeutic range before (3154 ng/mL/ho) versus 5532 ng/mL/h after shifting to the single-dose regimen (which was therapeutic).",Single daily dose administration of cyclosporine in renal transplant recipients: a preliminary report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16213292/),[ng] / [ho·ml],3154,94161,DB00635,Prednisone
,16213292,area under the curve,"In the study group, the mean area under the curve was significantly below the average therapeutic range before (3154 ng/mL/ho) versus 5532 ng/mL/h after shifting to the single-dose regimen (which was therapeutic).",Single daily dose administration of cyclosporine in renal transplant recipients: a preliminary report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16213292/),[ng] / [h·ml],5532,94162,DB00635,Prednisone
,11115437,Plasma levels,"Study 2. Plasma levels over days 7 to 28 were 100.3 +/- 5.9 pg/mL (mean +/- SEM) for MF DPI 400 microg bid, and 181.0 +/- 10.9 pg/mL for 800 microg bid.",Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11115437/),[pg] / [ml],100.3,95830,DB00635,Prednisone
,11115437,Plasma levels,"Study 2. Plasma levels over days 7 to 28 were 100.3 +/- 5.9 pg/mL (mean +/- SEM) for MF DPI 400 microg bid, and 181.0 +/- 10.9 pg/mL for 800 microg bid.",Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11115437/),[pg] / [ml],181.0,95831,DB00635,Prednisone
,6113924,total kidney clearance (CIT),The total kidney clearance (CIT) of Pn ranged from 0.39 to 1.24 ml/min/100 g of rat body weight with approximately half of the Pn dose unaccountable for as either Pn or prednisone.,Prednisolone metabolism and excretion in the isolated perfused rat kidney. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6113924/),[ml] / [100·g·min],0.39 to 1.24,95959,DB00635,Prednisone
,6113924,apparent percentage,The apparent percentage of the Pn dose excreted unchanged in the urine ranged from 1.9 to 6.4% and was not related to Pn dose.,Prednisolone metabolism and excretion in the isolated perfused rat kidney. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6113924/),%,1.9 to 6.4,95960,DB00635,Prednisone
,1941630,mean residence time,The mean residence time decreased from 0.60 +/- 0.15 (control) to 0.43 +/- 0.10 hr with ketoconazole (P less than .05) after 5 mg/kg of MPL (free alcohol).,Effect of ketoconazole on methylprednisolone pharmacokinetics and receptor/gene-mediated pharmacodynamics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941630/),h,0.60,96350,DB00635,Prednisone
,1941630,mean residence time,The mean residence time decreased from 0.60 +/- 0.15 (control) to 0.43 +/- 0.10 hr with ketoconazole (P less than .05) after 5 mg/kg of MPL (free alcohol).,Effect of ketoconazole on methylprednisolone pharmacokinetics and receptor/gene-mediated pharmacodynamics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941630/),h,0.43,96351,DB00635,Prednisone
,1941630,area under the curve ratio,The methylprednisone to MPL area under the curve ratio decreased from 0.19 +/- 0.04 in control to 0.14 +/- 0.03 in ketoconazole-treated rats (P less than .05) due to altered interconversion between these steroids.,Effect of ketoconazole on methylprednisolone pharmacokinetics and receptor/gene-mediated pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941630/),,0.19,96352,DB00635,Prednisone
,1941630,area under the curve ratio,The methylprednisone to MPL area under the curve ratio decreased from 0.19 +/- 0.04 in control to 0.14 +/- 0.03 in ketoconazole-treated rats (P less than .05) due to altered interconversion between these steroids.,Effect of ketoconazole on methylprednisolone pharmacokinetics and receptor/gene-mediated pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941630/),,0.14,96353,DB00635,Prednisone
,3806371,plasma clearance,"Dose, however, had a marked effect on prednisolone pharmacokinetics, with mean plasma clearance decreasing from 6.18 to 3.07 L/h per kg and mean steady-state volume of distribution decreasing from 2.14 to 1.05 L/kg from the lower to higher steroid dose.",Dose-dependent pharmacokinetics of prednisolone in normal and adrenalectomized rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806371/),[l] / [h·kg],6.18 to 3.07,97656,DB00635,Prednisone
,3806371,steady-state volume of distribution,"Dose, however, had a marked effect on prednisolone pharmacokinetics, with mean plasma clearance decreasing from 6.18 to 3.07 L/h per kg and mean steady-state volume of distribution decreasing from 2.14 to 1.05 L/kg from the lower to higher steroid dose.",Dose-dependent pharmacokinetics of prednisolone in normal and adrenalectomized rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806371/),[l] / [kg],2.14 to 1.05,97657,DB00635,Prednisone
,3806371,Half-life,Half-life (0.50 hr) and mean residence time (0.35 hr) were unaffected by dose.,Dose-dependent pharmacokinetics of prednisolone in normal and adrenalectomized rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806371/),h,0.50,97658,DB00635,Prednisone
,3806371,mean residence time,Half-life (0.50 hr) and mean residence time (0.35 hr) were unaffected by dose.,Dose-dependent pharmacokinetics of prednisolone in normal and adrenalectomized rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806371/),h,0.35,97659,DB00635,Prednisone
,12742493,trough sirolimus concentrations,High-risk recipients of black ethnicity (n = 68) were randomized to target whole-blood trough sirolimus concentrations between 8 and 12 ng/mL or 15 to 20 ng/mL.,Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742493/),[ng] / [ml],8 and 12,98662,DB00635,Prednisone
,12742493,trough sirolimus concentrations,High-risk recipients of black ethnicity (n = 68) were randomized to target whole-blood trough sirolimus concentrations between 8 and 12 ng/mL or 15 to 20 ng/mL.,Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742493/),[ng] / [ml],15 to 20,98663,DB00635,Prednisone
,12742493,late loss,"The 4-month follow-up angiography revealed no restenosis (stenosis diameter > 50%), a late loss of 0.56 +/- 0.40 mm, and a loss index of 0.33 +/- 0.30.",Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742493/),mm,0.56,98664,DB00635,Prednisone
,12742493,loss index,"The 4-month follow-up angiography revealed no restenosis (stenosis diameter > 50%), a late loss of 0.56 +/- 0.40 mm, and a loss index of 0.33 +/- 0.30.",Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742493/),,0.33,98665,DB00635,Prednisone
,8549229,half-life,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),h,1.150,98700,DB00635,Prednisone
,8549229,excretion constant,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),[ke] / [h],0.686,98701,DB00635,Prednisone
,8549229,volume of distribution,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),[ml] / [kg],607,98702,DB00635,Prednisone
,8549229,clearance rate,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),[ml] / [h·kg],374,98703,DB00635,Prednisone
,25403207,complete response (CR)/unconfirmed CR rate,"The complete response (CR)/unconfirmed CR rate was 85% in 189 evaluable patients, 90% for 90 good-prognosis patients (International Prognostic Index [IPI], 1 or 2), and 81% for 99 poor-prognosis patients (IPI, 3 to 5); 3-year event-free survival (EFS) was 71%, 75%, and 67%, respectively; and 3-year overall survival (OS) was 84%, 88%, and 80%, respectively, with no differences between men and women.",Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25403207/),%,85,99063,DB00635,Prednisone
,25403207,complete response (CR)/unconfirmed CR rate,"The complete response (CR)/unconfirmed CR rate was 85% in 189 evaluable patients, 90% for 90 good-prognosis patients (International Prognostic Index [IPI], 1 or 2), and 81% for 99 poor-prognosis patients (IPI, 3 to 5); 3-year event-free survival (EFS) was 71%, 75%, and 67%, respectively; and 3-year overall survival (OS) was 84%, 88%, and 80%, respectively, with no differences between men and women.",Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25403207/),%,90,99064,DB00635,Prednisone
,25403207,complete response (CR)/unconfirmed CR rate,"The complete response (CR)/unconfirmed CR rate was 85% in 189 evaluable patients, 90% for 90 good-prognosis patients (International Prognostic Index [IPI], 1 or 2), and 81% for 99 poor-prognosis patients (IPI, 3 to 5); 3-year event-free survival (EFS) was 71%, 75%, and 67%, respectively; and 3-year overall survival (OS) was 84%, 88%, and 80%, respectively, with no differences between men and women.",Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25403207/),%,81,99065,DB00635,Prednisone
,6213074,EC50,"The mean EC50 (+/- SD) for total prednisolone concentration following the oral and the i.v. dosing was 66.3 +/- 26.7 and 86.5 +/- 30.9 ng/ml, respectively; for free prednisolone concentration the corresponding values were 10.0 +/- 5.0 and 12.4 +/- 12.6 ng/ml.",Prednisolone pharmacodynamics assessed by inhibition of the mixed lymphocyte reaction. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6213074/),[ng] / [ml],66.3,99281,DB00635,Prednisone
,6213074,EC50,"The mean EC50 (+/- SD) for total prednisolone concentration following the oral and the i.v. dosing was 66.3 +/- 26.7 and 86.5 +/- 30.9 ng/ml, respectively; for free prednisolone concentration the corresponding values were 10.0 +/- 5.0 and 12.4 +/- 12.6 ng/ml.",Prednisolone pharmacodynamics assessed by inhibition of the mixed lymphocyte reaction. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6213074/),[ng] / [ml],86.5,99282,DB00635,Prednisone
,6213074,EC50,"The mean EC50 (+/- SD) for total prednisolone concentration following the oral and the i.v. dosing was 66.3 +/- 26.7 and 86.5 +/- 30.9 ng/ml, respectively; for free prednisolone concentration the corresponding values were 10.0 +/- 5.0 and 12.4 +/- 12.6 ng/ml.",Prednisolone pharmacodynamics assessed by inhibition of the mixed lymphocyte reaction. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6213074/),[ng] / [ml],10.0,99283,DB00635,Prednisone
,6213074,EC50,"The mean EC50 (+/- SD) for total prednisolone concentration following the oral and the i.v. dosing was 66.3 +/- 26.7 and 86.5 +/- 30.9 ng/ml, respectively; for free prednisolone concentration the corresponding values were 10.0 +/- 5.0 and 12.4 +/- 12.6 ng/ml.",Prednisolone pharmacodynamics assessed by inhibition of the mixed lymphocyte reaction. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6213074/),[ng] / [ml],12.4,99284,DB00635,Prednisone
,11907637,C(max.),"Values of C(max.) and AUC(0h-24h) were higher in the patient group than in the control group (day 1, patients vs. controls, C(max.): 869.4 +/- 604.0 ng/mL vs. 211.9 +/- 113.9 ng/mL; AUC(0h-24h): 1948.8 +/- 1347.9 ng/mL*h vs. 549.4 +/- 247.4 ng/mL*h), whereas the corresponding value of CL was lower in the patient group (33.3 +/- 24.5 L/h vs. 107.9 +/- 95.8 L/h), and the values of t(max.) and t(1/2) showed no differences.",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [ml],869.4,99577,DB00635,Prednisone
,11907637,C(max.),"Values of C(max.) and AUC(0h-24h) were higher in the patient group than in the control group (day 1, patients vs. controls, C(max.): 869.4 +/- 604.0 ng/mL vs. 211.9 +/- 113.9 ng/mL; AUC(0h-24h): 1948.8 +/- 1347.9 ng/mL*h vs. 549.4 +/- 247.4 ng/mL*h), whereas the corresponding value of CL was lower in the patient group (33.3 +/- 24.5 L/h vs. 107.9 +/- 95.8 L/h), and the values of t(max.) and t(1/2) showed no differences.",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [ml],211.9,99578,DB00635,Prednisone
,11907637,AUC(0h-24h),"Values of C(max.) and AUC(0h-24h) were higher in the patient group than in the control group (day 1, patients vs. controls, C(max.): 869.4 +/- 604.0 ng/mL vs. 211.9 +/- 113.9 ng/mL; AUC(0h-24h): 1948.8 +/- 1347.9 ng/mL*h vs. 549.4 +/- 247.4 ng/mL*h), whereas the corresponding value of CL was lower in the patient group (33.3 +/- 24.5 L/h vs. 107.9 +/- 95.8 L/h), and the values of t(max.) and t(1/2) showed no differences.",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [h·ml],1948.8,99579,DB00635,Prednisone
,11907637,AUC(0h-24h),"Values of C(max.) and AUC(0h-24h) were higher in the patient group than in the control group (day 1, patients vs. controls, C(max.): 869.4 +/- 604.0 ng/mL vs. 211.9 +/- 113.9 ng/mL; AUC(0h-24h): 1948.8 +/- 1347.9 ng/mL*h vs. 549.4 +/- 247.4 ng/mL*h), whereas the corresponding value of CL was lower in the patient group (33.3 +/- 24.5 L/h vs. 107.9 +/- 95.8 L/h), and the values of t(max.) and t(1/2) showed no differences.",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [h·ml],549.4,99580,DB00635,Prednisone
,11907637,CL,"Values of C(max.) and AUC(0h-24h) were higher in the patient group than in the control group (day 1, patients vs. controls, C(max.): 869.4 +/- 604.0 ng/mL vs. 211.9 +/- 113.9 ng/mL; AUC(0h-24h): 1948.8 +/- 1347.9 ng/mL*h vs. 549.4 +/- 247.4 ng/mL*h), whereas the corresponding value of CL was lower in the patient group (33.3 +/- 24.5 L/h vs. 107.9 +/- 95.8 L/h), and the values of t(max.) and t(1/2) showed no differences.",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[l] / [h],33.3,99581,DB00635,Prednisone
,11907637,CL,"Values of C(max.) and AUC(0h-24h) were higher in the patient group than in the control group (day 1, patients vs. controls, C(max.): 869.4 +/- 604.0 ng/mL vs. 211.9 +/- 113.9 ng/mL; AUC(0h-24h): 1948.8 +/- 1347.9 ng/mL*h vs. 549.4 +/- 247.4 ng/mL*h), whereas the corresponding value of CL was lower in the patient group (33.3 +/- 24.5 L/h vs. 107.9 +/- 95.8 L/h), and the values of t(max.) and t(1/2) showed no differences.",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[l] / [h],107.9,99582,DB00635,Prednisone
,11907637,C(max.),"In addition, values of C(max.) and AUC(0h-24h) after administration of 40 mg/day fluvastatin for 4 weeks in both groups were slightly higher than at the beginning, whereas the value of CL was slightly lower (day 28, patients vs. controls, C(max.): 1530.4 +/- 960.4 ng/mL vs. 254.7 +/- 199.8 ng/mL; AUC(0h-24h): 2615.3 +/- 1379.4 ng/mL*h vs. 841.8 +/- 421.4 ng/mL*h; CL: day 28, 21.4 +/- 15.3 L/h vs. 61.5 +/- 36.6 L/h).",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [ml],1530.4,99583,DB00635,Prednisone
,11907637,C(max.),"In addition, values of C(max.) and AUC(0h-24h) after administration of 40 mg/day fluvastatin for 4 weeks in both groups were slightly higher than at the beginning, whereas the value of CL was slightly lower (day 28, patients vs. controls, C(max.): 1530.4 +/- 960.4 ng/mL vs. 254.7 +/- 199.8 ng/mL; AUC(0h-24h): 2615.3 +/- 1379.4 ng/mL*h vs. 841.8 +/- 421.4 ng/mL*h; CL: day 28, 21.4 +/- 15.3 L/h vs. 61.5 +/- 36.6 L/h).",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [ml],254.7,99584,DB00635,Prednisone
,11907637,AUC(0h-24h),"In addition, values of C(max.) and AUC(0h-24h) after administration of 40 mg/day fluvastatin for 4 weeks in both groups were slightly higher than at the beginning, whereas the value of CL was slightly lower (day 28, patients vs. controls, C(max.): 1530.4 +/- 960.4 ng/mL vs. 254.7 +/- 199.8 ng/mL; AUC(0h-24h): 2615.3 +/- 1379.4 ng/mL*h vs. 841.8 +/- 421.4 ng/mL*h; CL: day 28, 21.4 +/- 15.3 L/h vs. 61.5 +/- 36.6 L/h).",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [h·ml],2615.3,99585,DB00635,Prednisone
,11907637,AUC(0h-24h),"In addition, values of C(max.) and AUC(0h-24h) after administration of 40 mg/day fluvastatin for 4 weeks in both groups were slightly higher than at the beginning, whereas the value of CL was slightly lower (day 28, patients vs. controls, C(max.): 1530.4 +/- 960.4 ng/mL vs. 254.7 +/- 199.8 ng/mL; AUC(0h-24h): 2615.3 +/- 1379.4 ng/mL*h vs. 841.8 +/- 421.4 ng/mL*h; CL: day 28, 21.4 +/- 15.3 L/h vs. 61.5 +/- 36.6 L/h).",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [h·ml],841.8,99586,DB00635,Prednisone
,11907637,CL,"In addition, values of C(max.) and AUC(0h-24h) after administration of 40 mg/day fluvastatin for 4 weeks in both groups were slightly higher than at the beginning, whereas the value of CL was slightly lower (day 28, patients vs. controls, C(max.): 1530.4 +/- 960.4 ng/mL vs. 254.7 +/- 199.8 ng/mL; AUC(0h-24h): 2615.3 +/- 1379.4 ng/mL*h vs. 841.8 +/- 421.4 ng/mL*h; CL: day 28, 21.4 +/- 15.3 L/h vs. 61.5 +/- 36.6 L/h).",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[l] / [h],21.4,99587,DB00635,Prednisone
,11907637,CL,"In addition, values of C(max.) and AUC(0h-24h) after administration of 40 mg/day fluvastatin for 4 weeks in both groups were slightly higher than at the beginning, whereas the value of CL was slightly lower (day 28, patients vs. controls, C(max.): 1530.4 +/- 960.4 ng/mL vs. 254.7 +/- 199.8 ng/mL; AUC(0h-24h): 2615.3 +/- 1379.4 ng/mL*h vs. 841.8 +/- 421.4 ng/mL*h; CL: day 28, 21.4 +/- 15.3 L/h vs. 61.5 +/- 36.6 L/h).",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[l] / [h],61.5,99588,DB00635,Prednisone
,7440853,apparent half-lifes,The apparent half-lifes of prednisolone in the asthmatics and normals were 3.33 +/- 0.71 and 3.25 +/- 0.58 hr (mean +/- SD).,Prednisolone disposition in steroid-dependent asthmatics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7440853/),h,3.33,100047,DB00635,Prednisone
,7440853,apparent half-lifes,The apparent half-lifes of prednisolone in the asthmatics and normals were 3.33 +/- 0.71 and 3.25 +/- 0.58 hr (mean +/- SD).,Prednisolone disposition in steroid-dependent asthmatics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7440853/),h,3.25,100048,DB00635,Prednisone
,7440853,apparent plasma clearances,"The apparent plasma clearances of prednisolone were 201 +/- 54 and 198 +/- 38 ml/min/1.73 m2 and the apparent volumes of distribution were 50.8 +/- 11.7 and 53.5 +/- 13.5 L/1.73 m2 for the asthmatic and normal groups, respectively.",Prednisolone disposition in steroid-dependent asthmatics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7440853/),[ml] / [1.73·m2·min],201,100049,DB00635,Prednisone
,7440853,apparent plasma clearances,"The apparent plasma clearances of prednisolone were 201 +/- 54 and 198 +/- 38 ml/min/1.73 m2 and the apparent volumes of distribution were 50.8 +/- 11.7 and 53.5 +/- 13.5 L/1.73 m2 for the asthmatic and normal groups, respectively.",Prednisolone disposition in steroid-dependent asthmatics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7440853/),[ml] / [1.73·m2·min],198,100050,DB00635,Prednisone
,7440853,apparent volumes of distribution,"The apparent plasma clearances of prednisolone were 201 +/- 54 and 198 +/- 38 ml/min/1.73 m2 and the apparent volumes of distribution were 50.8 +/- 11.7 and 53.5 +/- 13.5 L/1.73 m2 for the asthmatic and normal groups, respectively.",Prednisolone disposition in steroid-dependent asthmatics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7440853/),[l] / [1.73·m2],50.8,100051,DB00635,Prednisone
,7440853,apparent volumes of distribution,"The apparent plasma clearances of prednisolone were 201 +/- 54 and 198 +/- 38 ml/min/1.73 m2 and the apparent volumes of distribution were 50.8 +/- 11.7 and 53.5 +/- 13.5 L/1.73 m2 for the asthmatic and normal groups, respectively.",Prednisolone disposition in steroid-dependent asthmatics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7440853/),[l] / [1.73·m2],53.5,100052,DB00635,Prednisone
,11695718,tmax,"Peak serum concentrations occurred from 0.04 to 4.0 days after infusion (mean tmax = 1.79 +/- 1.55 d) with a mean cmax of 4,595 +/- 2,849 ng/ml.","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),d,1.79,102175,DB00635,Prednisone
,11695718,cmax,"Peak serum concentrations occurred from 0.04 to 4.0 days after infusion (mean tmax = 1.79 +/- 1.55 d) with a mean cmax of 4,595 +/- 2,849 ng/ml.","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),[ng] / [ml],"4,595",102176,DB00635,Prednisone
,11695718,Vp,"A total amount of 12.84 +/- 2.47 mg liposomal DOXO in the plasma volume (Vp = 2,794 + 537 ml) could be estimated at tmax (= 27 % of the mean dose of 47.6 mg).","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),ml,"2,794",102177,DB00635,Prednisone
,11695718,t 1/2el,Stealth liposomes were eliminated slowly from the blood with a mean t 1/2el of 1.9 + 0.5 days (MRT was 4.6 + 2.5 days).,"Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),d,1.9,102178,DB00635,Prednisone
,11695718,MRT,Stealth liposomes were eliminated slowly from the blood with a mean t 1/2el of 1.9 + 0.5 days (MRT was 4.6 + 2.5 days).,"Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),d,4.6,102179,DB00635,Prednisone
,11695718,AUClast,"AUClast values ranged from 8,070 to 33,446 ng/ml*d (mean 10,987 +/- 9,339 ng/ml*d).","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),[ng] / [d·ml],"8,070 to 33,446",102180,DB00635,Prednisone
,11695718,AUClast,"AUClast values ranged from 8,070 to 33,446 ng/ml*d (mean 10,987 +/- 9,339 ng/ml*d).","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),[ng] / [d·ml],"10,987",102181,DB00635,Prednisone
,11695718,plasma clearance (Cltot,"The low plasma clearance (Cltot = 4,681 +/- 2,835 ml/day) and the small volume of distribution (Vz = 11.7 +/- 6.31) suggested that stealth-liposomes were stable in the blood at least for 14 days.","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),[ml] / [d],"4,681",102182,DB00635,Prednisone
,11695718,volume of distribution (Vz,"The low plasma clearance (Cltot = 4,681 +/- 2,835 ml/day) and the small volume of distribution (Vz = 11.7 +/- 6.31) suggested that stealth-liposomes were stable in the blood at least for 14 days.","Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11695718/),,11.7,102183,DB00635,Prednisone
,26829599,Tmax,"Consistent with enteric coating, the mean Tmax was significantly longer after the intake of EC-MPS compared with MMF (2.2 versus 0.8 hours; P = 0.0002).",Pharmacokinetic Analysis of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium in Calcineurin Inhibitor-Free Renal Transplant Recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26829599/),h,2.2,102552,DB00635,Prednisone
,26829599,Tmax,"Consistent with enteric coating, the mean Tmax was significantly longer after the intake of EC-MPS compared with MMF (2.2 versus 0.8 hours; P = 0.0002).",Pharmacokinetic Analysis of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium in Calcineurin Inhibitor-Free Renal Transplant Recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26829599/),h,0.8,102553,DB00635,Prednisone
,26829599,AUC0-12,"Exposures as reflected by the median AUC0-12 values were 50.7 and 58.7 mg·h·L with MMF and EC-MPS, respectively (P = 0.340).",Pharmacokinetic Analysis of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium in Calcineurin Inhibitor-Free Renal Transplant Recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26829599/),h·l·mg,50.7,102554,DB00635,Prednisone
,26829599,AUC0-12,"Exposures as reflected by the median AUC0-12 values were 50.7 and 58.7 mg·h·L with MMF and EC-MPS, respectively (P = 0.340).",Pharmacokinetic Analysis of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium in Calcineurin Inhibitor-Free Renal Transplant Recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26829599/),h·l·mg,58.7,102555,DB00635,Prednisone
>,26829599,AUC,"All patients achieved a target AUC of >30 mg·h·L, and 61% had an AUC of >50 mg·h·L.",Pharmacokinetic Analysis of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium in Calcineurin Inhibitor-Free Renal Transplant Recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26829599/),h·l·mg,30,102556,DB00635,Prednisone
>,26829599,AUC,"All patients achieved a target AUC of >30 mg·h·L, and 61% had an AUC of >50 mg·h·L.",Pharmacokinetic Analysis of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium in Calcineurin Inhibitor-Free Renal Transplant Recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26829599/),h·l·mg,50,102557,DB00635,Prednisone
,30952111,Cmax,"Results Vaginal administration of PN suppositories was not bioequivalent to rectal administration: Cmax and AUC0-360 were significantly lower after vaginal compared to rectal administration: 22 ng/mL (109%) vs 161 ng/mL (28%), P < 0.001; 4390 ng/mL * min (116%) vs 40,302 ng/mL * min (26%), P < 0.001; (mean (coefficient of variation), respectively).",Emergency treatment of adrenal crisis with prednisone suppositories: a bioequivalence study in female patients with Addison's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30952111/),[ng] / [ml],22,103741,DB00635,Prednisone
,30952111,Cmax,"Results Vaginal administration of PN suppositories was not bioequivalent to rectal administration: Cmax and AUC0-360 were significantly lower after vaginal compared to rectal administration: 22 ng/mL (109%) vs 161 ng/mL (28%), P < 0.001; 4390 ng/mL * min (116%) vs 40,302 ng/mL * min (26%), P < 0.001; (mean (coefficient of variation), respectively).",Emergency treatment of adrenal crisis with prednisone suppositories: a bioequivalence study in female patients with Addison's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30952111/),[ng] / [ml],161,103742,DB00635,Prednisone
,30952111,Cmax,"Results Vaginal administration of PN suppositories was not bioequivalent to rectal administration: Cmax and AUC0-360 were significantly lower after vaginal compared to rectal administration: 22 ng/mL (109%) vs 161 ng/mL (28%), P < 0.001; 4390 ng/mL * min (116%) vs 40,302 ng/mL * min (26%), P < 0.001; (mean (coefficient of variation), respectively).",Emergency treatment of adrenal crisis with prednisone suppositories: a bioequivalence study in female patients with Addison's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30952111/),[ng] / [min·ml],4390,103743,DB00635,Prednisone
,30952111,AUC0-360,"Results Vaginal administration of PN suppositories was not bioequivalent to rectal administration: Cmax and AUC0-360 were significantly lower after vaginal compared to rectal administration: 22 ng/mL (109%) vs 161 ng/mL (28%), P < 0.001; 4390 ng/mL * min (116%) vs 40,302 ng/mL * min (26%), P < 0.001; (mean (coefficient of variation), respectively).",Emergency treatment of adrenal crisis with prednisone suppositories: a bioequivalence study in female patients with Addison's disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30952111/),[ng] / [min·ml],4390,103744,DB00635,Prednisone
,30952111,AUC0-360,"Results Vaginal administration of PN suppositories was not bioequivalent to rectal administration: Cmax and AUC0-360 were significantly lower after vaginal compared to rectal administration: 22 ng/mL (109%) vs 161 ng/mL (28%), P < 0.001; 4390 ng/mL * min (116%) vs 40,302 ng/mL * min (26%), P < 0.001; (mean (coefficient of variation), respectively).",Emergency treatment of adrenal crisis with prednisone suppositories: a bioequivalence study in female patients with Addison's disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30952111/),[ng] / [min·ml],"40,302",103745,DB00635,Prednisone
,2225699,clearance,"Eleven patients had unusually rapid methylprednisolone elimination (clearance, 565 to 837 ml/min/1.73 m2; population mean, [+/- SD] 380 +/- 100 ml/min/1.73 m2) without an identifiable cause.",Monitoring glucocorticoid therapy: a pharmacokinetic approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225699/),[ml] / [1.73·m2·min],565 to 837,104355,DB00635,Prednisone
,2225699,clearance,"Eleven patients had unusually rapid methylprednisolone elimination (clearance, 565 to 837 ml/min/1.73 m2; population mean, [+/- SD] 380 +/- 100 ml/min/1.73 m2) without an identifiable cause.",Monitoring glucocorticoid therapy: a pharmacokinetic approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225699/),[ml] / [1.73·m2·min],380,104356,DB00635,Prednisone
,18512312,complete remission (CR) rates,"The complete remission (CR) rates were 84.6% and 89.4%, total response rates were 92.3% and 93.9% (P < 0.05, respectively), and the incidence of adverse effects was 95.6% and 98.5% (P > 0.05) in the VDPAP and VDLP group, respectively.",[Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18512312/),%,84.6,104383,DB00635,Prednisone
,18512312,complete remission (CR) rates,"The complete remission (CR) rates were 84.6% and 89.4%, total response rates were 92.3% and 93.9% (P < 0.05, respectively), and the incidence of adverse effects was 95.6% and 98.5% (P > 0.05) in the VDPAP and VDLP group, respectively.",[Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18512312/),%,89.4,104384,DB00635,Prednisone
,18512312,total response rates,"The complete remission (CR) rates were 84.6% and 89.4%, total response rates were 92.3% and 93.9% (P < 0.05, respectively), and the incidence of adverse effects was 95.6% and 98.5% (P > 0.05) in the VDPAP and VDLP group, respectively.",[Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18512312/),%,92.3,104385,DB00635,Prednisone
,18512312,total response rates,"The complete remission (CR) rates were 84.6% and 89.4%, total response rates were 92.3% and 93.9% (P < 0.05, respectively), and the incidence of adverse effects was 95.6% and 98.5% (P > 0.05) in the VDPAP and VDLP group, respectively.",[Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18512312/),%,93.9,104386,DB00635,Prednisone
,18512312,half-life,"Pharmacokinetics showed that the half-life of PEG-Asp was (170 +/- 45) hours [about (7 +/- 2) days], the serum PEG-Asp activity levels > 0.1 IU/ml throughout induction.",[Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18512312/),h,170,104387,DB00635,Prednisone
,18512312,half-life,"Pharmacokinetics showed that the half-life of PEG-Asp was (170 +/- 45) hours [about (7 +/- 2) days], the serum PEG-Asp activity levels > 0.1 IU/ml throughout induction.",[Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18512312/),d,7,104388,DB00635,Prednisone
,21347736,ME,"After 21 days of treatment, there was an insignificant bias ME (0.22 ± 2.59 ng/ml), a reasonable precision MAE (1.97 ± 1.69 ng/ml) and RMSE (1.28 ± 0.58 ng/ml).",Prediction tacrolimus blood levels based on the Bayesian method in adult kidney transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21347736/),[ng] / [ml],0.22,104966,DB00635,Prednisone
,21347736,MAE,"After 21 days of treatment, there was an insignificant bias ME (0.22 ± 2.59 ng/ml), a reasonable precision MAE (1.97 ± 1.69 ng/ml) and RMSE (1.28 ± 0.58 ng/ml).",Prediction tacrolimus blood levels based on the Bayesian method in adult kidney transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21347736/),[ng] / [ml],1.97,104967,DB00635,Prednisone
,12495285,overall median survival,The overall median survival was 45 +/- 43 months after diagnosis.,Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12495285/),month,45,105070,DB00635,Prednisone
,7819002,clearances,"At 48 months post transplant, the iothalamate clearances (mean +/- SD) were 57.9 +/- 26.8 ml/min per 1.73 m2 in the CSA group and 68.5 +/- 20.2 in the Pred/AZA group (P > 0.05).",Effect of cyclosporine A on long-term allograft function in pediatric renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7819002/),[ml] / [1.73·m2·min],57.9,105531,DB00635,Prednisone
,7819002,clearances,"At 48 months post transplant, the iothalamate clearances (mean +/- SD) were 57.9 +/- 26.8 ml/min per 1.73 m2 in the CSA group and 68.5 +/- 20.2 in the Pred/AZA group (P > 0.05).",Effect of cyclosporine A on long-term allograft function in pediatric renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7819002/),[ml] / [1.73·m2·min],68.5,105532,DB00635,Prednisone
,3541320,serum trough radio,The CsA serum trough radioimmunoassay (RIA) was relatively high among hepatotoxic patients with a mean value of 225 +/- 17 ng/ml.,Hepatobiliary and pancreatic complications of cyclosporine therapy in 466 renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3541320/),[ng] / [ml],225,105552,DB00635,Prednisone
<,18758392,AUC0-12,"Presuming a therapeutic window of 30-60 mg h/L, 15 (60%) of 25 patients at day 7 had an MPA-AUC0-12 <30 mg h/L, indicating potential underexposure, whereas the proportion of patients with an MPA-AUC0-12 <30 mg h/L between months 3 and 36 was low (5%-17%).",Long-term pharmacokinetics of mycophenolic acid in pediatric renal transplant recipients over 3 years posttransplant. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18758392/),[h·mg] / [l],30,106622,DB00635,Prednisone
,3350994,systemic availability,"Using IV PN as reference, approximately 70% systemic availability was observed from both tablets, whereas using IV PL as reference, systemic availability was greater than unity.",Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3350994/),%,70,107519,DB00635,Prednisone
,30229398,clearance,The mean estimated total body MPA clearance of the elderly recipients was not significantly different from that of the controls at any analyzed time point (the mean clearance across all time points was 0.31 ± 0.17 vs 0.30 ± 0.25 L/h/kg).,Longitudinal Pharmacokinetics of Mycophenolic Acid in Elderly Renal Transplant Recipients Compared to a Younger Control Group: Data from the nEverOld Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30229398/),[l] / [h·kg],0.31,107867,DB00635,Prednisone
,30229398,clearance,The mean estimated total body MPA clearance of the elderly recipients was not significantly different from that of the controls at any analyzed time point (the mean clearance across all time points was 0.31 ± 0.17 vs 0.30 ± 0.25 L/h/kg).,Longitudinal Pharmacokinetics of Mycophenolic Acid in Elderly Renal Transplant Recipients Compared to a Younger Control Group: Data from the nEverOld Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30229398/),[l] / [h·kg],0.30,107868,DB00635,Prednisone
,30229398,exposure,"MPA exposure, as evaluated from the area under the 12-h time versus measured MPA concentration (adjusted for dose/body weight) curve, did not differ between the groups at any time point (mean exposure across all time points was 4.68 ± 3.61 vs 5.95 ± 4.29 µg·h/mL per mg/kg for the elderly recipients and the controls).",Longitudinal Pharmacokinetics of Mycophenolic Acid in Elderly Renal Transplant Recipients Compared to a Younger Control Group: Data from the nEverOld Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30229398/),[h·μg] / [kg·mg·ml],4.68,107869,DB00635,Prednisone
,30229398,exposure,"MPA exposure, as evaluated from the area under the 12-h time versus measured MPA concentration (adjusted for dose/body weight) curve, did not differ between the groups at any time point (mean exposure across all time points was 4.68 ± 3.61 vs 5.95 ± 4.29 µg·h/mL per mg/kg for the elderly recipients and the controls).",Longitudinal Pharmacokinetics of Mycophenolic Acid in Elderly Renal Transplant Recipients Compared to a Younger Control Group: Data from the nEverOld Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30229398/),[h·μg] / [kg·mg·ml],5.95,107870,DB00635,Prednisone
,32387086,CL/F,"MPA CL/F, V1/F, Q/F, V2/F, and Ka were 12.4 L/h, 45.6 L, 29.9 L/h, 658 L, and 1.67 h-1, respectively.",Population pharmacokinetics of mycophenolic acid in adult kidney transplant patients under prednisone and tacrolimus regimen. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32387086/),[l] / [h],12.4,108066,DB00635,Prednisone
,32387086,Q/F,"MPA CL/F, V1/F, Q/F, V2/F, and Ka were 12.4 L/h, 45.6 L, 29.9 L/h, 658 L, and 1.67 h-1, respectively.",Population pharmacokinetics of mycophenolic acid in adult kidney transplant patients under prednisone and tacrolimus regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32387086/),l,45.6,108067,DB00635,Prednisone
,32387086,V2/F,"MPA CL/F, V1/F, Q/F, V2/F, and Ka were 12.4 L/h, 45.6 L, 29.9 L/h, 658 L, and 1.67 h-1, respectively.",Population pharmacokinetics of mycophenolic acid in adult kidney transplant patients under prednisone and tacrolimus regimen. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32387086/),l,45.6,108068,DB00635,Prednisone
,32387086,Ka,"MPA CL/F, V1/F, Q/F, V2/F, and Ka were 12.4 L/h, 45.6 L, 29.9 L/h, 658 L, and 1.67 h-1, respectively.",Population pharmacokinetics of mycophenolic acid in adult kidney transplant patients under prednisone and tacrolimus regimen. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32387086/),1/[h],1.67,108069,DB00635,Prednisone
,23802659,peak levels,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),[μg] / [ml],299,110190,DB00635,Prednisone
,23802659,peak levels,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),[μg] / [ml],384,110191,DB00635,Prednisone
,23802659,peak levels,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),[μg] / [ml],245,110192,DB00635,Prednisone
,23802659,peak levels,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),[μg] / [ml],321,110193,DB00635,Prednisone
,23802659,troughs,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),d,26-29,110194,DB00635,Prednisone
,23802659,t½,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),d,26-29,110195,DB00635,Prednisone
,15848555,C0,Predose levels (C0) increased significantly during the first 6 months after transplantation: C0 at 6 and 180 days after transplantation was 0.8 +/- 0.6 and 1.9 +/- 1.1 microg/mL (P < .0001).,Mycophenolate mofetil pharmacokinetic monitoring in pediatric kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848555/),[μg] / [ml],0.8,111154,DB00635,Prednisone
,15848555,C0,Predose levels (C0) increased significantly during the first 6 months after transplantation: C0 at 6 and 180 days after transplantation was 0.8 +/- 0.6 and 1.9 +/- 1.1 microg/mL (P < .0001).,Mycophenolate mofetil pharmacokinetic monitoring in pediatric kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848555/),[μg] / [ml],1.9,111155,DB00635,Prednisone
,15848555,AUC(0-12),A significant time-dependent increase in the AUC of MPA was also observed during the first 6 posttransplant months: AUC(0-12) at 6 and 180 days after transplantation was 23.3 +/- 10.8 and 40 +/- 11.6 mg*h/L (P = .003).,Mycophenolate mofetil pharmacokinetic monitoring in pediatric kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848555/),[h·mg] / [l],23.3,111156,DB00635,Prednisone
,15848555,AUC(0-12),A significant time-dependent increase in the AUC of MPA was also observed during the first 6 posttransplant months: AUC(0-12) at 6 and 180 days after transplantation was 23.3 +/- 10.8 and 40 +/- 11.6 mg*h/L (P = .003).,Mycophenolate mofetil pharmacokinetic monitoring in pediatric kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848555/),[h·mg] / [l],40,111157,DB00635,Prednisone
,8011967,bioavailability,"After an oral prednisone dose of 0.8 mg kg-1 and an intravenous prednisolone dose of 0.66 mg kg-1, the bioavailability was found to be about 62%.",Bioavailability and reversible metabolism of prednisone and prednisolone in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8011967/),%,62,114265,DB00635,Prednisone
,15987748,Cockcroft calculated clearance,Renal function was improved in the MMF group compared with the CsA group (Cockcroft calculated clearance 64.7 +/- 18.7 versus 56.5 +/- 18.0 ml/min; P = 0.023).,"Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15987748/),[ml] / [min],64.7,114965,DB00635,Prednisone
,15987748,Cockcroft calculated clearance,Renal function was improved in the MMF group compared with the CsA group (Cockcroft calculated clearance 64.7 +/- 18.7 versus 56.5 +/- 18.0 ml/min; P = 0.023).,"Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15987748/),[ml] / [min],56.5,114966,DB00635,Prednisone
,15987748,area under the curve,"The 10 patients who developed acute rejection after CsA withdrawal had a significantly higher incidence of borderline changes on the randomization biopsy than the 44 rejection-free patients (five of 10 versus eight of 44; P = 0.034), and they displayed a lower area under the curve of mycophenolic acid (43 +/- 9 versus 58 +/- 22 mg/h per L; P = 0.045).","Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15987748/),[mg] / [h·l],43,114967,DB00635,Prednisone
,15987748,area under the curve,"The 10 patients who developed acute rejection after CsA withdrawal had a significantly higher incidence of borderline changes on the randomization biopsy than the 44 rejection-free patients (five of 10 versus eight of 44; P = 0.034), and they displayed a lower area under the curve of mycophenolic acid (43 +/- 9 versus 58 +/- 22 mg/h per L; P = 0.045).","Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15987748/),[mg] / [h·l],58,114968,DB00635,Prednisone
,10354967,Cmax,"The Cmax values were about 3 ng/mL, while the tmax occurred at 7 to 9 hours.",Pharmacokinetic and adrenal interactions of IL-10 and prednisone in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10354967/),[ng] / [ml],3,116749,DB00635,Prednisone
,10354967,tmax,"The Cmax values were about 3 ng/mL, while the tmax occurred at 7 to 9 hours.",Pharmacokinetic and adrenal interactions of IL-10 and prednisone in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10354967/),h,7 to 9,116750,DB00635,Prednisone
,10354967,Cmax,"Prednisolone exhibited rapid systemic kinetics with a Cmax of 235 ng/mL, tmax at 1.11 hours, and t1/2 of 2.54 hours with no significant alterations owing to IL-10.",Pharmacokinetic and adrenal interactions of IL-10 and prednisone in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10354967/),[ng] / [ml],235,116751,DB00635,Prednisone
,10354967,tmax,"Prednisolone exhibited rapid systemic kinetics with a Cmax of 235 ng/mL, tmax at 1.11 hours, and t1/2 of 2.54 hours with no significant alterations owing to IL-10.",Pharmacokinetic and adrenal interactions of IL-10 and prednisone in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10354967/),h,1.11,116752,DB00635,Prednisone
,10354967,t1/2,"Prednisolone exhibited rapid systemic kinetics with a Cmax of 235 ng/mL, tmax at 1.11 hours, and t1/2 of 2.54 hours with no significant alterations owing to IL-10.",Pharmacokinetic and adrenal interactions of IL-10 and prednisone in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10354967/),h,2.54,116753,DB00635,Prednisone
,12021639,area under the concentration-time curve (AUC),"The 12-hour area under the concentration-time curve (AUC) values for MPA and its major metabolite the phenolic glucuronide MPAG were 55.1 mg.h/L and 800 mg.h/L, respectively.",Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021639/),[h·mg] / [l],55.1,120123,DB00635,Prednisone
,12021639,area under the concentration-time curve (AUC),"The 12-hour area under the concentration-time curve (AUC) values for MPA and its major metabolite the phenolic glucuronide MPAG were 55.1 mg.h/L and 800 mg.h/L, respectively.",Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021639/),[h·mg] / [l],800,120124,DB00635,Prednisone
,12021639,12-h,"An unusually high concentration (12-h AUC, 165 mg.h/L) of the phenolic glucose conjugate of MPA was found.",Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021639/),[h·mg] / [l],165,120125,DB00635,Prednisone
,12021639,AUC,"An unusually high concentration (12-h AUC, 165 mg.h/L) of the phenolic glucose conjugate of MPA was found.",Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021639/),[h·mg] / [l],165,120126,DB00635,Prednisone
,12021639,apparent renal clearance,The apparent renal clearance of MPAG was only 2.2 mL/min.,Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021639/),[ml] / [min],2.2,120127,DB00635,Prednisone
,27447545,CL),"Population estimates for parent drug (CL) and metabolite (CLm ) clearance were 62 l h-1 and 27 l h-1 , respectively.",Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27447545/),[l] / [h],62,121257,DB00635,Prednisone
,27447545,clearance,"Population estimates for parent drug (CL) and metabolite (CLm ) clearance were 62 l h-1 and 27 l h-1 , respectively.",Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27447545/),[l] / [h],27,121258,DB00635,Prednisone
,27447545,fraction metabolized to DOXol (Fm ),The fraction metabolized to DOXol (Fm ) was estimated at 0.22.,Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27447545/),,0.22,121259,DB00635,Prednisone
,26919549,concentrations,"In TAC (STN → MPS) group, dose-adjusted TAC concentrations decreased from baseline to first week (2.3 ± 1.1 versus 1.5 ± 1.0 ng·mL·mg, P < 0.05).",Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26919549/),,1.5,121430,DB00635,Prednisone
,26919549,concentrations,"In EVR (STN → TAC) group, dose-adjusted EVR concentrations decreased from baseline to first week (3.6 ± 2.3 ng·mL·mg versus 1.9 ± 0.8 ng·mL·mg, P < 0.01).",Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26919549/),mg·ml·ng,3.,121431,DB00635,Prednisone
,26919549,concentrations,"In EVR (STN → TAC) group, dose-adjusted EVR concentrations decreased from baseline to first week (3.6 ± 2.3 ng·mL·mg versus 1.9 ± 0.8 ng·mL·mg, P < 0.01).",Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26919549/),mg·ml·ng,1.9,121432,DB00635,Prednisone
,8513854,AUCs,"From the data on PO, the active molecule, the systemic availability of PO-MS was significantly smaller than of PN, with the respective mean AUCs being 1.71 and 3.60 mg.h-1.",Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513854/),[mg] / [h],1.71,123716,DB00635,Prednisone
,8513854,AUCs,"From the data on PO, the active molecule, the systemic availability of PO-MS was significantly smaller than of PN, with the respective mean AUCs being 1.71 and 3.60 mg.h-1.",Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513854/),[mg] / [h],3.60,123717,DB00635,Prednisone
,8513854,Cmax,"The difference was associated with smaller mean Cmax, 0.20 vs 0.64 mg.l-1, higher mean tmax, 2.94 vs 2.06 h and lower mean ka, 0.98 vs 2.18 l/h after PO-MS.",Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513854/),[mg] / [l],0.20,123718,DB00635,Prednisone
,8513854,Cmax,"The difference was associated with smaller mean Cmax, 0.20 vs 0.64 mg.l-1, higher mean tmax, 2.94 vs 2.06 h and lower mean ka, 0.98 vs 2.18 l/h after PO-MS.",Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513854/),[mg] / [l],0.64,123719,DB00635,Prednisone
,8513854,tmax,"The difference was associated with smaller mean Cmax, 0.20 vs 0.64 mg.l-1, higher mean tmax, 2.94 vs 2.06 h and lower mean ka, 0.98 vs 2.18 l/h after PO-MS.",Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513854/),h,2.94,123720,DB00635,Prednisone
,8513854,tmax,"The difference was associated with smaller mean Cmax, 0.20 vs 0.64 mg.l-1, higher mean tmax, 2.94 vs 2.06 h and lower mean ka, 0.98 vs 2.18 l/h after PO-MS.",Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513854/),h,2.06,123721,DB00635,Prednisone
,8513854,ka,"The difference was associated with smaller mean Cmax, 0.20 vs 0.64 mg.l-1, higher mean tmax, 2.94 vs 2.06 h and lower mean ka, 0.98 vs 2.18 l/h after PO-MS.",Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513854/),[l] / [h],0.98,123722,DB00635,Prednisone
,8513854,ka,"The difference was associated with smaller mean Cmax, 0.20 vs 0.64 mg.l-1, higher mean tmax, 2.94 vs 2.06 h and lower mean ka, 0.98 vs 2.18 l/h after PO-MS.",Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513854/),[l] / [h],2.18,123723,DB00635,Prednisone
,8513854,MRT,"The mean MRT was significantly increased after PO-MS, 6.82 vs 5.30 h.",Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513854/),h,6.82,123724,DB00635,Prednisone
,8513854,MRT,"The mean MRT was significantly increased after PO-MS, 6.82 vs 5.30 h.",Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513854/),h,5.30,123725,DB00635,Prednisone
,8513854,absorption,The mean absorption in the test segment of PO-MS was significantly smaller at 17.4 vs 85.5% for PN.,Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513854/),%,17.4,123726,DB00635,Prednisone
,8513854,absorption,The mean absorption in the test segment of PO-MS was significantly smaller at 17.4 vs 85.5% for PN.,Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513854/),%,85.5,123727,DB00635,Prednisone
,10096263,IC50,"The steroid caused monocytopenia, lymphocytopenia, and neutrophilia, with IC50 or SC50 values of 10 to 20 ng/mL.",Pharmacoimmunodynamic interactions of interleukin-10 and prednisone in healthy volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10096263/),[ng] / [ml],10 to 20,126013,DB00635,Prednisone
,10096263,IC50,"Interleukin-10 elevated monocytes and neutrophils and lowered lymphocyte counts, with IC50 or SC50 values of 0.7 to 1.3 ng/mL.",Pharmacoimmunodynamic interactions of interleukin-10 and prednisone in healthy volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10096263/),[ng] / [ml],0.7 to 1.3,126014,DB00635,Prednisone
,32800518,overall un,"The overall unconfirmed response rate was 84%, and the confirmed complete response rate was 44%.",Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32800518/),%,84,126296,DB00635,Prednisone
,32800518,confirmed complete response rate,"The overall unconfirmed response rate was 84%, and the confirmed complete response rate was 44%.",Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32800518/),%,44,126297,DB00635,Prednisone
,32800518,progression free-survival,The median progression free-survival was 27.6 months.,Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32800518/),month,27.6,126298,DB00635,Prednisone
,32800518,total body residence time,The median total body residence time was 94.5 hours.,Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32800518/),h,94.5,126299,DB00635,Prednisone
,6726655,Kp,"The small intestine (Kp = 6.65), heart (2.92), kidney (2.91), lung (2.86), skeletal muscle (1.54) and spleen (1.16) exhibited linear Kp values and percentage of tissue binding.",Tissue distribution of prednisolone in the rabbit. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726655/),,6.65,130378,DB00635,Prednisone
,6726655,Kp,"The small intestine (Kp = 6.65), heart (2.92), kidney (2.91), lung (2.86), skeletal muscle (1.54) and spleen (1.16) exhibited linear Kp values and percentage of tissue binding.",Tissue distribution of prednisolone in the rabbit. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726655/),,2.92,130379,DB00635,Prednisone
,6726655,Kp,"The small intestine (Kp = 6.65), heart (2.92), kidney (2.91), lung (2.86), skeletal muscle (1.54) and spleen (1.16) exhibited linear Kp values and percentage of tissue binding.",Tissue distribution of prednisolone in the rabbit. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726655/),,2.91,130380,DB00635,Prednisone
,6726655,Kp,"The small intestine (Kp = 6.65), heart (2.92), kidney (2.91), lung (2.86), skeletal muscle (1.54) and spleen (1.16) exhibited linear Kp values and percentage of tissue binding.",Tissue distribution of prednisolone in the rabbit. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726655/),,2.86,130381,DB00635,Prednisone
,6726655,Kp,"The small intestine (Kp = 6.65), heart (2.92), kidney (2.91), lung (2.86), skeletal muscle (1.54) and spleen (1.16) exhibited linear Kp values and percentage of tissue binding.",Tissue distribution of prednisolone in the rabbit. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726655/),,1.54,130382,DB00635,Prednisone
,6726655,Kp,"The small intestine (Kp = 6.65), heart (2.92), kidney (2.91), lung (2.86), skeletal muscle (1.54) and spleen (1.16) exhibited linear Kp values and percentage of tissue binding.",Tissue distribution of prednisolone in the rabbit. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726655/),,1.16,130383,DB00635,Prednisone
,6726655,Kp,Liver uptake (Kp = 0.38-4.47) was nonlinear with apparent tissue binding ranging from less than 59 to 84%.,Tissue distribution of prednisolone in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726655/),,0.38-4.47,130384,DB00635,Prednisone
less,6726655,apparent tissue binding,Liver uptake (Kp = 0.38-4.47) was nonlinear with apparent tissue binding ranging from less than 59 to 84%.,Tissue distribution of prednisolone in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726655/),%,59 to 84,130385,DB00635,Prednisone
,7047863,bioavailability,"Since prednisolone exhibits dose-dependent pharmacokinetics because of nonlinear plasma protein binding, bioavailability from oral prednisone and oral prednisolone, compared to the intravenous dose, was 84.5 +/- 17.8% and 95.5 +/- 17.6% using unbound drug concentrations.",Prednisone and prednisolone bioavailability in renal transplant patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7047863/),%,84.5,132221,DB00635,Prednisone
,7047863,bioavailability,"Since prednisolone exhibits dose-dependent pharmacokinetics because of nonlinear plasma protein binding, bioavailability from oral prednisone and oral prednisolone, compared to the intravenous dose, was 84.5 +/- 17.8% and 95.5 +/- 17.6% using unbound drug concentrations.",Prednisone and prednisolone bioavailability in renal transplant patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7047863/),%,95.5,132222,DB00635,Prednisone
,16044096,C0,"Mean +/- SD values for CsA dose, C0, and C2 were 4.8 +/- 1.4 mg/kg/d, 240 +/- 62 microg/L, and 1319 +/- 469 microg/L, respectively.",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],240,133047,DB00635,Prednisone
,16044096,C2,"Mean +/- SD values for CsA dose, C0, and C2 were 4.8 +/- 1.4 mg/kg/d, 240 +/- 62 microg/L, and 1319 +/- 469 microg/L, respectively.",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],1319,133048,DB00635,Prednisone
,16044096,C0,"The mean +/- SD values for C0 (microg/L) and C2 (microg/L) for rejectors (n = 3) were 215 +/- 68 and 949 +/- 204 versus 242 +/- 62 and 1359 +/- 474 for the nonrejectors (P = 0.66 and 0.12, respectively).",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],215,133049,DB00635,Prednisone
,16044096,C2,"The mean +/- SD values for C0 (microg/L) and C2 (microg/L) for rejectors (n = 3) were 215 +/- 68 and 949 +/- 204 versus 242 +/- 62 and 1359 +/- 474 for the nonrejectors (P = 0.66 and 0.12, respectively).",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],215,133050,DB00635,Prednisone
,16044096,C2,"The mean +/- SD values for C0 (microg/L) and C2 (microg/L) for rejectors (n = 3) were 215 +/- 68 and 949 +/- 204 versus 242 +/- 62 and 1359 +/- 474 for the nonrejectors (P = 0.66 and 0.12, respectively).",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],949,133051,DB00635,Prednisone
,16044096,C2,"The mean +/- SD values for C0 (microg/L) and C2 (microg/L) for rejectors (n = 3) were 215 +/- 68 and 949 +/- 204 versus 242 +/- 62 and 1359 +/- 474 for the nonrejectors (P = 0.66 and 0.12, respectively).",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],242,133052,DB00635,Prednisone
,16044096,C2,"The mean +/- SD values for C0 (microg/L) and C2 (microg/L) for rejectors (n = 3) were 215 +/- 68 and 949 +/- 204 versus 242 +/- 62 and 1359 +/- 474 for the nonrejectors (P = 0.66 and 0.12, respectively).",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],1359,133053,DB00635,Prednisone
,16044096,C0,"Fisher exact test P values using the median as threshold value for C0 and C2 (234 microg/L and 1251 microg/L, respectively) were 0.6 and 0.1.",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],234,133054,DB00635,Prednisone
,16044096,C2,"Fisher exact test P values using the median as threshold value for C0 and C2 (234 microg/L and 1251 microg/L, respectively) were 0.6 and 0.1.",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],1251,133055,DB00635,Prednisone
,10551636,half-life,"The drug was absorbed within 2 hr and displayed a 16-19-hr half-life, which is shorter than that of rapamycin.",A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551636/),h,16-19-,136171,DB00635,Prednisone
,21068646,apparent clearance (CL/F),"Population parameters of apparent clearance (CL/F) and volume of distribution were estimated as 23.1 L/h and 105 L, respectively.",Population pharmacokinetic study of cyclosporine based on NONMEM in Chinese liver transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21068646/),[l] / [h],23.1,139526,DB00635,Prednisone
,21068646,volume of distribution,"Population parameters of apparent clearance (CL/F) and volume of distribution were estimated as 23.1 L/h and 105 L, respectively.",Population pharmacokinetic study of cyclosporine based on NONMEM in Chinese liver transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21068646/),l,105,139527,DB00635,Prednisone
,21099740,time to peak concentration,"For MPA and MPAG, the time to peak concentration was 2.5 ± 1.3 hours and 4.6 ± 3.1 hours, respectively; the peak concentration (Cmax) was 19.3 ± 17.2 mg/L and 109.4 ± 49.2 mg/L; and the area under the curve from 6 to 12 hours (AUC6-12) was 32.2 ± 19.3 mg·hr/L and 373.7 ± 235.8 mg·hr/L, respectively, which represents 41.3% and 43.0% of AUC0-12.",The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21099740/),h,2.5,139588,DB00635,Prednisone
,21099740,time to peak concentration,"For MPA and MPAG, the time to peak concentration was 2.5 ± 1.3 hours and 4.6 ± 3.1 hours, respectively; the peak concentration (Cmax) was 19.3 ± 17.2 mg/L and 109.4 ± 49.2 mg/L; and the area under the curve from 6 to 12 hours (AUC6-12) was 32.2 ± 19.3 mg·hr/L and 373.7 ± 235.8 mg·hr/L, respectively, which represents 41.3% and 43.0% of AUC0-12.",The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21099740/),h,4.6,139589,DB00635,Prednisone
,21099740,peak concentration (Cmax),"For MPA and MPAG, the time to peak concentration was 2.5 ± 1.3 hours and 4.6 ± 3.1 hours, respectively; the peak concentration (Cmax) was 19.3 ± 17.2 mg/L and 109.4 ± 49.2 mg/L; and the area under the curve from 6 to 12 hours (AUC6-12) was 32.2 ± 19.3 mg·hr/L and 373.7 ± 235.8 mg·hr/L, respectively, which represents 41.3% and 43.0% of AUC0-12.",The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21099740/),[mg] / [l],19.3,139590,DB00635,Prednisone
,21099740,peak concentration (Cmax),"For MPA and MPAG, the time to peak concentration was 2.5 ± 1.3 hours and 4.6 ± 3.1 hours, respectively; the peak concentration (Cmax) was 19.3 ± 17.2 mg/L and 109.4 ± 49.2 mg/L; and the area under the curve from 6 to 12 hours (AUC6-12) was 32.2 ± 19.3 mg·hr/L and 373.7 ± 235.8 mg·hr/L, respectively, which represents 41.3% and 43.0% of AUC0-12.",The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21099740/),[mg] / [l],109.4,139591,DB00635,Prednisone
,21099740,area under the curve from 6 to 12 hours (AUC6-12),"For MPA and MPAG, the time to peak concentration was 2.5 ± 1.3 hours and 4.6 ± 3.1 hours, respectively; the peak concentration (Cmax) was 19.3 ± 17.2 mg/L and 109.4 ± 49.2 mg/L; and the area under the curve from 6 to 12 hours (AUC6-12) was 32.2 ± 19.3 mg·hr/L and 373.7 ± 235.8 mg·hr/L, respectively, which represents 41.3% and 43.0% of AUC0-12.",The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21099740/),[h·mg] / [l],32.2,139592,DB00635,Prednisone
,21099740,area under the curve from 6 to 12 hours (AUC6-12),"For MPA and MPAG, the time to peak concentration was 2.5 ± 1.3 hours and 4.6 ± 3.1 hours, respectively; the peak concentration (Cmax) was 19.3 ± 17.2 mg/L and 109.4 ± 49.2 mg/L; and the area under the curve from 6 to 12 hours (AUC6-12) was 32.2 ± 19.3 mg·hr/L and 373.7 ± 235.8 mg·hr/L, respectively, which represents 41.3% and 43.0% of AUC0-12.",The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21099740/),[h·mg] / [l],373.7,139593,DB00635,Prednisone
,21099740,AUC0-12,The AUC0-12 for MPA measured 77.8 ± 53.1 mg·hr/L and for MPAG 869.2 ± 388.8 mg·hr/L.,The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21099740/),[h·mg] / [l],77.8,139594,DB00635,Prednisone
,21099740,AUC0-12,The AUC0-12 for MPA measured 77.8 ± 53.1 mg·hr/L and for MPAG 869.2 ± 388.8 mg·hr/L.,The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21099740/),[h·mg] / [l],869.2,139595,DB00635,Prednisone
,12164891,AUC0-12h,"Despite that the MMF dose did not change significantly with time, dose-normalized MPA AUC0-12h was lower during the first month (triple therapy, high doses of steroids) than at month 6 post-surgery (triple therapy, low maintenance dose of steroids (32.94 +/- 10.98 vs. 50.87 +/- 22.37 microg/mL. h; P < 0.01).",Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12164891/),[μg] / [h·ml],32.94,139829,DB00635,Prednisone
,12164891,AUC0-12h,"Despite that the MMF dose did not change significantly with time, dose-normalized MPA AUC0-12h was lower during the first month (triple therapy, high doses of steroids) than at month 6 post-surgery (triple therapy, low maintenance dose of steroids (32.94 +/- 10.98 vs. 50.87 +/- 22.37 microg/mL. h; P < 0.01).",Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12164891/),[μg] / [h·ml],50.87,139830,DB00635,Prednisone
<,10701434,run times,"The method has a lower limit of quantification (LLOQ) adequate for sensitive pharmacokinetic studies ( < or = 0.05 microg/ml), has run times of < or = 15 min, and uses aliquot volumes adequate for pediatric studies (0.25 ml).","A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),min,15,140499,DB00635,Prednisone
,10701434,lambda(ex),Detection and quantification of ganciclovir is by fluorescence (lambda(ex) = 278 nm; lambda(em) = 380 nm).,"A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),,278,140500,DB00635,Prednisone
,10701434,lambda(em),Detection and quantification of ganciclovir is by fluorescence (lambda(ex) = 278 nm; lambda(em) = 380 nm).,"A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),,380,140501,DB00635,Prednisone
<,10701434,% C.V.,All intra- and inter-assay % C.V. values were < 8%; all recoveries (accuracy) were within 7% of nominal values.,"A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),%,8,140502,DB00635,Prednisone
,17144102,AUC(0-4),"There was statistically significant difference for MPA AUC(0-4), C40, C(max) between patients with acute rejection and patients with uneventful outcomes: mean MPA AUC(0-4): 11,4 +/- 7,23 microg x h/ml versus 34,0 26,8 microgxh/ml (p 0,01).",[Mycophenolic acid concentration profiles may select recipients with high-risk of acute rejection in renal transplant recipients]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17144102/),[h·μg] / [ml],"11,4",142114,DB00635,Prednisone
,17144102,AUC(0-4),"There was statistically significant difference for MPA AUC(0-4), C40, C(max) between patients with acute rejection and patients with uneventful outcomes: mean MPA AUC(0-4): 11,4 +/- 7,23 microg x h/ml versus 34,0 26,8 microgxh/ml (p 0,01).",[Mycophenolic acid concentration profiles may select recipients with high-risk of acute rejection in renal transplant recipients]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17144102/),[h·μg] / [ml],"34,0",142115,DB00635,Prednisone
<,17144102,AUC(0-4),Recipients with MPA AUC(0-4) <20 g x h/ml had a greater risk of acute rejection.,[Mycophenolic acid concentration profiles may select recipients with high-risk of acute rejection in renal transplant recipients]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17144102/),[g·h] / [ml],20,142116,DB00635,Prednisone
,3512355,elimination capacity,"The systemic availability of total prednisone and unbound prednisolone, and the urinary excretion of 6 beta-hydroxyprednisolone, were measured after an oral dose of prednisone and an i.v. dose of prednisolone in 22 patients covering a wide range of liver function (galactose elimination capacity ranging from 3.3 mg/min X kg body wt to 9.2 mg/min X kg body wt).",Effect of liver function on the metabolism of prednisone and prednisolone in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512355/),[mg] / [body·kg·min·wt],3.3,142587,DB00635,Prednisone
,3512355,elimination capacity,"The systemic availability of total prednisone and unbound prednisolone, and the urinary excretion of 6 beta-hydroxyprednisolone, were measured after an oral dose of prednisone and an i.v. dose of prednisolone in 22 patients covering a wide range of liver function (galactose elimination capacity ranging from 3.3 mg/min X kg body wt to 9.2 mg/min X kg body wt).",Effect of liver function on the metabolism of prednisone and prednisolone in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512355/),[mg] / [kg·min],9.2,142588,DB00635,Prednisone
,17425625,minimal clearance,The typical value of minimal clearance was 1.8 +/- 0.2 l h(-1).,Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17425625/),[l] / [h],1.8,143249,DB00635,Prednisone
,17425625,maximal,"Clearance increased with time post transplantation to reach 50% of maximal value after 3.8 +/- 0.5 days, with a maximal value of 5.6 l h(-1).",Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17425625/),[l] / [h],5.6,143250,DB00635,Prednisone
,17425625,"volume of distribution, V","The typical value for volume of distribution, V, (98 +/- 13 l kg(-1)) was similar to reported values in kidney transplant patients.",Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17425625/),[l] / [kg],98,143251,DB00635,Prednisone
,17425625,oral bioavailability,The oral bioavailability of tacrolimus was poor and ranged from 11.2 to 19.1%.,Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17425625/),%,11.2 to 19.1,143252,DB00635,Prednisone
,22777155,Area under the time-concentration curve,Area under the time-concentration curve of prednisolone was 3-13 μg·h·mL·mg·kg with maximum concentrations (Cmax) between 0.37 and 2.5 μg·mL·mg·kg and trough concentrations (C0) between 0.13 and 1.1 μg·mL·mg·kg.,The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22777155/),h·kg·mg·ml·μg,3-13,143749,DB00635,Prednisone
,22777155,maximum concentrations (Cmax),Area under the time-concentration curve of prednisolone was 3-13 μg·h·mL·mg·kg with maximum concentrations (Cmax) between 0.37 and 2.5 μg·mL·mg·kg and trough concentrations (C0) between 0.13 and 1.1 μg·mL·mg·kg.,The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22777155/),kg·mg·ml·μg,0.37 and 2.5,143750,DB00635,Prednisone
,22777155,trough concentrations (C0),Area under the time-concentration curve of prednisolone was 3-13 μg·h·mL·mg·kg with maximum concentrations (Cmax) between 0.37 and 2.5 μg·mL·mg·kg and trough concentrations (C0) between 0.13 and 1.1 μg·mL·mg·kg.,The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22777155/),kg·mg·ml·μg,0.13 and 1.1,143751,DB00635,Prednisone
,22777155,elimination half-lives,The elimination half-lives were 1.9-10.3 hours.,The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22777155/),h,1.9-10.3,143752,DB00635,Prednisone
,22777155,Apparent volume of distribution (VD/F),"Apparent volume of distribution (VD/F) and apparent clearance (Cl/F) were 23-159 L and 4.7-28.7 L/h, respectively.",The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22777155/),l,23-159,143753,DB00635,Prednisone
,22777155,apparent clearance (Cl/F),"Apparent volume of distribution (VD/F) and apparent clearance (Cl/F) were 23-159 L and 4.7-28.7 L/h, respectively.",The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22777155/),[l] / [h],4.7-28.7,143754,DB00635,Prednisone
,12919182,dose-adjusted,At month 1 the tacrolimus dose-adjusted C0 in the corticosteroid group was 83 +/- 8 vs 119 +/- 17 ng ml-1 mg-1 kg-1 in the daclizumab group.,Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919182/),[ng] / [kg·mg·ml],83,143834,DB00635,Prednisone
,12919182,dose-adjusted,At month 1 the tacrolimus dose-adjusted C0 in the corticosteroid group was 83 +/- 8 vs 119 +/- 17 ng ml-1 mg-1 kg-1 in the daclizumab group.,Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919182/),[ng] / [kg·mg·ml],119,143835,DB00635,Prednisone
,12919182,C0,At month 1 the tacrolimus dose-adjusted C0 in the corticosteroid group was 83 +/- 8 vs 119 +/- 17 ng ml-1 mg-1 kg-1 in the daclizumab group.,Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919182/),[ng] / [kg·mg·ml],83,143836,DB00635,Prednisone
,12919182,C0,At month 1 the tacrolimus dose-adjusted C0 in the corticosteroid group was 83 +/- 8 vs 119 +/- 17 ng ml-1 mg-1 kg-1 in the daclizumab group.,Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919182/),[ng] / [kg·mg·ml],119,143837,DB00635,Prednisone
,7229914,systemic availability,"There were no statistically significant differences between smokers and nonsmokers in the systemic availability of prednisolone (75 versus 84%), oral dose clearance of prednisone (29 verus 27 ml/min/kg), systemic prednisolone clearance (2.8 versus 2.9 ml/min/kg), or in the interconversion rates, volumes of distribution, or urinary recoveries of prednisone and prednisolone.","Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229914/),%,75,144191,DB00635,Prednisone
,7229914,systemic availability,"There were no statistically significant differences between smokers and nonsmokers in the systemic availability of prednisolone (75 versus 84%), oral dose clearance of prednisone (29 verus 27 ml/min/kg), systemic prednisolone clearance (2.8 versus 2.9 ml/min/kg), or in the interconversion rates, volumes of distribution, or urinary recoveries of prednisone and prednisolone.","Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229914/),%,84,144192,DB00635,Prednisone
,7229914,oral dose clearance,"There were no statistically significant differences between smokers and nonsmokers in the systemic availability of prednisolone (75 versus 84%), oral dose clearance of prednisone (29 verus 27 ml/min/kg), systemic prednisolone clearance (2.8 versus 2.9 ml/min/kg), or in the interconversion rates, volumes of distribution, or urinary recoveries of prednisone and prednisolone.","Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229914/),[ml] / [kg·min],29,144193,DB00635,Prednisone
,7229914,oral dose clearance,"There were no statistically significant differences between smokers and nonsmokers in the systemic availability of prednisolone (75 versus 84%), oral dose clearance of prednisone (29 verus 27 ml/min/kg), systemic prednisolone clearance (2.8 versus 2.9 ml/min/kg), or in the interconversion rates, volumes of distribution, or urinary recoveries of prednisone and prednisolone.","Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229914/),[ml] / [kg·min],27,144194,DB00635,Prednisone
,7229914,systemic prednisolone clearance,"There were no statistically significant differences between smokers and nonsmokers in the systemic availability of prednisolone (75 versus 84%), oral dose clearance of prednisone (29 verus 27 ml/min/kg), systemic prednisolone clearance (2.8 versus 2.9 ml/min/kg), or in the interconversion rates, volumes of distribution, or urinary recoveries of prednisone and prednisolone.","Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229914/),[ml] / [kg·min],2.8,144195,DB00635,Prednisone
,7229914,systemic prednisolone clearance,"There were no statistically significant differences between smokers and nonsmokers in the systemic availability of prednisolone (75 versus 84%), oral dose clearance of prednisone (29 verus 27 ml/min/kg), systemic prednisolone clearance (2.8 versus 2.9 ml/min/kg), or in the interconversion rates, volumes of distribution, or urinary recoveries of prednisone and prednisolone.","Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229914/),[ml] / [kg·min],2.9,144196,DB00635,Prednisone
,7229914,oral dose clearances,A limited correlation (r = 0.55) was found between the high oral dose clearances of prednisone and the lower values of dexamethasone (6.73 and 5.71 ml/min/kg in smokers and nonsmokers).,"Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229914/),[ml] / [kg·min],6.73,144197,DB00635,Prednisone
,7229914,oral dose clearances,A limited correlation (r = 0.55) was found between the high oral dose clearances of prednisone and the lower values of dexamethasone (6.73 and 5.71 ml/min/kg in smokers and nonsmokers).,"Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229914/),[ml] / [kg·min],5.71,144198,DB00635,Prednisone
,2863117,clearance,"The ranges of clearance values at low and high rates of infusion were 2.51-4.08 and 6.08-10.98 ml/min/kg, respectively.",Pharmacokinetics of prednisone and prednisolone at steady state in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863117/),[ml] / [kg·min],2.51-4.08,145000,DB00635,Prednisone
,2863117,clearance,"The ranges of clearance values at low and high rates of infusion were 2.51-4.08 and 6.08-10.98 ml/min/kg, respectively.",Pharmacokinetics of prednisone and prednisolone at steady state in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863117/),[ml] / [kg·min],6.08-10.98,145001,DB00635,Prednisone
,2863117,unbound plasma prednisolone clearance,"The ranges of unbound plasma prednisolone clearance at low and high rates of infusions were 30.3-67.7 and 50.6-110.2 ml/min/kg, respectively.",Pharmacokinetics of prednisone and prednisolone at steady state in the rabbit. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863117/),[ml] / [kg·min],30.3-67.7,145002,DB00635,Prednisone
,2863117,unbound plasma prednisolone clearance,"The ranges of unbound plasma prednisolone clearance at low and high rates of infusions were 30.3-67.7 and 50.6-110.2 ml/min/kg, respectively.",Pharmacokinetics of prednisone and prednisolone at steady state in the rabbit. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863117/),[ml] / [kg·min],50.6-110.2,145003,DB00635,Prednisone
,21372831,overall response rate (ORR),"The overall response rate (ORR) was 45.5%, and the CR rate was 27.3%.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),%,45.5,147623,DB00635,Prednisone
,21372831,CR rate,"The overall response rate (ORR) was 45.5%, and the CR rate was 27.3%.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),%,27,147624,DB00635,Prednisone
,21372831,progression-free survival (PFS) rate,"The 1-year overall survival rate was 45.5%, and the median progression-free survival (PFS) rate was 6.5 [95% confidence interval (95% CI) 3.17-19.02] with a survival rate of 11.5 months (95% CI 6.65-16.36).",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),,6.5,147625,DB00635,Prednisone
,21372831,survival rate,"The 1-year overall survival rate was 45.5%, and the median progression-free survival (PFS) rate was 6.5 [95% confidence interval (95% CI) 3.17-19.02] with a survival rate of 11.5 months (95% CI 6.65-16.36).",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),,11,147626,DB00635,Prednisone
,21372831,plasma concentration,The PLD plasma concentration from nine patients ranged from 1.7036 to 9.2207 mg·L(-1) after administration of the CCOP regimen (0-168 h).,Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),[mg] / [l],1.7036 to 9.2207,147627,DB00635,Prednisone
,21372831,AUC(0-∞),"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),[mg] / [h·l],910.76,147628,DB00635,Prednisone
,21372831,CL,"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),[l] / [(m)^2·h],0.043,147629,DB00635,Prednisone
,21372831,CL,"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),h,68.40,147630,DB00635,Prednisone
,21372831,t(1/2),"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),[l] / [(m)^2·h],0.043,147631,DB00635,Prednisone
,21372831,t(1/2),"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),h,68.40,147632,DB00635,Prednisone
,21372831,V(d),"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),[l] / [m(2],3.56,147633,DB00635,Prednisone
,23267661,AUC(0-24h),"After 14 days of co-administration of WZ and PRED, the AUC(0-24h) of oral TAC was increased (from 59.6±37.3 to 95.3±39.4 ng h/ml, p=0.18) and the clearance was decreased (from 38.4±28.4 to 17.7±6.4 l/h/kg, p=0.15).",Effect of long-term co-administration of Wuzhi tablet (Schisandra sphenanthera extract) and prednisone on the pharmacokinetics of tacrolimus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23267661/),[h·ng] / [ml],59.6,148133,DB00635,Prednisone
,23267661,AUC(0-24h),"After 14 days of co-administration of WZ and PRED, the AUC(0-24h) of oral TAC was increased (from 59.6±37.3 to 95.3±39.4 ng h/ml, p=0.18) and the clearance was decreased (from 38.4±28.4 to 17.7±6.4 l/h/kg, p=0.15).",Effect of long-term co-administration of Wuzhi tablet (Schisandra sphenanthera extract) and prednisone on the pharmacokinetics of tacrolimus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23267661/),[h·ng] / [ml],95.3,148134,DB00635,Prednisone
,23267661,clearance,"After 14 days of co-administration of WZ and PRED, the AUC(0-24h) of oral TAC was increased (from 59.6±37.3 to 95.3±39.4 ng h/ml, p=0.18) and the clearance was decreased (from 38.4±28.4 to 17.7±6.4 l/h/kg, p=0.15).",Effect of long-term co-administration of Wuzhi tablet (Schisandra sphenanthera extract) and prednisone on the pharmacokinetics of tacrolimus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23267661/),[l] / [h·kg],38.4,148135,DB00635,Prednisone
,23267661,clearance,"After 14 days of co-administration of WZ and PRED, the AUC(0-24h) of oral TAC was increased (from 59.6±37.3 to 95.3±39.4 ng h/ml, p=0.18) and the clearance was decreased (from 38.4±28.4 to 17.7±6.4 l/h/kg, p=0.15).",Effect of long-term co-administration of Wuzhi tablet (Schisandra sphenanthera extract) and prednisone on the pharmacokinetics of tacrolimus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23267661/),[l] / [h·kg],17.7,148136,DB00635,Prednisone
,23267661,AUC(0-24h),"When only co-administered with WZ, AUC(0-24h) of TAC was demonstrated a significantly increase (from 59.6±37.3 to 135.9±34.8 ng h/ml, p<0.05).",Effect of long-term co-administration of Wuzhi tablet (Schisandra sphenanthera extract) and prednisone on the pharmacokinetics of tacrolimus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23267661/),[h·ng] / [ml],59.6,148137,DB00635,Prednisone
,23267661,AUC(0-24h),"When only co-administered with WZ, AUC(0-24h) of TAC was demonstrated a significantly increase (from 59.6±37.3 to 135.9±34.8 ng h/ml, p<0.05).",Effect of long-term co-administration of Wuzhi tablet (Schisandra sphenanthera extract) and prednisone on the pharmacokinetics of tacrolimus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23267661/),[h·ng] / [ml],135.9,148138,DB00635,Prednisone
more,34219092,serum half-life,"The pharmacokinetics of rituximab differs substantially among individuals and its serum half-life is approximately more than 500 hours; therefore, the peak concentration increases cumulatively by weekly infusion.",[Optimization of rituximab dosing schedule in R-CHOP therapy for diffuse large B-cell lymphoma]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34219092/),h,500,148482,DB00635,Prednisone
,21176194,areas under the time-concentration curve between 0 and 12 hours (AUC(0-12 h)),"For failures and successes, respectively, entry MPA areas under the time-concentration curve between 0 and 12 hours (AUC(0-12 h)) (medians: 37.7 vs 73.1 mg/h/L, P = 0.003) and MPA 12-hour trough concentrations (C(12 h)) (medians: 1.5 vs 3.7 mg/L, P = 0.008) were significantly lower, and inclusion MPAG/MPA C(12 h) ratios (medians: 18.7 vs 10.2, P = 0.02) were significantly higher.",Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21176194/),[mg] / [h·l],37.7,151136,DB00635,Prednisone
,21176194,areas under the time-concentration curve between 0 and 12 hours (AUC(0-12 h)),"For failures and successes, respectively, entry MPA areas under the time-concentration curve between 0 and 12 hours (AUC(0-12 h)) (medians: 37.7 vs 73.1 mg/h/L, P = 0.003) and MPA 12-hour trough concentrations (C(12 h)) (medians: 1.5 vs 3.7 mg/L, P = 0.008) were significantly lower, and inclusion MPAG/MPA C(12 h) ratios (medians: 18.7 vs 10.2, P = 0.02) were significantly higher.",Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21176194/),[mg] / [h·l],73.1,151137,DB00635,Prednisone
,21176194,trough concentrations (C(12 h)),"For failures and successes, respectively, entry MPA areas under the time-concentration curve between 0 and 12 hours (AUC(0-12 h)) (medians: 37.7 vs 73.1 mg/h/L, P = 0.003) and MPA 12-hour trough concentrations (C(12 h)) (medians: 1.5 vs 3.7 mg/L, P = 0.008) were significantly lower, and inclusion MPAG/MPA C(12 h) ratios (medians: 18.7 vs 10.2, P = 0.02) were significantly higher.",Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21176194/),[mg] / [l],1.5,151138,DB00635,Prednisone
,21176194,trough concentrations (C(12 h)),"For failures and successes, respectively, entry MPA areas under the time-concentration curve between 0 and 12 hours (AUC(0-12 h)) (medians: 37.7 vs 73.1 mg/h/L, P = 0.003) and MPA 12-hour trough concentrations (C(12 h)) (medians: 1.5 vs 3.7 mg/L, P = 0.008) were significantly lower, and inclusion MPAG/MPA C(12 h) ratios (medians: 18.7 vs 10.2, P = 0.02) were significantly higher.",Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21176194/),[mg] / [l],3.7,151139,DB00635,Prednisone
,21176194,C(12 h) ratios,"For failures and successes, respectively, entry MPA areas under the time-concentration curve between 0 and 12 hours (AUC(0-12 h)) (medians: 37.7 vs 73.1 mg/h/L, P = 0.003) and MPA 12-hour trough concentrations (C(12 h)) (medians: 1.5 vs 3.7 mg/L, P = 0.008) were significantly lower, and inclusion MPAG/MPA C(12 h) ratios (medians: 18.7 vs 10.2, P = 0.02) were significantly higher.",Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21176194/),,18.7,151140,DB00635,Prednisone
,21176194,C(12 h) ratios,"For failures and successes, respectively, entry MPA areas under the time-concentration curve between 0 and 12 hours (AUC(0-12 h)) (medians: 37.7 vs 73.1 mg/h/L, P = 0.003) and MPA 12-hour trough concentrations (C(12 h)) (medians: 1.5 vs 3.7 mg/L, P = 0.008) were significantly lower, and inclusion MPAG/MPA C(12 h) ratios (medians: 18.7 vs 10.2, P = 0.02) were significantly higher.",Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21176194/),,10.2,151141,DB00635,Prednisone
<,21176194,steady-state,"For our SLE patients without renal manifestations, clinical flares developing under maintenance therapy were associated with steady-state inclusion MPA C(12 h) < 3 mg/L.",Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21176194/),[mg] / [l],3,151142,DB00635,Prednisone
<,21176194,C(12 h),"For our SLE patients without renal manifestations, clinical flares developing under maintenance therapy were associated with steady-state inclusion MPA C(12 h) < 3 mg/L.",Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21176194/),[mg] / [l],3,151143,DB00635,Prednisone
,28430745,overall response rate,A total of 35 patients with complete data were analyzed and the overall response rate was 91.4%.,Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28430745/),%,91.4,151188,DB00635,Prednisone
,27504016,IC50,"Abiraterone acetate and abiraterone and its major metabolites, abiraterone sulfate and abiraterone sulfate N-oxide, inhibited CYP2C8 in human liver microsomes, with IC50 values near or below the peak total concentrations observed in patients with metastatic castration-resistant prostate cancer (IC50 values: 1.3-3.0 µM, 1.6-2.9 µM, 0.044-0.15 µM, and 5.4-5.9 µM, respectively).","In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27504016/),μM,1.3-3.0,151300,DB00635,Prednisone
,27504016,IC50,"Abiraterone acetate and abiraterone and its major metabolites, abiraterone sulfate and abiraterone sulfate N-oxide, inhibited CYP2C8 in human liver microsomes, with IC50 values near or below the peak total concentrations observed in patients with metastatic castration-resistant prostate cancer (IC50 values: 1.3-3.0 µM, 1.6-2.9 µM, 0.044-0.15 µM, and 5.4-5.9 µM, respectively).","In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27504016/),μM,1.6-2.9,151301,DB00635,Prednisone
,27504016,IC50,"Abiraterone acetate and abiraterone and its major metabolites, abiraterone sulfate and abiraterone sulfate N-oxide, inhibited CYP2C8 in human liver microsomes, with IC50 values near or below the peak total concentrations observed in patients with metastatic castration-resistant prostate cancer (IC50 values: 1.3-3.0 µM, 1.6-2.9 µM, 0.044-0.15 µM, and 5.4-5.9 µM, respectively).","In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27504016/),μM,0.044-0.15,151302,DB00635,Prednisone
,27504016,IC50,"Abiraterone acetate and abiraterone and its major metabolites, abiraterone sulfate and abiraterone sulfate N-oxide, inhibited CYP2C8 in human liver microsomes, with IC50 values near or below the peak total concentrations observed in patients with metastatic castration-resistant prostate cancer (IC50 values: 1.3-3.0 µM, 1.6-2.9 µM, 0.044-0.15 µM, and 5.4-5.9 µM, respectively).","In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27504016/),μM,5.4-5.9,151303,DB00635,Prednisone
,24232127,area under the curve,CF patients had significantly lower MPA area under the curve (47.7 versus 83.1 mg·h·L(-1); P = 0.016) and MPAG area under the curve (569 versus 911 mg·h·L(-1); P = 0.047) when compared with NCF patients.,Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[h·mg] / [l],47.7,154308,DB00635,Prednisone
,24232127,area under the curve,CF patients had significantly lower MPA area under the curve (47.7 versus 83.1 mg·h·L(-1); P = 0.016) and MPAG area under the curve (569 versus 911 mg·h·L(-1); P = 0.047) when compared with NCF patients.,Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[h·mg] / [l],83.1,154309,DB00635,Prednisone
,24232127,area under the curve,CF patients had significantly lower MPA area under the curve (47.7 versus 83.1 mg·h·L(-1); P = 0.016) and MPAG area under the curve (569 versus 911 mg·h·L(-1); P = 0.047) when compared with NCF patients.,Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[h·mg] / [l],569,154310,DB00635,Prednisone
,24232127,area under the curve,CF patients had significantly lower MPA area under the curve (47.7 versus 83.1 mg·h·L(-1); P = 0.016) and MPAG area under the curve (569 versus 911 mg·h·L(-1); P = 0.047) when compared with NCF patients.,Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[h·mg] / [l],911,154311,DB00635,Prednisone
,24232127,C(0),"In addition, C(0) (2.6 versus 4.6 mg/L; P = 0.026) and maximum serum concentration (9.2 versus 20.3 mg/L; P = 0.016) were significantly lower, and apparent oral clearance (0.26 versus 0.13 L·h·kg(-1); P = 0.009) was significantly higher in CF patients.",Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[mg] / [l],2.6,154312,DB00635,Prednisone
,24232127,C(0),"In addition, C(0) (2.6 versus 4.6 mg/L; P = 0.026) and maximum serum concentration (9.2 versus 20.3 mg/L; P = 0.016) were significantly lower, and apparent oral clearance (0.26 versus 0.13 L·h·kg(-1); P = 0.009) was significantly higher in CF patients.",Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[mg] / [l],4.6,154313,DB00635,Prednisone
,24232127,maximum serum concentration,"In addition, C(0) (2.6 versus 4.6 mg/L; P = 0.026) and maximum serum concentration (9.2 versus 20.3 mg/L; P = 0.016) were significantly lower, and apparent oral clearance (0.26 versus 0.13 L·h·kg(-1); P = 0.009) was significantly higher in CF patients.",Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[mg] / [l],9.2,154314,DB00635,Prednisone
,24232127,maximum serum concentration,"In addition, C(0) (2.6 versus 4.6 mg/L; P = 0.026) and maximum serum concentration (9.2 versus 20.3 mg/L; P = 0.016) were significantly lower, and apparent oral clearance (0.26 versus 0.13 L·h·kg(-1); P = 0.009) was significantly higher in CF patients.",Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[mg] / [l],20.3,154315,DB00635,Prednisone
,24232127,apparent oral clearance,"In addition, C(0) (2.6 versus 4.6 mg/L; P = 0.026) and maximum serum concentration (9.2 versus 20.3 mg/L; P = 0.016) were significantly lower, and apparent oral clearance (0.26 versus 0.13 L·h·kg(-1); P = 0.009) was significantly higher in CF patients.",Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[h·l] / [kg],0.26,154316,DB00635,Prednisone
,24232127,apparent oral clearance,"In addition, C(0) (2.6 versus 4.6 mg/L; P = 0.026) and maximum serum concentration (9.2 versus 20.3 mg/L; P = 0.016) were significantly lower, and apparent oral clearance (0.26 versus 0.13 L·h·kg(-1); P = 0.009) was significantly higher in CF patients.",Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[h·l] / [kg],0.13,154317,DB00635,Prednisone
,3152911,First-phase elimination half-lives (t1/2(alpha)),First-phase elimination half-lives (t1/2(alpha)) of MTX and 7-hydroxy-methotrexate (7-OH-MTX) after 21 infusions were 2.7 +/- 0.4 h and 6.5 +/- 1.8 h (mean +/- SD).,High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,2.7,155899,DB00635,Prednisone
,3152911,First-phase elimination half-lives (t1/2(alpha)),First-phase elimination half-lives (t1/2(alpha)) of MTX and 7-hydroxy-methotrexate (7-OH-MTX) after 21 infusions were 2.7 +/- 0.4 h and 6.5 +/- 1.8 h (mean +/- SD).,High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,6.5,155900,DB00635,Prednisone
,3152911,first-phase elimination half-lives (t1/2(alpha],"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,4.2,155901,DB00635,Prednisone
,3152911,first-phase elimination half-lives (t1/2(alpha],"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,9.9,155902,DB00635,Prednisone
,3152911,second-phase elimination half-lives (t1/2(beta)),"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,43,155903,DB00635,Prednisone
,3152911,second-phase elimination half-lives (t1/2(beta)),"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,58,155904,DB00635,Prednisone
,20497746,clearance,"Typical mean value of tacrolimus clearance, estimated by the base model (without covariates), in our population was 1.03 l h-1.",Population pharmacokinetics of tacrolimus in kidney transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20497746/),[l] / [h],1.03,155926,DB00635,Prednisone
,32883831,blood-to-plasma ratio,The blood-to-plasma ratio of PNL was 0.71 with similar red blood cell and unbound-plasma concentrations.,Physiologically Based Pharmacokinetic Modeling Involving Nonlinear Plasma and Tissue Binding: Application to Prednisolone and Prednisone in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32883831/),,0.71,156520,DB00635,Prednisone
,32883831,Plasma protein binding,Plasma protein binding (60%-90%) was related to corticosteroid-binding globulin (CBG) saturation.,Physiologically Based Pharmacokinetic Modeling Involving Nonlinear Plasma and Tissue Binding: Application to Prednisolone and Prednisone in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32883831/),%,60,156521,DB00635,Prednisone
,32883831,equilibrium dissociation constant (K d ),"The equilibrium dissociation constant (K d ) of PNL shared by all tissues was 3.01 ng/ml, with the highest binding in muscle, followed by liver, heart, intestine, and bone and the lowest binding in skin, spleen, fat, kidney, lung, and brain.",Physiologically Based Pharmacokinetic Modeling Involving Nonlinear Plasma and Tissue Binding: Application to Prednisolone and Prednisone in Rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32883831/),[ng] / [ml],3.01,156522,DB00635,Prednisone
,32883831,Clearances,Clearances of CBG-free PNL were 1789 from liver and 191.2 ml/h from kidney.,Physiologically Based Pharmacokinetic Modeling Involving Nonlinear Plasma and Tissue Binding: Application to Prednisolone and Prednisone in Rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32883831/),[ml] / [h],1789,156523,DB00635,Prednisone
,32883831,Clearances,Clearances of CBG-free PNL were 1789 from liver and 191.2 ml/h from kidney.,Physiologically Based Pharmacokinetic Modeling Involving Nonlinear Plasma and Tissue Binding: Application to Prednisolone and Prednisone in Rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32883831/),[ml] / [h],191.2,156524,DB00635,Prednisone
<,20498245,AUC,"Significantly more acute rejections (treated, biopsy-proven including and excluding borderline) occurred in patients with MPA AUC levels<30 mg.h/L compared with those >or=30 mg.h/L at day 5.","The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498245/),[h·mg] / [l],30,156812,DB00635,Prednisone
>,20498245,AUC,"Significantly more acute rejections (treated, biopsy-proven including and excluding borderline) occurred in patients with MPA AUC levels<30 mg.h/L compared with those >or=30 mg.h/L at day 5.","The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498245/),[h·mg] / [l],30,156813,DB00635,Prednisone
,1932610,unbound fraction,The unbound fraction of POH ranged between 3 and 15 per cent from tracer to total concentrations of 2000 micrograms-1.,Prednisone and prednisolone interconversion in the rabbit utilizing unbound concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932610/),%,3 and 15,156863,DB00635,Prednisone
,1932610,total concentrations,The unbound fraction of POH ranged between 3 and 15 per cent from tracer to total concentrations of 2000 micrograms-1.,Prednisone and prednisolone interconversion in the rabbit utilizing unbound concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932610/),1/[μg],2000,156864,DB00635,Prednisone
,1932610,unbound fraction,The unbound fraction of PO ranged between 23 and 34 per cent and appeared nonlinear for four of the rabbits.,Prednisone and prednisolone interconversion in the rabbit utilizing unbound concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932610/),%,23 and 34,156865,DB00635,Prednisone
,1932610,apparent unbound clearances,"The mean apparent unbound clearances of POH ranged from 4.4 to 6.1 lh-1kg-1 and from 4.1 to 5.9 lh-1kg-1 for PO, and were dose-independent for both compounds.",Prednisone and prednisolone interconversion in the rabbit utilizing unbound concentrations. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932610/),1/[lh],4.4 to 6.1,156866,DB00635,Prednisone
,1932610,apparent unbound clearances,"The mean apparent unbound clearances of POH ranged from 4.4 to 6.1 lh-1kg-1 and from 4.1 to 5.9 lh-1kg-1 for PO, and were dose-independent for both compounds.",Prednisone and prednisolone interconversion in the rabbit utilizing unbound concentrations. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932610/),1/[lh],4.1 to 5.9,156867,DB00635,Prednisone
,1932610,available fraction,The available fraction of POH from PO was 50 to 70 per cent and independent of dose.,Prednisone and prednisolone interconversion in the rabbit utilizing unbound concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932610/),%,50 to 70,156868,DB00635,Prednisone
,1932610,available fraction,The available fraction of PO from POH averaged 44 per cent at the low infusion rate decreasing to 16 and 20 per cent at the medium and high infusion rates.,Prednisone and prednisolone interconversion in the rabbit utilizing unbound concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932610/),%,44,156869,DB00635,Prednisone
,1932610,available fraction,The available fraction of PO from POH averaged 44 per cent at the low infusion rate decreasing to 16 and 20 per cent at the medium and high infusion rates.,Prednisone and prednisolone interconversion in the rabbit utilizing unbound concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932610/),%,16,156870,DB00635,Prednisone
,1932610,available fraction,The available fraction of PO from POH averaged 44 per cent at the low infusion rate decreasing to 16 and 20 per cent at the medium and high infusion rates.,Prednisone and prednisolone interconversion in the rabbit utilizing unbound concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932610/),%,20,156871,DB00635,Prednisone
,9156373,time to peak blood concentration,"Mean values for the pharmacokinetic parameters of sirolimus calculated in all dose groups were as follows: time to peak blood concentration, 1.4 +/- 1.2 hours; terminal half-life, 62 +/- 16 hours; oral dose clearance, 208 +/- 95 mL/h/kg; apparent oral steady-state volume of distribution, 12 +/- 5 L/kg; and blood/plasma ratio, 38 +/- 13.",Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156373/),h,1.4,159990,DB00635,Prednisone
,9156373,terminal half-life,"Mean values for the pharmacokinetic parameters of sirolimus calculated in all dose groups were as follows: time to peak blood concentration, 1.4 +/- 1.2 hours; terminal half-life, 62 +/- 16 hours; oral dose clearance, 208 +/- 95 mL/h/kg; apparent oral steady-state volume of distribution, 12 +/- 5 L/kg; and blood/plasma ratio, 38 +/- 13.",Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156373/),h,62,159991,DB00635,Prednisone
,9156373,oral dose clearance,"Mean values for the pharmacokinetic parameters of sirolimus calculated in all dose groups were as follows: time to peak blood concentration, 1.4 +/- 1.2 hours; terminal half-life, 62 +/- 16 hours; oral dose clearance, 208 +/- 95 mL/h/kg; apparent oral steady-state volume of distribution, 12 +/- 5 L/kg; and blood/plasma ratio, 38 +/- 13.",Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156373/),[ml] / [h·kg],208,159992,DB00635,Prednisone
,9156373,apparent oral steady-state volume of distribution,"Mean values for the pharmacokinetic parameters of sirolimus calculated in all dose groups were as follows: time to peak blood concentration, 1.4 +/- 1.2 hours; terminal half-life, 62 +/- 16 hours; oral dose clearance, 208 +/- 95 mL/h/kg; apparent oral steady-state volume of distribution, 12 +/- 5 L/kg; and blood/plasma ratio, 38 +/- 13.",Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156373/),[l] / [kg],12,159993,DB00635,Prednisone
,9156373,blood/plasma ratio,"Mean values for the pharmacokinetic parameters of sirolimus calculated in all dose groups were as follows: time to peak blood concentration, 1.4 +/- 1.2 hours; terminal half-life, 62 +/- 16 hours; oral dose clearance, 208 +/- 95 mL/h/kg; apparent oral steady-state volume of distribution, 12 +/- 5 L/kg; and blood/plasma ratio, 38 +/- 13.",Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156373/),,38,159994,DB00635,Prednisone
,7441495,steady-state levels,Six dogs were given four different zero-order infusions of prednisolone resulting in steady-state levels from 23 to 5884 ng/ml.,Prednisolone clearance at steady state in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7441495/),[ng] / [ml],23 to 5884,160555,DB00635,Prednisone
,7441495,Km,"The conversion of prednisolone to prednisone, defined by the prednisolone/prednisone ratio, exhibited saturable characteristics which, when data for all dogs was fitted to a Michaelis-Menten type equation (r2 = 0.938), gave a Km of 658 ng/ml, i.e., total prednisolone concentration at half-maximal saturation.",Prednisolone clearance at steady state in dogs. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7441495/),[ng] / [ml],658,160556,DB00635,Prednisone
,6374250,half-life,"Pharmacokinetic analysis showed that the half-life of prednisolone was shorter in the anticonvulsant group compared to the controls, based on both total (2.3 +/- 0.4 vs. 3.4 +/- 0.2 hr (SD), P less than 0.01) and unbound (1.7 +/- 0.3 vs. 2.4 +/- 0.2 hr, P less than 0.01) concentrations.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),h,2.3,160807,DB00635,Prednisone
,6374250,half-life,"Pharmacokinetic analysis showed that the half-life of prednisolone was shorter in the anticonvulsant group compared to the controls, based on both total (2.3 +/- 0.4 vs. 3.4 +/- 0.2 hr (SD), P less than 0.01) and unbound (1.7 +/- 0.3 vs. 2.4 +/- 0.2 hr, P less than 0.01) concentrations.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),h,3.4,160808,DB00635,Prednisone
,6374250,unbound,"Pharmacokinetic analysis showed that the half-life of prednisolone was shorter in the anticonvulsant group compared to the controls, based on both total (2.3 +/- 0.4 vs. 3.4 +/- 0.2 hr (SD), P less than 0.01) and unbound (1.7 +/- 0.3 vs. 2.4 +/- 0.2 hr, P less than 0.01) concentrations.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),h,1.7,160809,DB00635,Prednisone
,6374250,unbound,"Pharmacokinetic analysis showed that the half-life of prednisolone was shorter in the anticonvulsant group compared to the controls, based on both total (2.3 +/- 0.4 vs. 3.4 +/- 0.2 hr (SD), P less than 0.01) and unbound (1.7 +/- 0.3 vs. 2.4 +/- 0.2 hr, P less than 0.01) concentrations.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),h,2.4,160810,DB00635,Prednisone
,6374250,Total drug clearance,Total drug clearance was 10.4 +/- 2.8 liters/hr (0.171 +/- 0.087 liters/hr X kg) in the anticonvulsant group versus 7.2 +/- 1.2 liters/hr (0.100 +/- 0.014 liters/hr X kg) in the controls (P less than 0.05).,Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h],10.4,160811,DB00635,Prednisone
,6374250,Total drug clearance,Total drug clearance was 10.4 +/- 2.8 liters/hr (0.171 +/- 0.087 liters/hr X kg) in the anticonvulsant group versus 7.2 +/- 1.2 liters/hr (0.100 +/- 0.014 liters/hr X kg) in the controls (P less than 0.05).,Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h·kg],0.171,160812,DB00635,Prednisone
,6374250,Total drug clearance,Total drug clearance was 10.4 +/- 2.8 liters/hr (0.171 +/- 0.087 liters/hr X kg) in the anticonvulsant group versus 7.2 +/- 1.2 liters/hr (0.100 +/- 0.014 liters/hr X kg) in the controls (P less than 0.05).,Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h],7.2,160813,DB00635,Prednisone
,6374250,Total drug clearance,Total drug clearance was 10.4 +/- 2.8 liters/hr (0.171 +/- 0.087 liters/hr X kg) in the anticonvulsant group versus 7.2 +/- 1.2 liters/hr (0.100 +/- 0.014 liters/hr X kg) in the controls (P less than 0.05).,Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h·kg],0.100,160814,DB00635,Prednisone
,6374250,Unbound prednisolone clearance,"Unbound prednisolone clearance was 57.2 +/- 12.1 versus 46.4 +/- 8.7 liters/hr (P greater than 0.05) and for weight-corrected estimates 0.886 +/- 0.224 liters/hr X kg versus 0.644 +/- 0.115 liters/hr X kg (P less than 0.05) in the two groups, respectively.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h],57.2,160815,DB00635,Prednisone
,6374250,Unbound prednisolone clearance,"Unbound prednisolone clearance was 57.2 +/- 12.1 versus 46.4 +/- 8.7 liters/hr (P greater than 0.05) and for weight-corrected estimates 0.886 +/- 0.224 liters/hr X kg versus 0.644 +/- 0.115 liters/hr X kg (P less than 0.05) in the two groups, respectively.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h],46.4,160816,DB00635,Prednisone
,6374250,Unbound prednisolone clearance,"Unbound prednisolone clearance was 57.2 +/- 12.1 versus 46.4 +/- 8.7 liters/hr (P greater than 0.05) and for weight-corrected estimates 0.886 +/- 0.224 liters/hr X kg versus 0.644 +/- 0.115 liters/hr X kg (P less than 0.05) in the two groups, respectively.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h·kg],0.886,160817,DB00635,Prednisone
,6374250,Unbound prednisolone clearance,"Unbound prednisolone clearance was 57.2 +/- 12.1 versus 46.4 +/- 8.7 liters/hr (P greater than 0.05) and for weight-corrected estimates 0.886 +/- 0.224 liters/hr X kg versus 0.644 +/- 0.115 liters/hr X kg (P less than 0.05) in the two groups, respectively.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h·kg],0.644,160818,DB00635,Prednisone
,30689002,CL,"The population PK parameters for CP were: CL = 3.58 L/h, Vmale = 32.2 L, and Vfemale = 28.7 L.",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),[l] / [h],3.58,161752,DB00635,Prednisone
,30689002,Vmale,"The population PK parameters for CP were: CL = 3.58 L/h, Vmale = 32.2 L, and Vfemale = 28.7 L.",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,32.2,161753,DB00635,Prednisone
,30689002,Vfemale,"The population PK parameters for CP were: CL = 3.58 L/h, Vmale = 32.2 L, and Vfemale = 28.7 L.",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,28.7,161754,DB00635,Prednisone
,30689002,CL,"The population PK parameters for DOXO obtained for the structural model were: CL = 51.1 L/h, Q = 49.6 L/h, V1 = 29.4 L, V2 = 1,130 L (clearances: CL, Q, volumes of distribution: V1, V2).",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),[l] / [h],51.1,161755,DB00635,Prednisone
,30689002,Q,"The population PK parameters for DOXO obtained for the structural model were: CL = 51.1 L/h, Q = 49.6 L/h, V1 = 29.4 L, V2 = 1,130 L (clearances: CL, Q, volumes of distribution: V1, V2).",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),[l] / [h],49.6,161756,DB00635,Prednisone
,30689002,V1,"The population PK parameters for DOXO obtained for the structural model were: CL = 51.1 L/h, Q = 49.6 L/h, V1 = 29.4 L, V2 = 1,130 L (clearances: CL, Q, volumes of distribution: V1, V2).",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,29.4,161757,DB00635,Prednisone
,30689002,V2,"The population PK parameters for DOXO obtained for the structural model were: CL = 51.1 L/h, Q = 49.6 L/h, V1 = 29.4 L, V2 = 1,130 L (clearances: CL, Q, volumes of distribution: V1, V2).",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,"1,130",161758,DB00635,Prednisone
,30689002,V1,VCR increases DOXO V1 from 29.4 L to 57.5 L (p = 0.02).,Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,29.4,161759,DB00635,Prednisone
,30689002,V1,VCR increases DOXO V1 from 29.4 L to 57.5 L (p = 0.02).,Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,57.5,161760,DB00635,Prednisone
,32222808,volume of distribution,"Geometric mean volume of distribution and clearance of acMMAE ranged from 57.3 to 95.6 mL/kg and 12.7 to 18.2 mL/kg/day, respectively.",Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222808/),[ml] / [kg],57.3 to 95.6,163246,DB00635,Prednisone
,32222808,clearance,"Geometric mean volume of distribution and clearance of acMMAE ranged from 57.3 to 95.6 mL/kg and 12.7 to 18.2 mL/kg/day, respectively.",Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222808/),[ml] / [d·kg],12.7 to 18.2,163247,DB00635,Prednisone
,32222808,elimination half-life,acMMAE exhibited multi-exponential decay (elimination half-life ~ 1 week).,Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222808/),week,1,163248,DB00635,Prednisone
,11861442,AUC,"According to ROC analysis, an AUC value of 33.8 mg x h/L for MPA from t(0) to t(12h) (MPA-AUC(0-12)) determined by HPLC had a diagnostic sensitivity of 80% and a diagnostic specificity of 57%.",Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861442/),[h·mg] / [l],33.8,163321,DB00635,Prednisone
,11861442,Emit,The corresponding value of the Emit was 36.1 mg x h/L.,Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861442/),[h·mg] / [l],36.1,163322,DB00635,Prednisone
,8366177,steady-state concentrations,"The steady-state concentrations of AZN observed in these patients ranged from 6 to 583 micrograms/L, and the interday coefficients of variation of the concentration in three randomly selected patients were 38%, 12%, and 4.6%.",Pharmacokinetics of azathioprine after repeated oral and single intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8366177/),[μg] / [l],6 to 583,164031,DB00635,Prednisone
,8366177,TCLor,The frequency distribution pattern of the apparent oral clearance (TCLor) of AZN separates the patients almost equally into poor (TCLor = 0.126 to 4 L/hour.kg) and extensive metabolizers (TCLor = 5 to 12 L/hour.kg).,Pharmacokinetics of azathioprine after repeated oral and single intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8366177/),[l] / [h·kg],0.126 to 4,164032,DB00635,Prednisone
,8366177,TCLor,The frequency distribution pattern of the apparent oral clearance (TCLor) of AZN separates the patients almost equally into poor (TCLor = 0.126 to 4 L/hour.kg) and extensive metabolizers (TCLor = 5 to 12 L/hour.kg).,Pharmacokinetics of azathioprine after repeated oral and single intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8366177/),[l] / [h·kg],5 to 12,164033,DB00635,Prednisone
,8366177,alpha,"The data obtained from the IV administration displayed the two-compartment model characteristics with mean (standard error of the mean) of alpha, beta, Vc, and total body clearance of 15.3 (2)/hour, 2.38 (.64)/hour, 1.05 (.3) L/kg, and 8.12 (1.26) L/hour.kg, respectively.",Pharmacokinetics of azathioprine after repeated oral and single intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8366177/),1/[h],15.3,164034,DB00635,Prednisone
,8366177,total body clearance,"The data obtained from the IV administration displayed the two-compartment model characteristics with mean (standard error of the mean) of alpha, beta, Vc, and total body clearance of 15.3 (2)/hour, 2.38 (.64)/hour, 1.05 (.3) L/kg, and 8.12 (1.26) L/hour.kg, respectively.",Pharmacokinetics of azathioprine after repeated oral and single intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8366177/),[l] / [h·kg],8.12,164035,DB00635,Prednisone
,8820952,peak concentrations,"Pharmacokinetic analysis revealed median peak concentrations of dexverapamil and its metabolite, nor-dexverapamil, of 1.66 mumol/l and 1.58 mumol/l, respectively.",Clinical reversal of multidrug resistance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820952/),[μM] / [l],1.66,165049,DB00635,Prednisone
,8820952,peak concentrations,"Pharmacokinetic analysis revealed median peak concentrations of dexverapamil and its metabolite, nor-dexverapamil, of 1.66 mumol/l and 1.58 mumol/l, respectively.",Clinical reversal of multidrug resistance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820952/),[μM] / [l],1.58,165050,DB00635,Prednisone
,8820952,peak total reversing concentration,"Since both are comparable antagonists, a median peak total reversing concentration of 3.24 mumol/l was achieved.",Clinical reversal of multidrug resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820952/),[μM] / [l],3.24,165051,DB00635,Prednisone
,30737835,AUC0-inf,"Docetaxel concentration with concomitant prednisone (AUC0-inf 2784 ng*h/mL, 95% confidence interval 2436-3183 ng*h/mL) was similar to the concentration of docetaxel monotherapy (AUC0-inf 2647 ng*h/mL, 95% confidence interval 2377-2949 ng*h/mL).",Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: A randomized drug-drug interaction study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30737835/),[h·ng] / [ml],2784,165911,DB00635,Prednisone
,30737835,AUC0-inf,"Docetaxel concentration with concomitant prednisone (AUC0-inf 2784 ng*h/mL, 95% confidence interval 2436-3183 ng*h/mL) was similar to the concentration of docetaxel monotherapy (AUC0-inf 2647 ng*h/mL, 95% confidence interval 2377-2949 ng*h/mL).",Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: A randomized drug-drug interaction study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30737835/),[h·ng] / [ml],2647,165912,DB00635,Prednisone
,20484171,trough concentration,Sirolimus concentrations obtained 3 days after initiation of dronedarone revealed a trough concentration that was increased by more than 3-fold (38.6 ng/mL) from his baseline trough concentration.,Significant sirolimus and dronedarone interaction in a kidney transplant recipient. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20484171/),[ng] / [ml],38.6,168424,DB00635,Prednisone
,20484171,trough concentration,"After sirolimus was held for 6 days, the trough concentration was 7.8 ng/mL.",Significant sirolimus and dronedarone interaction in a kidney transplant recipient. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20484171/),[ng] / [ml],7.8,168425,DB00635,Prednisone
exceeded,7870352,fractional renal clearance,"The fractional renal clearance of unbound prednisolone during the high, but not during the low infusion rate exceeded 1.",Renal handling of prednisolone/prednisone: effect of steroid dose and 11 beta-hydroxysteroid dehydrogenase. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7870352/),,1,171300,DB00635,Prednisone
,1673428,Hepatic extraction,Hepatic extraction of POH averaged 0.49 and that of PO was nearly complete at 0.96.,Prednisolone and prednisone exhibit linear extraction in the perfused rabbit liver. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673428/),,0.49,171380,DB00635,Prednisone
,1673428,Hepatic extraction,Hepatic extraction of POH averaged 0.49 and that of PO was nearly complete at 0.96.,Prednisolone and prednisone exhibit linear extraction in the perfused rabbit liver. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673428/),,0,171381,DB00635,Prednisone
,1673428,apparent hepatic blood clearance,"The apparent hepatic blood clearance of POH was about 16 ml/min and that of PO approximated liver blood flow, at 30 ml/min.",Prednisolone and prednisone exhibit linear extraction in the perfused rabbit liver. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673428/),[ml] / [min],16,171382,DB00635,Prednisone
,1673428,apparent hepatic blood clearance,"The apparent hepatic blood clearance of POH was about 16 ml/min and that of PO approximated liver blood flow, at 30 ml/min.",Prednisolone and prednisone exhibit linear extraction in the perfused rabbit liver. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673428/),[ml] / [min],30,171383,DB00635,Prednisone
,33181621,AUC0-24,"In renal Tx recipients (n = 28), our results indicated a relatively high PL exposure [median, range AUC0-24 = 3821 (2232-5382) mcg h/L], paralleled by strong suppression of endogenous CL profile, demonstrated by a low CL evening-to-morning ratio [median, range 11 (3-47)%].",Prednisolone and Prednisone Pharmacokinetics in Adult Renal Transplant Recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33181621/),[h·mcg] / [l],3821,174699,DB00635,Prednisone
,33181621,evening-to-morning ratio,"In renal Tx recipients (n = 28), our results indicated a relatively high PL exposure [median, range AUC0-24 = 3821 (2232-5382) mcg h/L], paralleled by strong suppression of endogenous CL profile, demonstrated by a low CL evening-to-morning ratio [median, range 11 (3-47)%].",Prednisolone and Prednisone Pharmacokinetics in Adult Renal Transplant Recipients. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33181621/),%,11,174700,DB00635,Prednisone
,8547077,maximum rhIL-3 serum concentration,Following s.c. injection on cycle day 2. the maximum rhIL-3 serum concentration ranged from 289 pg/ml (0.5 micrograms/kg) to 4690 pg/ml (10 micrograms/kg).,Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547077/),[pg] / [ml],289,175451,DB00635,Prednisone
,8547077,maximum rhIL-3 serum concentration,Following s.c. injection on cycle day 2. the maximum rhIL-3 serum concentration ranged from 289 pg/ml (0.5 micrograms/kg) to 4690 pg/ml (10 micrograms/kg).,Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547077/),[pg] / [ml],4690,175452,DB00635,Prednisone
,8547077,elimination half-life T1/2 beta,"The elimination half-life T1/2 beta was 160 min for 0.5 micrograms/kg and 134 min for 10 micrograms/kg, with no apparent dose relationship.",Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547077/),min,160,175453,DB00635,Prednisone
,8547077,elimination half-life T1/2 beta,"The elimination half-life T1/2 beta was 160 min for 0.5 micrograms/kg and 134 min for 10 micrograms/kg, with no apparent dose relationship.",Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547077/),min,134,175454,DB00635,Prednisone
,8547077,systemic clearance,The systemic clearance of 3.0-6.0 ml/min/kg was comparable at all dose levels.,Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547077/),[ml] / [kg·min],3.0-6.0,175455,DB00635,Prednisone
,27862097,progression-free survival,The proportion of men with a ≥30% PSA decline was 63% and the median composite progression-free survival (PFS) was 8.5 months (95% CI 4.2-16.4 months) based on 12 PFS events.,Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27862097/),month,8.5,176460,DB00635,Prednisone
,18348335,m/z,"The ionization was optimized using ESI(-) and selectivity was achieved by MS/MS analysis, m/z 338.0 --> 77.5 and m/z 357.1 --> 327.2 for topiramate and prednisone, respectively.",Determination of plasma topiramate concentration using LC-MS/MS for pharmacokinetic and bioequivalence studies in healthy Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18348335/),,338.0,176998,DB00635,Prednisone
,18348335,m/z,"The ionization was optimized using ESI(-) and selectivity was achieved by MS/MS analysis, m/z 338.0 --> 77.5 and m/z 357.1 --> 327.2 for topiramate and prednisone, respectively.",Determination of plasma topiramate concentration using LC-MS/MS for pharmacokinetic and bioequivalence studies in healthy Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18348335/),,77.5,176999,DB00635,Prednisone
,18348335,m/z,"The ionization was optimized using ESI(-) and selectivity was achieved by MS/MS analysis, m/z 338.0 --> 77.5 and m/z 357.1 --> 327.2 for topiramate and prednisone, respectively.",Determination of plasma topiramate concentration using LC-MS/MS for pharmacokinetic and bioequivalence studies in healthy Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18348335/),,357.1,177000,DB00635,Prednisone
,18348335,m/z,"The ionization was optimized using ESI(-) and selectivity was achieved by MS/MS analysis, m/z 338.0 --> 77.5 and m/z 357.1 --> 327.2 for topiramate and prednisone, respectively.",Determination of plasma topiramate concentration using LC-MS/MS for pharmacokinetic and bioequivalence studies in healthy Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18348335/),,327.2,177001,DB00635,Prednisone
,18348335,total run time,The method had a total run time of 2.5 min and showed good linearity over a working range of 20-5000 ng/mL in human plasma with a lower limit of quantification of 20 ng/mL.,Determination of plasma topiramate concentration using LC-MS/MS for pharmacokinetic and bioequivalence studies in healthy Korean volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18348335/),min,2.5,177002,DB00635,Prednisone
,3356080,renal,"7.7 +/- 1.6 ml/min/kg, mean +/- SD; P less than 0.001) and renal (0.9 +/- 0.3 vs. 2.9 +/- 0.7 ml/min/kg; P less than 0.001) clearances of unbound prednisolone were lower in the elderly.",Kinetics of prednisolone and endogenous cortisol suppression in the elderly. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356080/),[ml] / [kg·min],0.9,177087,DB00635,Prednisone
,3356080,renal,"7.7 +/- 1.6 ml/min/kg, mean +/- SD; P less than 0.001) and renal (0.9 +/- 0.3 vs. 2.9 +/- 0.7 ml/min/kg; P less than 0.001) clearances of unbound prednisolone were lower in the elderly.",Kinetics of prednisolone and endogenous cortisol suppression in the elderly. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356080/),[ml] / [kg·min],2.9,177088,DB00635,Prednisone
≥,30864060,Cmax,Therapeutically effective serum concentrations were estimated to be Cmax ≥ about 2 μg/mL or AUC ≥ about 10 μg h/mL.,"Usefulness of mizoribine administration in children with frequently relapsing nephrotic syndrome, and the relationship between pharmacokinetic parameters and efficacy: a multicenter prospective cohort study in China. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30864060/),[μg] / [ml],2,179433,DB00635,Prednisone
≥,30864060,AUC,Therapeutically effective serum concentrations were estimated to be Cmax ≥ about 2 μg/mL or AUC ≥ about 10 μg h/mL.,"Usefulness of mizoribine administration in children with frequently relapsing nephrotic syndrome, and the relationship between pharmacokinetic parameters and efficacy: a multicenter prospective cohort study in China. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30864060/),[h·μg] / [ml],10,179434,DB00635,Prednisone
,22027711,maximum tolerated dose,The maximum tolerated dose was 250 mg BID of BIBF 1120.,Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22027711/),,250,180564,DB00635,Prednisone
,14632536,AUC,"Drug exposure as evaluated by AUC was 39.95 +/- 44.86, 25.24 +/- 25.68, and 43.96 +/- 38.67 micro g*h/mL during sampling periods 1, 2, and 3, respectively, (p > 0.05).",Mycophenolate pharmacokinetics in early period following lung or heart transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14632536/),[h·μg] / [ml],39.95,182275,DB00635,Prednisone
,14632536,AUC,"Drug exposure as evaluated by AUC was 39.95 +/- 44.86, 25.24 +/- 25.68, and 43.96 +/- 38.67 micro g*h/mL during sampling periods 1, 2, and 3, respectively, (p > 0.05).",Mycophenolate pharmacokinetics in early period following lung or heart transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14632536/),[h·μg] / [ml],25.24,182276,DB00635,Prednisone
,14632536,AUC,"Drug exposure as evaluated by AUC was 39.95 +/- 44.86, 25.24 +/- 25.68, and 43.96 +/- 38.67 micro g*h/mL during sampling periods 1, 2, and 3, respectively, (p > 0.05).",Mycophenolate pharmacokinetics in early period following lung or heart transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14632536/),[h·μg] / [ml],43.96,182277,DB00635,Prednisone
,26686828,relative recoveries,The method was validated over a concentration range of 0.1-100ng/mL for all the three analytes with relative recoveries ranging from 69 to 82%.,"A high throughput flow gradient LC-MS/MS method for simultaneous determination of fingolimod, fampridine and prednisone in rat plasma, application to in vivo perfusion study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26686828/),%,69 to 82,183278,DB00635,Prednisone
≥,31790556,AUC24/MIC,An AUC24/MIC of ≥125 was defined as target ratio.,Population Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Prophylaxis in Pediatric Acute Lymphoblastic Leukemia Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31790556/),,125,186070,DB00635,Prednisone
,31790556,AUC24,Ciprofloxacin AUC24 was 16.9 mg*h/L in the prednisone prophase versus 29.3 mg*h/L with concomitant chemotherapy.,Population Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Prophylaxis in Pediatric Acute Lymphoblastic Leukemia Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31790556/),[h·mg] / [l],16.9,186071,DB00635,Prednisone
,31790556,AUC24,Ciprofloxacin AUC24 was 16.9 mg*h/L in the prednisone prophase versus 29.3 mg*h/L with concomitant chemotherapy.,Population Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Prophylaxis in Pediatric Acute Lymphoblastic Leukemia Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31790556/),[h·mg] / [l],29.3,186072,DB00635,Prednisone
,31790556,MIC,"Overall, 100%, 81%, and 18% of patients at, respectively, MIC of 0.063, 0.125, and 0.25 mg/L achieved AUC24/MIC ≥ 125.",Population Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Prophylaxis in Pediatric Acute Lymphoblastic Leukemia Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31790556/),[mg] / [l],0.063,186073,DB00635,Prednisone
,31790556,MIC,"Overall, 100%, 81%, and 18% of patients at, respectively, MIC of 0.063, 0.125, and 0.25 mg/L achieved AUC24/MIC ≥ 125.",Population Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Prophylaxis in Pediatric Acute Lymphoblastic Leukemia Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31790556/),[mg] / [l],0.125,186074,DB00635,Prednisone
,31790556,MIC,"Overall, 100%, 81%, and 18% of patients at, respectively, MIC of 0.063, 0.125, and 0.25 mg/L achieved AUC24/MIC ≥ 125.",Population Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Prophylaxis in Pediatric Acute Lymphoblastic Leukemia Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31790556/),[mg] / [l],0.25,186075,DB00635,Prednisone
≥,31790556,AUC24/MIC,"Overall, 100%, 81%, and 18% of patients at, respectively, MIC of 0.063, 0.125, and 0.25 mg/L achieved AUC24/MIC ≥ 125.",Population Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Prophylaxis in Pediatric Acute Lymphoblastic Leukemia Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31790556/),,125,186076,DB00635,Prednisone
,14756266,AUC(0-8),"The concomitant administration of daclizumab and MMF had no effect on the pharmacokinetics of MPA: AUC(0-8) values (microg h/mL +/- SD) on day 28 were 30.1 +/- 13.3 for daclizumab-treat patients vs. 31.1 +/- 12.4 for placebo and on day 56, 37.7 +/- 18.2 for daclizumab-treated patients vs. 35.7 +/- 14.0 for placebo.",Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756266/),[h·μg] / [ml],30.1,186660,DB00635,Prednisone
,14756266,AUC(0-8),"The concomitant administration of daclizumab and MMF had no effect on the pharmacokinetics of MPA: AUC(0-8) values (microg h/mL +/- SD) on day 28 were 30.1 +/- 13.3 for daclizumab-treat patients vs. 31.1 +/- 12.4 for placebo and on day 56, 37.7 +/- 18.2 for daclizumab-treated patients vs. 35.7 +/- 14.0 for placebo.",Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756266/),[h·μg] / [ml],31.1,186661,DB00635,Prednisone
,14756266,AUC(0-8),"The concomitant administration of daclizumab and MMF had no effect on the pharmacokinetics of MPA: AUC(0-8) values (microg h/mL +/- SD) on day 28 were 30.1 +/- 13.3 for daclizumab-treat patients vs. 31.1 +/- 12.4 for placebo and on day 56, 37.7 +/- 18.2 for daclizumab-treated patients vs. 35.7 +/- 14.0 for placebo.",Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756266/),[h·μg] / [ml],37.7,186662,DB00635,Prednisone
,14756266,AUC(0-8),"The concomitant administration of daclizumab and MMF had no effect on the pharmacokinetics of MPA: AUC(0-8) values (microg h/mL +/- SD) on day 28 were 30.1 +/- 13.3 for daclizumab-treat patients vs. 31.1 +/- 12.4 for placebo and on day 56, 37.7 +/- 18.2 for daclizumab-treated patients vs. 35.7 +/- 14.0 for placebo.",Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756266/),[h·μg] / [ml],35.7,186663,DB00635,Prednisone
,9646011,elimination half-life,Peak concentration in serum is reached after 1 to 2 hours and the elimination half-life is between 1 and 3 hours.,Pharmacokinetic optimisation of the treatment of neurocysticercosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646011/),h,1 and 3,187764,DB00635,Prednisone
,9646011,half-life,Concentrations of ALBSO are highly variable between individuals and it has a half-life of between 6 and 15 hours.,Pharmacokinetic optimisation of the treatment of neurocysticercosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646011/),h,6 and 15,187765,DB00635,Prednisone
<,17154474,Mw,Amphiphilic chitosan-based polymers (Mw < 20 kDa) self-assemble in aqueous media at low micromolar concentrations to give previously unknown micellar clusters of 100-300 nm in size.,Carbohydrate-based micelle clusters which enhance hydrophobic drug bioavailability by up to 1 order of magnitude. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17154474/),kda,20,190969,DB00635,Prednisone
,9832298,systemic clearance,"During the acute phase, the systemic clearance of methylprednisolone was 0.98 (1 kg(-1) x h(-1)) and the elimination half-life was 1.67 h.",Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832298/),[1] / [h·kg],0.98,191717,DB00635,Prednisone
,9832298,elimination half-life,"During the acute phase, the systemic clearance of methylprednisolone was 0.98 (1 kg(-1) x h(-1)) and the elimination half-life was 1.67 h.",Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832298/),h,1.67,191718,DB00635,Prednisone
,9832298,area under the plasma concentration-versus-time curve,"The area under the plasma concentration-versus-time curve of prednisolone was 4.00 and 3.20 x mg x h x l(-1) respectively during the active disease and remission, while its elimination half-life was 3.51 h during the acute phase and 2.42 h in remission.",Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832298/),[h·mg] / [l],4.00,191719,DB00635,Prednisone
,9832298,area under the plasma concentration-versus-time curve,"The area under the plasma concentration-versus-time curve of prednisolone was 4.00 and 3.20 x mg x h x l(-1) respectively during the active disease and remission, while its elimination half-life was 3.51 h during the acute phase and 2.42 h in remission.",Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832298/),[h·mg] / [l],3.20,191720,DB00635,Prednisone
,9832298,elimination half-life,"The area under the plasma concentration-versus-time curve of prednisolone was 4.00 and 3.20 x mg x h x l(-1) respectively during the active disease and remission, while its elimination half-life was 3.51 h during the acute phase and 2.42 h in remission.",Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832298/),h,3.51,191721,DB00635,Prednisone
,9832298,elimination half-life,"The area under the plasma concentration-versus-time curve of prednisolone was 4.00 and 3.20 x mg x h x l(-1) respectively during the active disease and remission, while its elimination half-life was 3.51 h during the acute phase and 2.42 h in remission.",Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832298/),h,2.42,191722,DB00635,Prednisone
,32915419,maximum tolerated dose,The maximum tolerated dose was 75 mg in F1 and 100 mg in F2.,Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915419/),mg,75,192506,DB00635,Prednisone
,32915419,maximum tolerated dose,The maximum tolerated dose was 75 mg in F1 and 100 mg in F2.,Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32915419/),,100,192507,DB00635,Prednisone
,2897213,volume of distribution,"When given alone, metronidazole had a mean volume of distribution of 0.667 +/- 0.15 lkg-1, a half-life of 9.7 +/- 3.1 h and an oral clearance of 0.852 +/- 0.23 (ml-1 min) kg-1.","Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn's disease. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897213/),1/[lkg],0.667,192515,DB00635,Prednisone
,2897213,half-life,"When given alone, metronidazole had a mean volume of distribution of 0.667 +/- 0.15 lkg-1, a half-life of 9.7 +/- 3.1 h and an oral clearance of 0.852 +/- 0.23 (ml-1 min) kg-1.","Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn's disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897213/),h,9.7,192516,DB00635,Prednisone
,2897213,oral clearance,"When given alone, metronidazole had a mean volume of distribution of 0.667 +/- 0.15 lkg-1, a half-life of 9.7 +/- 3.1 h and an oral clearance of 0.852 +/- 0.23 (ml-1 min) kg-1.","Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn's disease. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897213/),[min] / [kg·ml],0.852,192517,DB00635,Prednisone
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,6.1,192732,DB00635,Prednisone
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,7.1,192733,DB00635,Prednisone
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,26.5,192734,DB00635,Prednisone
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,16.7,192735,DB00635,Prednisone
,34287102,metabolic ratio,"M1 metabolic ratio (0.12) was 2-fold reduced, M2 metabolic ratio (197) 1000-fold increased and M5 metabolic ratio (0.12) normal.",Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),,0.12,192736,DB00635,Prednisone
,34287102,metabolic ratio,"M1 metabolic ratio (0.12) was 2-fold reduced, M2 metabolic ratio (197) 1000-fold increased and M5 metabolic ratio (0.12) normal.",Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),,197,192737,DB00635,Prednisone
,17921190,EC(50),"An exposure-response relationship was demonstrated, with an estimated EC(50) of 391 nM (total) and 17 nM (free).","Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11 -hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921190/),nM,391,193001,DB00635,Prednisone
,17921190,EC(50),"An exposure-response relationship was demonstrated, with an estimated EC(50) of 391 nM (total) and 17 nM (free).","Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11 -hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921190/),nM,17,193002,DB00635,Prednisone
,15012174,half-life stabilization time,"In the final model, the Dmax parameter is affected by plasmatic urea values and shows a half-life stabilization time of 90.90 days (95% CI: 52.60 to 250 days).",[Cyclosporin pharmacokinetic modeling in renal transplant patients]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15012174/),d,90.90,194572,DB00635,Prednisone
,15012174,Dmax,"Plasmatic urea values of 50 mg/dL are related to an initial Dmax value of 3 mg/kg daily (95% CI: 1.81 to 4.19 mg/kg daily) which decreases exponentially throughout the post-transplant period until it reaches a constant value of 2.16 mg/kg daily (95% CI: 1.41 to 2.91 mg/kg daily) In the same way, the Km parameter presents a central tendency value of 93.60 ng/mL (95% CI: 28.60 to 158.60 ng/mL) and the half-life necessary for its stabilization is 12.70 days (95% CI: 9.80 to 17.90 days).",[Cyclosporin pharmacokinetic modeling in renal transplant patients]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15012174/),[mg] / [kg],3,194573,DB00635,Prednisone
,15012174,Km,"Plasmatic urea values of 50 mg/dL are related to an initial Dmax value of 3 mg/kg daily (95% CI: 1.81 to 4.19 mg/kg daily) which decreases exponentially throughout the post-transplant period until it reaches a constant value of 2.16 mg/kg daily (95% CI: 1.41 to 2.91 mg/kg daily) In the same way, the Km parameter presents a central tendency value of 93.60 ng/mL (95% CI: 28.60 to 158.60 ng/mL) and the half-life necessary for its stabilization is 12.70 days (95% CI: 9.80 to 17.90 days).",[Cyclosporin pharmacokinetic modeling in renal transplant patients]. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15012174/),[ng] / [ml],93.60,194574,DB00635,Prednisone
,15012174,half-life,"Plasmatic urea values of 50 mg/dL are related to an initial Dmax value of 3 mg/kg daily (95% CI: 1.81 to 4.19 mg/kg daily) which decreases exponentially throughout the post-transplant period until it reaches a constant value of 2.16 mg/kg daily (95% CI: 1.41 to 2.91 mg/kg daily) In the same way, the Km parameter presents a central tendency value of 93.60 ng/mL (95% CI: 28.60 to 158.60 ng/mL) and the half-life necessary for its stabilization is 12.70 days (95% CI: 9.80 to 17.90 days).",[Cyclosporin pharmacokinetic modeling in renal transplant patients]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15012174/),d,12.70,194575,DB00635,Prednisone
greater,21695772,area under the plasma concentration-time curve from 0 to 12 hours (AUC(0-12) ),The aim of this study was to determine the MMF dosage required for pediatric liver transplant recipients to achieve an area under the plasma concentration-time curve from 0 to 12 hours (AUC(0-12) ) for mycophenolic acid (MPA) greater than 30 mg hour/L.,Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695772/),[h·mg] / [l],30,194863,DB00635,Prednisone
less,21695772,AUC(0-12),Thirteen of the 15 patients had an MPA AUC(0-12) value less than 30 mg hour/L.,Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695772/),[h·mg] / [l],30,194864,DB00635,Prednisone
greater,21695772,AUC(0-12),The MMF dosage required to reach an MPA AUC(0-12) value greater than the defined target of 30 mg hour/L ranged from 371 to 1014 mg/m(2) /day.,Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695772/),[h·mg] / [l],30,194865,DB00635,Prednisone
,21695772,AUC(0-12),The MMF dosage required to reach an MPA AUC(0-12) value greater than the defined target of 30 mg hour/L ranged from 371 to 1014 mg/m(2) /day.,Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695772/),[mg] / [·d·m(2)],371 to 1014,194866,DB00635,Prednisone
greater,21695772,AUC(0-12),"In conclusion, an initial MMF dose of 600 mg/m(2) twice a day led to MPA AUC(0-12) values greater than the 30 mg hour/L threshold except when rifampin was coadministered.",Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695772/),[h·mg] / [l],30,194867,DB00635,Prednisone
,27798513,trough level (Ctrough,"Patients received EVL (target trough level (Ctrough, 3-8 ng/mL), prednisone, and tacrolimus (TCL) (target Ctrough, 2-5 ng/mL).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],3-8,195366,DB00635,Prednisone
,27798513,Ctrough,"Patients received EVL (target trough level (Ctrough, 3-8 ng/mL), prednisone, and tacrolimus (TCL) (target Ctrough, 2-5 ng/mL).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],2-5,195367,DB00635,Prednisone
,27798513,TCL-Ctrough,"Mean TCL-Ctrough was 7.2 ± 3.8, 4.9 ± 2.2, 4.9 ± 2.2, and 4.5 ± 1.2 ng/mL at PK1, PK2, PK3, and PK4, respectively.",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],7.2,195368,DB00635,Prednisone
,27798513,TCL-Ctrough,"Mean TCL-Ctrough was 7.2 ± 3.8, 4.9 ± 2.2, 4.9 ± 2.2, and 4.5 ± 1.2 ng/mL at PK1, PK2, PK3, and PK4, respectively.",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],4.9,195369,DB00635,Prednisone
,27798513,TCL-Ctrough,"Mean TCL-Ctrough was 7.2 ± 3.8, 4.9 ± 2.2, 4.9 ± 2.2, and 4.5 ± 1.2 ng/mL at PK1, PK2, PK3, and PK4, respectively.",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],4.5,195370,DB00635,Prednisone
,27798513,Ctrough,"There were no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 ± 1.3 mg/d), Ctrough (4.7 ± 2.5 ng/mL), AUC0-12h (106 ± 51 ng/h per mL), Caverage (8.8 ± 4.2 ng/mL), Cmax (19.2 ± 9.7 ng/mL), apparent Half-life (11.7 ± 4.2 hours), estimated total body clearance (0.39 ± 0.27 L/h), or fluctuation (166 ± 65%).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],4.7,195371,DB00635,Prednisone
,27798513,AUC0-12h,"There were no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 ± 1.3 mg/d), Ctrough (4.7 ± 2.5 ng/mL), AUC0-12h (106 ± 51 ng/h per mL), Caverage (8.8 ± 4.2 ng/mL), Cmax (19.2 ± 9.7 ng/mL), apparent Half-life (11.7 ± 4.2 hours), estimated total body clearance (0.39 ± 0.27 L/h), or fluctuation (166 ± 65%).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [h·ml],106,195372,DB00635,Prednisone
,27798513,Caverage,"There were no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 ± 1.3 mg/d), Ctrough (4.7 ± 2.5 ng/mL), AUC0-12h (106 ± 51 ng/h per mL), Caverage (8.8 ± 4.2 ng/mL), Cmax (19.2 ± 9.7 ng/mL), apparent Half-life (11.7 ± 4.2 hours), estimated total body clearance (0.39 ± 0.27 L/h), or fluctuation (166 ± 65%).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],8.8,195373,DB00635,Prednisone
,27798513,Cmax,"There were no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 ± 1.3 mg/d), Ctrough (4.7 ± 2.5 ng/mL), AUC0-12h (106 ± 51 ng/h per mL), Caverage (8.8 ± 4.2 ng/mL), Cmax (19.2 ± 9.7 ng/mL), apparent Half-life (11.7 ± 4.2 hours), estimated total body clearance (0.39 ± 0.27 L/h), or fluctuation (166 ± 65%).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],19.2,195374,DB00635,Prednisone
,27798513,apparent Half-life,"There were no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 ± 1.3 mg/d), Ctrough (4.7 ± 2.5 ng/mL), AUC0-12h (106 ± 51 ng/h per mL), Caverage (8.8 ± 4.2 ng/mL), Cmax (19.2 ± 9.7 ng/mL), apparent Half-life (11.7 ± 4.2 hours), estimated total body clearance (0.39 ± 0.27 L/h), or fluctuation (166 ± 65%).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),h,11.7,195375,DB00635,Prednisone
,27798513,total body clearance,"There were no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 ± 1.3 mg/d), Ctrough (4.7 ± 2.5 ng/mL), AUC0-12h (106 ± 51 ng/h per mL), Caverage (8.8 ± 4.2 ng/mL), Cmax (19.2 ± 9.7 ng/mL), apparent Half-life (11.7 ± 4.2 hours), estimated total body clearance (0.39 ± 0.27 L/h), or fluctuation (166 ± 65%).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[l] / [h],0.39,195376,DB00635,Prednisone
,1938000,AUC,"In responder patients, PO AUC values were 6,225.5 +/- 575.5 ngh/ml, range 3,933-9,080.5 on day 1 and 5,687 +/- 535 ngh/ml, range 4,513.5-9,828.5 on day Y.",Pharmacokinetics of prednisone and prednisolone in bullous pemphigoid patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1938000/),[ngh] / [ml],"6,225.5",196103,DB00635,Prednisone
,1938000,AUC,"In responder patients, PO AUC values were 6,225.5 +/- 575.5 ngh/ml, range 3,933-9,080.5 on day 1 and 5,687 +/- 535 ngh/ml, range 4,513.5-9,828.5 on day Y.",Pharmacokinetics of prednisone and prednisolone in bullous pemphigoid patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1938000/),[ngh] / [ml],"5,687",196104,DB00635,Prednisone
,3179172,whole body clearance,Concomitant prednisone therapy did not increase the whole body clearance of single doses of salicylate in these subjects (0.0275 +/- 0.08 l kg-1 h-1 before prednisone; 0.0247 +/- 0.03 l kg-1 h-1 during prednisone therapy; P greater than 0.05).,Interaction of salicylate and corticosteroids in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179172/),[l] / [h·kg],0.0275,196137,DB00635,Prednisone
,3179172,whole body clearance,Concomitant prednisone therapy did not increase the whole body clearance of single doses of salicylate in these subjects (0.0275 +/- 0.08 l kg-1 h-1 before prednisone; 0.0247 +/- 0.03 l kg-1 h-1 during prednisone therapy; P greater than 0.05).,Interaction of salicylate and corticosteroids in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179172/),[l] / [h·kg],0.0247,196138,DB00635,Prednisone
,31497882,objective response rate,The objective response rate was 31%; median PFS was 14.1 months (95% confidence interval [CI]: 7.1 and 22.2); and OS was 18.6 months (95% CI: 11.8 and 22.2).,"Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31497882/),%,31,196141,DB00635,Prednisone
,31497882,PFS,The objective response rate was 31%; median PFS was 14.1 months (95% confidence interval [CI]: 7.1 and 22.2); and OS was 18.6 months (95% CI: 11.8 and 22.2).,"Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31497882/),month,14.1,196142,DB00635,Prednisone
,31497882,OS,The objective response rate was 31%; median PFS was 14.1 months (95% confidence interval [CI]: 7.1 and 22.2); and OS was 18.6 months (95% CI: 11.8 and 22.2).,"Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31497882/),month,18.6,196143,DB00635,Prednisone
,7310640,oral dose plasma clearances,The mean oral dose plasma clearances of prednisone ranged from 572 ml/min/1.73 m 2 for the 5 mg dose to 2271 ml/min/1.73 m 2 for the 50 mg dose.,Dose dependent pharmacokinetics of prednisone and prednisolone in man. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7310640/),[ml] / [1.73·2·m·min],572,196705,DB00635,Prednisone
,7310640,oral dose plasma clearances,The mean oral dose plasma clearances of prednisone ranged from 572 ml/min/1.73 m 2 for the 5 mg dose to 2271 ml/min/1.73 m 2 for the 50 mg dose.,Dose dependent pharmacokinetics of prednisone and prednisolone in man. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7310640/),[ml] / [1.73·2·m·min],2271,196706,DB00635,Prednisone
,7310640,systemic plasma clearance,The systemic plasma clearance of i.v. prednisolone was dose-dependent and increased from 111 to 194 ml/min/1.73 m 2 over the 5 to 40 mg i.v. dosage range.,Dose dependent pharmacokinetics of prednisone and prednisolone in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7310640/),[ml] / [1.73·2·m·min],111 to 194,196707,DB00635,Prednisone
,9428817,serum half-life,"The serum half-life of daclizumab was 20 days, and its administration resulted in prolonged saturation of interleukin-2alpha receptors on circulating lymphocytes.",Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428817/),d,20,198235,DB00635,Prednisone
,429520,MCR2,"In subjects with normal gastrointestinal function, MCR0 was consistently lower than MCR2 (mean MCR2 = 0.175 liters/h.kg; MCR0 = 0.145 liters/h.kg).","Studies comparing the metabolic clearance rate of 11 beta,17,21-trihydroxypregn-1,4-diene-3,20-dione (prednisolone) after oral 17,21-dihydroxypregn-1,4-diene-3,11,20-trione and intravenous prednisolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/429520/),[l] / [h·kg],0.175,199453,DB00635,Prednisone
,429520,MCR0,"In subjects with normal gastrointestinal function, MCR0 was consistently lower than MCR2 (mean MCR2 = 0.175 liters/h.kg; MCR0 = 0.145 liters/h.kg).","Studies comparing the metabolic clearance rate of 11 beta,17,21-trihydroxypregn-1,4-diene-3,20-dione (prednisolone) after oral 17,21-dihydroxypregn-1,4-diene-3,11,20-trione and intravenous prednisolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/429520/),[l] / [h·kg],0.145,199454,DB00635,Prednisone
,28039155,progression-free survival,Median PSA-progression-free survival was 6.9 months (95% CI: 4.1-10.3 months).,Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28039155/),month,6.9,200333,DB00635,Prednisone
,27329361,volume of distribution of central compartment,"The volume of distribution of central compartment and clearance of Reditux™ were estimated at 0.95 L and 5.98 mL/h, respectively.","Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27329361/),l,0.95,200467,DB00635,Prednisone
,27329361,clearance of Reditux™,"The volume of distribution of central compartment and clearance of Reditux™ were estimated at 0.95 L and 5.98 mL/h, respectively.","Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27329361/),[ml] / [h],5.98,200468,DB00635,Prednisone
,27154915,overall response rate (ORR),"Among patients receiving the MTD (n = 38), the overall response rate (ORR) was 84% (n = 32), including 24% (n = 9) with complete response; the ORR was 100% for patients with indolent lymphoma (n = 27) and 57% for those with aggressive histology lymphoma (n = 21).",Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27154915/),%,84,202921,DB00635,Prednisone
,27154915,overall response rate (ORR),"Among patients receiving the MTD (n = 38), the overall response rate (ORR) was 84% (n = 32), including 24% (n = 9) with complete response; the ORR was 100% for patients with indolent lymphoma (n = 27) and 57% for those with aggressive histology lymphoma (n = 21).",Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27154915/),%,24,202922,DB00635,Prednisone
,27154915,ORR,"Among patients receiving the MTD (n = 38), the overall response rate (ORR) was 84% (n = 32), including 24% (n = 9) with complete response; the ORR was 100% for patients with indolent lymphoma (n = 27) and 57% for those with aggressive histology lymphoma (n = 21).",Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27154915/),,100,202923,DB00635,Prednisone
,27154915,ORR,"Among patients receiving the MTD (n = 38), the overall response rate (ORR) was 84% (n = 32), including 24% (n = 9) with complete response; the ORR was 100% for patients with indolent lymphoma (n = 27) and 57% for those with aggressive histology lymphoma (n = 21).",Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27154915/),,57,202924,DB00635,Prednisone
,11187897,MTD,The MTD of cinchonine administered by continuous i.v. infusion was 30 mg/kg/d.,"Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11187897/),[mg] / [d·kg],30,204899,DB00635,Prednisone
,20555126,Trough levels,"Trough levels of 4 patients on three-monthly schedule maintenance therapy remained constant, with a median concentration of 6 mu g/mL (range 0.5-11.7 microg/mL).",Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20555126/),[g·mu] / [ml],6,204913,DB00635,Prednisone
,20555126,elimination half-life at steady state,"The elimination half-life at steady state of rituximab in all patients was estimated to be 19.2 (+/- 15.2%) days with a between-subject variability of 54%, indicating wide variability.",Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20555126/),d,19.2,204914,DB00635,Prednisone
,3883592,peak concentrations,"The mean (+/- SD) peak concentrations of unbound prednisolone were higher after i.v. prednisolone phosphate (18.5 +/- 3.4 micrograms/ml) than after i.v. prednisolone phthalate (2.9 +/- 0.5 micrograms/ml) or after oral prednisone (3.1 +/- 0.8 micrograms/ml), (P less than 0.001).",Pharmacokinetics of 3 prednisolone prodrugs. Evidence of therapeutic inequivalence in renal transplant patients with rejection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3883592/),[μg] / [ml],18.5,206638,DB00635,Prednisone
,3883592,peak concentrations,"The mean (+/- SD) peak concentrations of unbound prednisolone were higher after i.v. prednisolone phosphate (18.5 +/- 3.4 micrograms/ml) than after i.v. prednisolone phthalate (2.9 +/- 0.5 micrograms/ml) or after oral prednisone (3.1 +/- 0.8 micrograms/ml), (P less than 0.001).",Pharmacokinetics of 3 prednisolone prodrugs. Evidence of therapeutic inequivalence in renal transplant patients with rejection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3883592/),[μg] / [ml],2.9,206639,DB00635,Prednisone
,3883592,peak concentrations,"The mean (+/- SD) peak concentrations of unbound prednisolone were higher after i.v. prednisolone phosphate (18.5 +/- 3.4 micrograms/ml) than after i.v. prednisolone phthalate (2.9 +/- 0.5 micrograms/ml) or after oral prednisone (3.1 +/- 0.8 micrograms/ml), (P less than 0.001).",Pharmacokinetics of 3 prednisolone prodrugs. Evidence of therapeutic inequivalence in renal transplant patients with rejection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3883592/),[μg] / [ml],3.1,206640,DB00635,Prednisone
,3883592,AUCs,"The mean AUCs of unbound prednisolone were 2324 +/- 683 micrograms/ml/min from prednisolone phosphate, 1209 +/- 324 micrograms/ml/min from prednisolone phthalate, and 1584 +/- 556 micrograms/ml/min from oral prednisone.",Pharmacokinetics of 3 prednisolone prodrugs. Evidence of therapeutic inequivalence in renal transplant patients with rejection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3883592/),[μg] / [min·ml],2324,206641,DB00635,Prednisone
,3883592,AUCs,"The mean AUCs of unbound prednisolone were 2324 +/- 683 micrograms/ml/min from prednisolone phosphate, 1209 +/- 324 micrograms/ml/min from prednisolone phthalate, and 1584 +/- 556 micrograms/ml/min from oral prednisone.",Pharmacokinetics of 3 prednisolone prodrugs. Evidence of therapeutic inequivalence in renal transplant patients with rejection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3883592/),[μg] / [min·ml],1209,206642,DB00635,Prednisone
,3883592,AUCs,"The mean AUCs of unbound prednisolone were 2324 +/- 683 micrograms/ml/min from prednisolone phosphate, 1209 +/- 324 micrograms/ml/min from prednisolone phthalate, and 1584 +/- 556 micrograms/ml/min from oral prednisone.",Pharmacokinetics of 3 prednisolone prodrugs. Evidence of therapeutic inequivalence in renal transplant patients with rejection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3883592/),[μg] / [min·ml],1584,206643,DB00635,Prednisone
,2898348,area under the blood concentration versus time curve,The mean area under the blood concentration versus time curve of CyA (HPLC measurements) was lower in pigs than in humans after oral (67 +/- 31 micrograms/ml x min vs. 296 +/- 101 micrograms/ml x min) and after iv (358 +/- 71 micrograms/ml x min vs. 858 +/- 292 micrograms/ml x min) doses of CyA.,Marked interspecies differences between humans and pigs in cyclosporine and prednisolone disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898348/),[μg] / [min·ml],67,207360,DB00635,Prednisone
,2898348,area under the blood concentration versus time curve,The mean area under the blood concentration versus time curve of CyA (HPLC measurements) was lower in pigs than in humans after oral (67 +/- 31 micrograms/ml x min vs. 296 +/- 101 micrograms/ml x min) and after iv (358 +/- 71 micrograms/ml x min vs. 858 +/- 292 micrograms/ml x min) doses of CyA.,Marked interspecies differences between humans and pigs in cyclosporine and prednisolone disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898348/),[μg] / [min·ml],296,207361,DB00635,Prednisone
,2898348,area under the blood concentration versus time curve,The mean area under the blood concentration versus time curve of CyA (HPLC measurements) was lower in pigs than in humans after oral (67 +/- 31 micrograms/ml x min vs. 296 +/- 101 micrograms/ml x min) and after iv (358 +/- 71 micrograms/ml x min vs. 858 +/- 292 micrograms/ml x min) doses of CyA.,Marked interspecies differences between humans and pigs in cyclosporine and prednisolone disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898348/),[μg] / [min·ml],358,207362,DB00635,Prednisone
,2898348,area under the blood concentration versus time curve,The mean area under the blood concentration versus time curve of CyA (HPLC measurements) was lower in pigs than in humans after oral (67 +/- 31 micrograms/ml x min vs. 296 +/- 101 micrograms/ml x min) and after iv (358 +/- 71 micrograms/ml x min vs. 858 +/- 292 micrograms/ml x min) doses of CyA.,Marked interspecies differences between humans and pigs in cyclosporine and prednisolone disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898348/),[μg] / [min·ml],858,207363,DB00635,Prednisone
,16387090,AUC12,"In 16 patients, AUC12 values were within the range of 44.40 ng x h/mL to 158.01 ng x h/mL (mean = 92.23 +/- 34.97 ng x h/mL).",Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16387090/),[h·ng] / [ml],44.40,209031,DB00635,Prednisone
,16387090,AUC12,"In 16 patients, AUC12 values were within the range of 44.40 ng x h/mL to 158.01 ng x h/mL (mean = 92.23 +/- 34.97 ng x h/mL).",Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16387090/),[h·ng] / [ml],158.01,209032,DB00635,Prednisone
,16387090,AUC12,"In 16 patients, AUC12 values were within the range of 44.40 ng x h/mL to 158.01 ng x h/mL (mean = 92.23 +/- 34.97 ng x h/mL).",Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16387090/),[h·ng] / [ml],92.23,209033,DB00635,Prednisone
,9085328,Peak concentration,"Peak concentration was significantly higher with liquid prednisolone (mean +/- SD 430.3 +/- 62.5 vs 333.0 +/- 27.8 ng/ml, p = 0.013), with similar times to peak concentration.",A pharmacokinetic comparison of two oral liquid glucocorticoid formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9085328/),[ng] / [ml],430.3,214051,DB00635,Prednisone
,9085328,Peak concentration,"Peak concentration was significantly higher with liquid prednisolone (mean +/- SD 430.3 +/- 62.5 vs 333.0 +/- 27.8 ng/ml, p = 0.013), with similar times to peak concentration.",A pharmacokinetic comparison of two oral liquid glucocorticoid formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9085328/),[ng] / [ml],333.0,214052,DB00635,Prednisone
,9085328,total area under the curve,"Prednisolone liquid gave higher concentrations at every time point (statistically significant for all except 0.25 hrs after the dose), resulting in a significantly greater total area under the curve (2029.8 +/- 246.9 vs 1633.3 +/- 221.1 ng/ml.hour, respectively, p = 0.002).",A pharmacokinetic comparison of two oral liquid glucocorticoid formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9085328/),[ng] / [h·ml],2029.8,214053,DB00635,Prednisone
,9085328,total area under the curve,"Prednisolone liquid gave higher concentrations at every time point (statistically significant for all except 0.25 hrs after the dose), resulting in a significantly greater total area under the curve (2029.8 +/- 246.9 vs 1633.3 +/- 221.1 ng/ml.hour, respectively, p = 0.002).",A pharmacokinetic comparison of two oral liquid glucocorticoid formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9085328/),[ng] / [h·ml],1633.3,214054,DB00635,Prednisone
,9085328,Clearance,"Clearance was slower for prednisolone (128.3 +/- 15.1 vs 149.1 +/- 17.6 ml/min/1.73 m2, p = 0.01), and the relative bioavailability of the prednisolone liquid using prednisone liquid as the reference standard was 116 +/- 14%.",A pharmacokinetic comparison of two oral liquid glucocorticoid formulations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9085328/),[ml] / [1.73·m2·min],128.3,214055,DB00635,Prednisone
,9085328,Clearance,"Clearance was slower for prednisolone (128.3 +/- 15.1 vs 149.1 +/- 17.6 ml/min/1.73 m2, p = 0.01), and the relative bioavailability of the prednisolone liquid using prednisone liquid as the reference standard was 116 +/- 14%.",A pharmacokinetic comparison of two oral liquid glucocorticoid formulations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9085328/),[ml] / [1.73·m2·min],149.1,214056,DB00635,Prednisone
,9085328,relative bioavailability,"Clearance was slower for prednisolone (128.3 +/- 15.1 vs 149.1 +/- 17.6 ml/min/1.73 m2, p = 0.01), and the relative bioavailability of the prednisolone liquid using prednisone liquid as the reference standard was 116 +/- 14%.",A pharmacokinetic comparison of two oral liquid glucocorticoid formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9085328/),%,116,214057,DB00635,Prednisone
,17925494,area under the curves (AUCs),Oral administration of prednisone resulted in prednisone mean +/- SD area under the curves (AUCs) of 115.89 +/- 39.52 microg x h/L prior to SJW treatment and 128.76 +/- 32.71 microg x h/L after 28 days of treatment.,Lack of pharmacokinetic interaction between St. John's wort and prednisone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17925494/),[h·μg] / [l],115.89,214237,DB00635,Prednisone
,17925494,area under the curves (AUCs),Oral administration of prednisone resulted in prednisone mean +/- SD area under the curves (AUCs) of 115.89 +/- 39.52 microg x h/L prior to SJW treatment and 128.76 +/- 32.71 microg x h/L after 28 days of treatment.,Lack of pharmacokinetic interaction between St. John's wort and prednisone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17925494/),[h·μg] / [l],128.76,214238,DB00635,Prednisone
,17925494,AUCs,Prednisolone mean AUCs were 714.19 +/- 153.29 microg x h/L before SJW administration and 700.74 +/- 89.68 microg x h/L after treatment.,Lack of pharmacokinetic interaction between St. John's wort and prednisone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17925494/),[h·μg] / [l],714.19,214239,DB00635,Prednisone
,17925494,AUCs,Prednisolone mean AUCs were 714.19 +/- 153.29 microg x h/L before SJW administration and 700.74 +/- 89.68 microg x h/L after treatment.,Lack of pharmacokinetic interaction between St. John's wort and prednisone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17925494/),[h·μg] / [l],700.74,214240,DB00635,Prednisone
,11707060,elimination half-life (t1/2beta),"The corticosteroids have a short elimination half-life (t1/2beta) of 1.5 to 4 hours, but their biological half-lives are much longer (12 to 36 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,1.5 to 4,214390,DB00635,Prednisone
,11707060,biological half-lives,"The corticosteroids have a short elimination half-life (t1/2beta) of 1.5 to 4 hours, but their biological half-lives are much longer (12 to 36 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,12 to 36,214391,DB00635,Prednisone
,11707060,t1/2beta,"Rapid acetylation in the intestinal wall and liver (t1/2beta 0.5 to 2 hours) and transport probably by P-glycoprotein affect mucosal concentrations of mesalazine, which apparently determine clinical response.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,0.5 to 2,214392,DB00635,Prednisone
,11707060,oral bioavailability,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),%,90,214393,DB00635,Prednisone
,11707060,t1/2beta,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,6 to 10,214394,DB00635,Prednisone
,11707060,total clearance,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),[l] / [h·kg],4,214395,DB00635,Prednisone
,11707060,t1/2beta,"Ciprofloxacin is largely excreted unchanged both renally (about 45% of dose) and extrarenally (25%), with a relatively short t1/2beta (3.5 to 7 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,3.5 to 7,214396,DB00635,Prednisone
,11707060,t1/2beta,"Both mercaptopurine and azathioprine have a short t1/2beta (1 to 2 hours), but the t1/2beta of 6-TGN ranges from 3 to 13 days.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,1 to 2,214397,DB00635,Prednisone
,11707060,t1/2beta,"Both mercaptopurine and azathioprine have a short t1/2beta (1 to 2 hours), but the t1/2beta of 6-TGN ranges from 3 to 13 days.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),d,3 to 13,214398,DB00635,Prednisone
up to,11707060,t1/2beta,"Almost complete bioavailability has been observed after intramuscular and subcutaneous administration of methotrexate, which is predominantly (85%) excreted as unchanged drug with a t1/2beta of up to 50 hours.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,50,214399,DB00635,Prednisone
,11707060,t1/2beta,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,7.9,214400,DB00635,Prednisone
,11707060,clearance,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,7.9,214401,DB00635,Prednisone
,11707060,clearance,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),[l] / [h·kg],0.46,214402,DB00635,Prednisone
,11707060,t1/2beta,Infliximab is predominantly distributed to the vascular compartment and eliminated with a t1/2beta between 10 and 14 days.,Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),d,10 and 14,214403,DB00635,Prednisone
,17445555,area under the curve (AUC 0-6),"The area under the curve (AUC 0-6) of MPA was 52.68 +/- 17.5 microg/mL*hr, with 61.5% of basal determinations (Co) under 5 microg/mL (4.08 +/- 0.74).",Converting to a generic formulation of mycophenolate mofetil in stable kidney transplant recipients: 1 year of drug surveillance and outcome. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17445555/),[μg] / [h·ml],52.68,215239,DB00635,Prednisone
,17445555,area under the curve (AUC 0-6),"The area under the curve (AUC 0-6) of MPA was 52.68 +/- 17.5 microg/mL*hr, with 61.5% of basal determinations (Co) under 5 microg/mL (4.08 +/- 0.74).",Converting to a generic formulation of mycophenolate mofetil in stable kidney transplant recipients: 1 year of drug surveillance and outcome. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17445555/),,4,215240,DB00635,Prednisone
,7107818,fraction of unbound prednisolone,The fraction of unbound prednisolone increased from 0.12 +/- 0.02 to 0.24 +/- 0.02 with increasing dose.,Prednisolone clearance at steady state in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7107818/),,0.12,216422,DB00635,Prednisone
,7107818,fraction of unbound prednisolone,The fraction of unbound prednisolone increased from 0.12 +/- 0.02 to 0.24 +/- 0.02 with increasing dose.,Prednisolone clearance at steady state in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7107818/),,0.24,216423,DB00635,Prednisone
,7107818,maximum prednisone concentration,"In humans, we found this maximum prednisone concentration to be 52 ng/ml when prednisolone is infused.",Prednisolone clearance at steady state in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7107818/),[ng] / [ml],52,216424,DB00635,Prednisone
,383357,bioavailability,"Prednisone is effectively absorbed and converted to its active therapeutic derivative, prednisolone, in healthy volunteers and in patients with liver disease; the bioavailability of oral prednisone approximates 100% of an intravenous dose and is comparable after administration of either prednisone or prednisolone.",Corticosteroid pharmacokinetics in liver disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/383357/),%,100,217713,DB00635,Prednisone
,18387858,protein binding,"Since the protein binding of prednisolone did not change in the presence of prednisone (114.0 ng/ml), it appeared that prednisone produced from the therapeutic dose of prednisolone did not affect the unbound fraction of prednisolone.","Simultaneous determination of prednisolone, prednisone, cortisol, and cortisone in plasma by GC-MS: estimating unbound prednisolone concentration in patients with nephrotic syndrome during oral prednisolone therapy. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18387858/),[ng] / [ml],114.0,221418,DB00635,Prednisone
,12395976,Cmax,"Mean values for Cmax of pravastatin were 384.2 ng/ml, 392.0 ng/ml and 115.1 ng/ml in patients on Days 1, 8 and 29, respectively.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],384.2,223848,DB00635,Prednisone
,12395976,Cmax,"Mean values for Cmax of pravastatin were 384.2 ng/ml, 392.0 ng/ml and 115.1 ng/ml in patients on Days 1, 8 and 29, respectively.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],392.0,223849,DB00635,Prednisone
,12395976,Cmax,"Mean values for Cmax of pravastatin were 384.2 ng/ml, 392.0 ng/ml and 115.1 ng/ml in patients on Days 1, 8 and 29, respectively.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],115.1,223850,DB00635,Prednisone
,12395976,C(max-DN10mg),"After normalization for a dose of 10 mg, the corresponding values of C(max-DN10mg) and Cmax were 96.0 ng/ml, 98.0 ng/ml and 115.1 ng/ml on study Days 1, 8 and 29.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],96.0,223851,DB00635,Prednisone
,12395976,C(max-DN10mg),"After normalization for a dose of 10 mg, the corresponding values of C(max-DN10mg) and Cmax were 96.0 ng/ml, 98.0 ng/ml and 115.1 ng/ml on study Days 1, 8 and 29.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],98.0,223852,DB00635,Prednisone
,12395976,Cmax,"After normalization for a dose of 10 mg, the corresponding values of C(max-DN10mg) and Cmax were 96.0 ng/ml, 98.0 ng/ml and 115.1 ng/ml on study Days 1, 8 and 29.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],115.1,223853,DB00635,Prednisone
,12395976,C(max-DN10mg),These values were 7-8 times higher than the normalized value of C(max-DN10mg) for the control group (13.7 ng/ml).,Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],13.7,223854,DB00635,Prednisone
,12395976,AUC(0-24h),"The corresponding values of AUC(0-24h) were 1228.2 ng/ml x h, 1214.1 ng/ml x h and 345.9 ng/ml x h in the patient group on study Days 1, 8 and 29 as well as 157.5 ng/ml x h in the control group prior to normalization.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [h·ml],1228.2,223855,DB00635,Prednisone
,12395976,AUC(0-24h),"The corresponding values of AUC(0-24h) were 1228.2 ng/ml x h, 1214.1 ng/ml x h and 345.9 ng/ml x h in the patient group on study Days 1, 8 and 29 as well as 157.5 ng/ml x h in the control group prior to normalization.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [h·ml],1214.1,223856,DB00635,Prednisone
,12395976,AUC(0-24h),"The corresponding values of AUC(0-24h) were 1228.2 ng/ml x h, 1214.1 ng/ml x h and 345.9 ng/ml x h in the patient group on study Days 1, 8 and 29 as well as 157.5 ng/ml x h in the control group prior to normalization.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [h·ml],345.9,223857,DB00635,Prednisone
,12395976,AUC(0-24h),"The corresponding values of AUC(0-24h) were 1228.2 ng/ml x h, 1214.1 ng/ml x h and 345.9 ng/ml x h in the patient group on study Days 1, 8 and 29 as well as 157.5 ng/ml x h in the control group prior to normalization.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [h·ml],157.5,223858,DB00635,Prednisone
,9506007,oral clearance,"In all three patient populations, the pharmacokinetics of BQR were characterized by a lower oral clearance (12-19 mL/min) than that seen in previous studies in patients with cancer (approximately 30 mL/min at similar doses) and a long terminal half life (13-18 hrs).","Phase I safety and pharmacokinetic studies of brequinar sodium after single ascending oral doses in stable renal, hepatic, and cardiac allograft recipients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506007/),[ml] / [min],12-19,224153,DB00635,Prednisone
,9506007,oral clearance,"In all three patient populations, the pharmacokinetics of BQR were characterized by a lower oral clearance (12-19 mL/min) than that seen in previous studies in patients with cancer (approximately 30 mL/min at similar doses) and a long terminal half life (13-18 hrs).","Phase I safety and pharmacokinetic studies of brequinar sodium after single ascending oral doses in stable renal, hepatic, and cardiac allograft recipients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506007/),[ml] / [min],30,224154,DB00635,Prednisone
,9506007,terminal half life,"In all three patient populations, the pharmacokinetics of BQR were characterized by a lower oral clearance (12-19 mL/min) than that seen in previous studies in patients with cancer (approximately 30 mL/min at similar doses) and a long terminal half life (13-18 hrs).","Phase I safety and pharmacokinetic studies of brequinar sodium after single ascending oral doses in stable renal, hepatic, and cardiac allograft recipients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506007/),h,13-18,224155,DB00635,Prednisone
,29735215,peak concentration (Cmax),"The peak concentration (Cmax) in the MMF dispersible tablets (MMFdt) group (7.0 ± 2.8) mg/L was reduced compared with that in the MMF capsules (MMFc) group (10.8 ± 6.2 mg/L; P = .012); time to peak concentration in the MMFdt group was 3.2 ± 2.3 hours, which was nonsignificantly elevated compared with that of the MMFc group (2.2 ± 1.7 hours).",Limited Sampling Strategy for Estimating Mycophenolic Acid Exposure on Day 7 Post-Transplant for Two Mycophenolate Mofetil Formulations Derived From 20 Chinese Renal Transplant Recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29735215/),[mg] / [l],7.0,225227,DB00635,Prednisone
,29735215,peak concentration (Cmax),"The peak concentration (Cmax) in the MMF dispersible tablets (MMFdt) group (7.0 ± 2.8) mg/L was reduced compared with that in the MMF capsules (MMFc) group (10.8 ± 6.2 mg/L; P = .012); time to peak concentration in the MMFdt group was 3.2 ± 2.3 hours, which was nonsignificantly elevated compared with that of the MMFc group (2.2 ± 1.7 hours).",Limited Sampling Strategy for Estimating Mycophenolic Acid Exposure on Day 7 Post-Transplant for Two Mycophenolate Mofetil Formulations Derived From 20 Chinese Renal Transplant Recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29735215/),[mg] / [l],10.8,225228,DB00635,Prednisone
,29735215,time to peak concentration,"The peak concentration (Cmax) in the MMF dispersible tablets (MMFdt) group (7.0 ± 2.8) mg/L was reduced compared with that in the MMF capsules (MMFc) group (10.8 ± 6.2 mg/L; P = .012); time to peak concentration in the MMFdt group was 3.2 ± 2.3 hours, which was nonsignificantly elevated compared with that of the MMFc group (2.2 ± 1.7 hours).",Limited Sampling Strategy for Estimating Mycophenolic Acid Exposure on Day 7 Post-Transplant for Two Mycophenolate Mofetil Formulations Derived From 20 Chinese Renal Transplant Recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29735215/),h,3.2,225229,DB00635,Prednisone
,29735215,time to peak concentration,"The peak concentration (Cmax) in the MMF dispersible tablets (MMFdt) group (7.0 ± 2.8) mg/L was reduced compared with that in the MMF capsules (MMFc) group (10.8 ± 6.2 mg/L; P = .012); time to peak concentration in the MMFdt group was 3.2 ± 2.3 hours, which was nonsignificantly elevated compared with that of the MMFc group (2.2 ± 1.7 hours).",Limited Sampling Strategy for Estimating Mycophenolic Acid Exposure on Day 7 Post-Transplant for Two Mycophenolate Mofetil Formulations Derived From 20 Chinese Renal Transplant Recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29735215/),h,2.2,225230,DB00635,Prednisone
,20926996,steady-state area under the concentration-time curve,"Based on individual estimates oral clearance from the population pharmacokinetic model, mean steady-state area under the concentration-time curve values for a mycophenolate mofetil dose of 1000 mg twice daily were 63 mg·hr/L (22%) and 59 mg·hr/L (36%) for the tasocitinib and tacrolimus groups, respectively.","Population pharmacokinetic analysis of mycophenolic acid coadministered with either tasocitinib (CP-690,550) or tacrolimus in adult renal allograft recipients. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20926996/),[h·mg] / [l],63,225694,DB00635,Prednisone
,20926996,steady-state area under the concentration-time curve,"Based on individual estimates oral clearance from the population pharmacokinetic model, mean steady-state area under the concentration-time curve values for a mycophenolate mofetil dose of 1000 mg twice daily were 63 mg·hr/L (22%) and 59 mg·hr/L (36%) for the tasocitinib and tacrolimus groups, respectively.","Population pharmacokinetic analysis of mycophenolic acid coadministered with either tasocitinib (CP-690,550) or tacrolimus in adult renal allograft recipients. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20926996/),[h·mg] / [l],59,225695,DB00635,Prednisone
,23802738,overall response rate,The overall response rate was 96% (69/72) including complete response (CR) in 65 (90%) and unconfirmed CR in 2 (3%).,"Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802738/),%,96,226475,DB00635,Prednisone
,3943272,volume of distribution,"Prednisolone volume of distribution, elimination clearance, and elimination t1/2 averaged 0.606 +/- 0.061 and 0.553 +/- 0.162 L/kg, 2.28 +/- 0.43 and 1.93 +/- 0.54 ml/min/kg, and 204 +/- 44 and 214 +/- 19 minutes in patients receiving alternate-day or daily prednisone therapy, respectively.",Comparison of prednisolone kinetics in patients receiving daily or alternate-day prednisone for asthma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943272/),[l] / [kg],0.606,226932,DB00635,Prednisone
,3943272,elimination clearance,"Prednisolone volume of distribution, elimination clearance, and elimination t1/2 averaged 0.606 +/- 0.061 and 0.553 +/- 0.162 L/kg, 2.28 +/- 0.43 and 1.93 +/- 0.54 ml/min/kg, and 204 +/- 44 and 214 +/- 19 minutes in patients receiving alternate-day or daily prednisone therapy, respectively.",Comparison of prednisolone kinetics in patients receiving daily or alternate-day prednisone for asthma. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943272/),[l] / [kg],0.553,226933,DB00635,Prednisone
,3943272,elimination clearance,"Prednisolone volume of distribution, elimination clearance, and elimination t1/2 averaged 0.606 +/- 0.061 and 0.553 +/- 0.162 L/kg, 2.28 +/- 0.43 and 1.93 +/- 0.54 ml/min/kg, and 204 +/- 44 and 214 +/- 19 minutes in patients receiving alternate-day or daily prednisone therapy, respectively.",Comparison of prednisolone kinetics in patients receiving daily or alternate-day prednisone for asthma. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943272/),[ml] / [kg·min],2.28,226934,DB00635,Prednisone
,3943272,elimination t1/2,"Prednisolone volume of distribution, elimination clearance, and elimination t1/2 averaged 0.606 +/- 0.061 and 0.553 +/- 0.162 L/kg, 2.28 +/- 0.43 and 1.93 +/- 0.54 ml/min/kg, and 204 +/- 44 and 214 +/- 19 minutes in patients receiving alternate-day or daily prednisone therapy, respectively.",Comparison of prednisolone kinetics in patients receiving daily or alternate-day prednisone for asthma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943272/),[ml] / [kg·min],1.93,226935,DB00635,Prednisone
,3943272,elimination t1/2,"Prednisolone volume of distribution, elimination clearance, and elimination t1/2 averaged 0.606 +/- 0.061 and 0.553 +/- 0.162 L/kg, 2.28 +/- 0.43 and 1.93 +/- 0.54 ml/min/kg, and 204 +/- 44 and 214 +/- 19 minutes in patients receiving alternate-day or daily prednisone therapy, respectively.",Comparison of prednisolone kinetics in patients receiving daily or alternate-day prednisone for asthma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943272/),min,204,226936,DB00635,Prednisone
,3943272,elimination t1/2,"Prednisolone volume of distribution, elimination clearance, and elimination t1/2 averaged 0.606 +/- 0.061 and 0.553 +/- 0.162 L/kg, 2.28 +/- 0.43 and 1.93 +/- 0.54 ml/min/kg, and 204 +/- 44 and 214 +/- 19 minutes in patients receiving alternate-day or daily prednisone therapy, respectively.",Comparison of prednisolone kinetics in patients receiving daily or alternate-day prednisone for asthma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943272/),min,214,226937,DB00635,Prednisone
,15728147,AUC(0-8),"When indinavir was given concomitantly with CHOP, the AUC(0-8) increased by 38% (20.5 +/- 9.0 versus 14.9 +/- 9.5 mg.h/L; P=0.03), and was comparable to historical controls.",Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15728147/),[h·mg] / [l],20.5,227142,DB00635,Prednisone
,15728147,AUC(0-8),"When indinavir was given concomitantly with CHOP, the AUC(0-8) increased by 38% (20.5 +/- 9.0 versus 14.9 +/- 9.5 mg.h/L; P=0.03), and was comparable to historical controls.",Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15728147/),[h·mg] / [l],14.9,227143,DB00635,Prednisone
,15728147,IC(50),"Likewise, we observed a significant number of patients with C(0) and C(8) below the IC(50) for the wild-type virus (0.1 mg/L) when the drug was administered without CHOP.",Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15728147/),[mg] / [l],0.1,227144,DB00635,Prednisone
,29590007,response rate,"The PSA response rate was 58% in LOW and 50% in STD, and the median PFS was approximately 9 months in both groups.",Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29590007/),%,58,227698,DB00635,Prednisone
,29590007,response rate,"The PSA response rate was 58% in LOW and 50% in STD, and the median PFS was approximately 9 months in both groups.",Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29590007/),%,50,227699,DB00635,Prednisone
,29590007,PFS,"The PSA response rate was 58% in LOW and 50% in STD, and the median PFS was approximately 9 months in both groups.",Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29590007/),month,9,227700,DB00635,Prednisone
,10533695,plasma clearance,Mean Pred plasma clearance was 0.655 L/hr (interrat++ variability: 11%) and significantly increased with weight.,Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),[l] / [h],0.655,227701,DB00635,Prednisone
,10533695,whole blood volume of distribution,"Mean SIR whole blood volume of distribution and clearance were 5.6 L (62%) and 0.28 L/hr (32%), and animal scaling showed weight-power proportionality.",Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),l,5.6,227702,DB00635,Prednisone
,10533695,clearance,"Mean SIR whole blood volume of distribution and clearance were 5.6 L (62%) and 0.28 L/hr (32%), and animal scaling showed weight-power proportionality.",Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),[l] / [h],0.28,227703,DB00635,Prednisone
,10533695,IC50,Pred decreased numbers of T-helper lymphocytes with a mean IC50 of 37.8 nM (21%) alone or 12.3 nM (130%) with SIR.,Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),nM,37.8,227704,DB00635,Prednisone
,10533695,IC50,Pred decreased numbers of T-helper lymphocytes with a mean IC50 of 37.8 nM (21%) alone or 12.3 nM (130%) with SIR.,Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),nM,12.3,227705,DB00635,Prednisone
,10533695,IC50,SIR increased lymphocyte numbers with a mean IC50 of 52.2 nM (24%) for T-helper and 28.8 nM (51%) for T-cytotoxic cells.,Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),nM,52.2,227706,DB00635,Prednisone
,10533695,IC50,SIR increased lymphocyte numbers with a mean IC50 of 52.2 nM (24%) for T-helper and 28.8 nM (51%) for T-cytotoxic cells.,Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),nM,28.8,227707,DB00635,Prednisone
,10533695,IC50,"Taking into account drug effects on lymphocyte trafficking, Pred directly inhibited ex vivo lymphocyte proliferation with a mean IC50 of 1.08 nM (38%).",Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),nM,1.08,227708,DB00635,Prednisone
,10533695,IC50,"SIR, after a transduction step, inhibited proliferation with a mean IC50 of 1.00 nM (26%).",Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),nM,1.00,227709,DB00635,Prednisone
,15059136,Rate of absorption,"Rate of absorption, rate of elimination, volume of distribution, clearance and elimination half-life were calculated to be 0.200/h, 0.140/h, 0.886 l/kg, 0.126 l/h/kg and 4.98 h respectively.",Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15059136/),1/[h],0.200,229630,DB00635,Prednisone
,15059136,volume of distribution,"Rate of absorption, rate of elimination, volume of distribution, clearance and elimination half-life were calculated to be 0.200/h, 0.140/h, 0.886 l/kg, 0.126 l/h/kg and 4.98 h respectively.",Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15059136/),1/[h],0.140,229631,DB00635,Prednisone
,15059136,clearance,"Rate of absorption, rate of elimination, volume of distribution, clearance and elimination half-life were calculated to be 0.200/h, 0.140/h, 0.886 l/kg, 0.126 l/h/kg and 4.98 h respectively.",Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15059136/),1/[h],0.140,229632,DB00635,Prednisone
,15059136,elimination half-life,"Rate of absorption, rate of elimination, volume of distribution, clearance and elimination half-life were calculated to be 0.200/h, 0.140/h, 0.886 l/kg, 0.126 l/h/kg and 4.98 h respectively.",Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15059136/),h,4.98,229633,DB00635,Prednisone
,31081533,DTL,"Considerable inter-patient variability in DTL was seen, with initial DTL for abiraterone ranging between 1.5 and 25.4 ng/ml (CV 61%) and for D4A between 0.2 and 2.5 ng/ml (CV 61%).",Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31081533/),ng,1,229856,DB00635,Prednisone
,16647462,AUC0-12,Mean AUC0-12 of 4431 +/- 2400 microg x h/L at week 1 remained stable at week 3 (5119 +/- 1190 microg x h/L).,Pharmacokinetic profiling of cyclosporine microemulsion during the first 3 weeks after simultaneous pancreas-kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16647462/),[h·μg] / [l],4431,229962,DB00635,Prednisone
,16647462,AUC0-12,Mean AUC0-12 of 4431 +/- 2400 microg x h/L at week 1 remained stable at week 3 (5119 +/- 1190 microg x h/L).,Pharmacokinetic profiling of cyclosporine microemulsion during the first 3 weeks after simultaneous pancreas-kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16647462/),[h·μg] / [l],5119,229963,DB00635,Prednisone
,2713960,elimination half-life,"For total prednisolone, the mean elimination half-life was relatively short (1.37 h) and the total clearance, relatively high (15.1 ml min-1 kg-1).",Pharmacokinetics of prednisolone in children with acute lymphoblastic leukaemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713960/),h,1.37,230108,DB00635,Prednisone
,2713960,total clearance,"For total prednisolone, the mean elimination half-life was relatively short (1.37 h) and the total clearance, relatively high (15.1 ml min-1 kg-1).",Pharmacokinetics of prednisolone in children with acute lymphoblastic leukaemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713960/),[ml] / [kg·min],15.1,230109,DB00635,Prednisone
,2713960,free fraction,The mean free fraction was high (0.37).,Pharmacokinetics of prednisolone in children with acute lymphoblastic leukaemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713960/),,0.37,230110,DB00635,Prednisone
> or =,14692520,time to absolute neutrophil count (ANC) recovery,"The pharmacokinetics of pegfilgrastim were characterized and the duration of grade 4 neutropenia, time to absolute neutrophil count (ANC) recovery to > or = 2.0 x 10(9)/l, neutrophil nadir, and incidence of febrile neutropenia were determined in the first 21-day chemotherapy cycle.",Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14692520/),,2.0 x 10(9),234938,DB00635,Prednisone
,14692520,duration of grade 4 neutropenia,The incidence of grade 4 neutropenia in cycle 1 was 43% with a mean (SD) duration of grade 4 neutropenia value of 1.0 (1.4) day.,Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14692520/),d,1.0,234939,DB00635,Prednisone
,14692520,time to ANC recovery,"The median [quartiles] time to ANC recovery was 10 [9, 11] days.",Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14692520/),d,10,234940,DB00635,Prednisone
,14692520,terminal half-life,"After the second peak, concentration of pegfilgrastim declined linearly with a median terminal half-life of approximately 42 h.",Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14692520/),h,42,234941,DB00635,Prednisone
,29761906,Plasma drug concentrations,Plasma drug concentrations ranged from 0.05 to 2.8 μg/ml.,"The pharmacokinetics of cytarabine administered subcutaneously, combined with prednisone, in dogs with meningoencephalomyelitis of unknown etiology. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29761906/),[μg] / [ml],0.05 to 2.8,235292,DB00635,Prednisone
,29761906,elimination half-life,"The population estimate (CV%) for elimination half-life and Tmax of cytarabine in dogs was 1.09 (21.93) hr and 0.55 (51.03) hr, respectively.","The pharmacokinetics of cytarabine administered subcutaneously, combined with prednisone, in dogs with meningoencephalomyelitis of unknown etiology. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29761906/),h,1.09,235293,DB00635,Prednisone
,29761906,Tmax,"The population estimate (CV%) for elimination half-life and Tmax of cytarabine in dogs was 1.09 (21.93) hr and 0.55 (51.03) hr, respectively.","The pharmacokinetics of cytarabine administered subcutaneously, combined with prednisone, in dogs with meningoencephalomyelitis of unknown etiology. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29761906/),h,0.55,235294,DB00635,Prednisone
,29761906,volume of distribution per fraction absorbed,The volume of distribution per fraction absorbed was 976.31 (10.85%) ml/kg.,"The pharmacokinetics of cytarabine administered subcutaneously, combined with prednisone, in dogs with meningoencephalomyelitis of unknown etiology. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29761906/),[ml] / [kg],976.31,235295,DB00635,Prednisone
,9238794,physical half-life (T1/2,Potential limitations of this radiopharmaceutical include cost and prolonged isolation of the animal prior to release to the client due to the long physical half-life (T1/2 = 2.82 days).,Scintigraphic evaluation of four dogs with protein-losing enteropathy using 111indium-labeled transferrin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9238794/),d,2.82,238235,DB00635,Prednisone
,7120877,peak serum levels,"After 5, 7.5 and 10 mg prednisone peak serum levels averaged 11.9 +/- 2.2, 15.9+/-3.4 and 21.5+/-5.9 microgram/dl, respectively.",[Pharmacokinetics of prednisolone in adrenal insufficiency ]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7120877/),[μg] / [dl],11.9,239579,DB00635,Prednisone
,7120877,peak serum levels,"After 5, 7.5 and 10 mg prednisone peak serum levels averaged 11.9 +/- 2.2, 15.9+/-3.4 and 21.5+/-5.9 microgram/dl, respectively.",[Pharmacokinetics of prednisolone in adrenal insufficiency ]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7120877/),[μg] / [dl],15.9,239580,DB00635,Prednisone
,7120877,peak serum levels,"After 5, 7.5 and 10 mg prednisone peak serum levels averaged 11.9 +/- 2.2, 15.9+/-3.4 and 21.5+/-5.9 microgram/dl, respectively.",[Pharmacokinetics of prednisolone in adrenal insufficiency ]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7120877/),[μg] / [dl],21.5,239581,DB00635,Prednisone
,7120877,plasma half-time,The plasma half-time of approximately 5 1/2 h suggests that prednisolone is present in serum far about 2 days after application of higher doses.,[Pharmacokinetics of prednisolone in adrenal insufficiency ]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7120877/),h,5 1/2,239582,DB00635,Prednisone
,7120877,metabolic clearance rate,The metabolic clearance rate of prednisolone was decreased (56.0+/-7.2 1/24 h/m2) in patients with adrenal insufficiency.,[Pharmacokinetics of prednisolone in adrenal insufficiency ]. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7120877/),[1] / [24·h·m2],56.0,239583,DB00635,Prednisone
,6702820,association constants,"Compared to normal volunteers, nephrotic patients had significantly higher mean (+/- SD) association constants for the albumin-prednisolone complex (4.20 +/- 2.10 X 10(3) M-1 v 2.26 +/- 0.46 X 10(3) M-1, P less than 0.005) and tended to have higher association constants for the transcortin-prednisolone complex.",Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6702820/),1/[M],4.20,240771,DB00635,Prednisone
,6702820,association constants,"Compared to normal volunteers, nephrotic patients had significantly higher mean (+/- SD) association constants for the albumin-prednisolone complex (4.20 +/- 2.10 X 10(3) M-1 v 2.26 +/- 0.46 X 10(3) M-1, P less than 0.005) and tended to have higher association constants for the transcortin-prednisolone complex.",Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6702820/),1/[M],2.26,240772,DB00635,Prednisone
,6702820,nonrenal clearance rate,"When calculated with reference to total prednisolone concentrations in plasma, the mean nonrenal clearance rate, but not the mean renal clearance rate, was higher in the nephrotic patients than in the controls (2.63 +/- 0.61 mL/min/kg v 1.85 +/- 0.33 mL/min/kg, P less than 0.005).",Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6702820/),[ml] / [kg·min],2.63,240773,DB00635,Prednisone
,6702820,renal clearance rate,"When calculated with reference to total prednisolone concentrations in plasma, the mean nonrenal clearance rate, but not the mean renal clearance rate, was higher in the nephrotic patients than in the controls (2.63 +/- 0.61 mL/min/kg v 1.85 +/- 0.33 mL/min/kg, P less than 0.005).",Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6702820/),[ml] / [kg·min],1.85,240774,DB00635,Prednisone
,6702820,renal clearance rates,"Compared to normal volunteers, patients with the nephrotic syndrome had lower renal clearance rates of unbound prednisolone when prednisolone was given intravenously (1.58 +/- 0.88 mL/min/kg v 2.89 +/- 0.89 mL/min/kg, P less than 0.005) or when prednisone was given orally (1.18 +/- 0.86 mL/min/kg v 2.80 +/- 1.13 mL/min/kg, P less than 0.005).",Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6702820/),[ml] / [kg·min],1.58,240775,DB00635,Prednisone
,6702820,renal clearance rates,"Compared to normal volunteers, patients with the nephrotic syndrome had lower renal clearance rates of unbound prednisolone when prednisolone was given intravenously (1.58 +/- 0.88 mL/min/kg v 2.89 +/- 0.89 mL/min/kg, P less than 0.005) or when prednisone was given orally (1.18 +/- 0.86 mL/min/kg v 2.80 +/- 1.13 mL/min/kg, P less than 0.005).",Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6702820/),[ml] / [kg·min],2.89,240776,DB00635,Prednisone
,6702820,renal clearance rates,"Compared to normal volunteers, patients with the nephrotic syndrome had lower renal clearance rates of unbound prednisolone when prednisolone was given intravenously (1.58 +/- 0.88 mL/min/kg v 2.89 +/- 0.89 mL/min/kg, P less than 0.005) or when prednisone was given orally (1.18 +/- 0.86 mL/min/kg v 2.80 +/- 1.13 mL/min/kg, P less than 0.005).",Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6702820/),[ml] / [kg·min],1.18,240777,DB00635,Prednisone
,6702820,renal clearance rates,"Compared to normal volunteers, patients with the nephrotic syndrome had lower renal clearance rates of unbound prednisolone when prednisolone was given intravenously (1.58 +/- 0.88 mL/min/kg v 2.89 +/- 0.89 mL/min/kg, P less than 0.005) or when prednisone was given orally (1.18 +/- 0.86 mL/min/kg v 2.80 +/- 1.13 mL/min/kg, P less than 0.005).",Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6702820/),[ml] / [kg·min],2.80,240778,DB00635,Prednisone
,12595513,trough,Lowering CsA to low target CsA trough (30 to 70 ng/ml) never led to acute rejection or major renal function deterioration.,Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12595513/),[ng] / [ml],30 to 70,240980,DB00635,Prednisone
,3799579,time of peak concentration,No significant differences were noted in any of the treatment phases for any of the parameters except for the time of peak concentration which was slightly delayed from 1.0 +/- 0.6 to 1.7 +/- 0.9 h when sucralfate was concomitantly administered with the prednisone.,Lack of effect of sucralfate on prednisone bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3799579/),h,1.0,241300,DB00635,Prednisone
,3799579,time of peak concentration,No significant differences were noted in any of the treatment phases for any of the parameters except for the time of peak concentration which was slightly delayed from 1.0 +/- 0.6 to 1.7 +/- 0.9 h when sucralfate was concomitantly administered with the prednisone.,Lack of effect of sucralfate on prednisone bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3799579/),h,1.7,241301,DB00635,Prednisone
,8890711,half-life,"Recent pharmacokinetic studies have revealed a prolonged release of the cytotoxic agent cytosine arabinoside (araC) from hepatocytes into the systemic circulation, resulting in a half-life of approximately 24 h for araC.","Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantrone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8890711/),h,24,241594,DB00635,Prednisone
,12969965,clearance,"On day 29, etoposide clearance was higher (47.4 versus 29.2 mL/min/m2, P <.0001) than at week 54.",Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12969965/),[ml] / [m2·min],47.4,241630,DB00635,Prednisone
,12969965,clearance,"On day 29, etoposide clearance was higher (47.4 versus 29.2 mL/min/m2, P <.0001) than at week 54.",Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12969965/),[ml] / [m2·min],29.2,241631,DB00635,Prednisone
,6237151,AUIC,"After i.v. prednisolone phthalate or oral prednisone, the mean AUC of unbound prednisolone were 45 and 61% of that obtained after i.v. prednisolone phosphate, and the corresponding AUIC were 76 and 68%, respectively, indicating lower systemic availability of prednisolone and less of an immunosuppressive effect in plasma after i.v. prednisolone phthalate or oral prednisone than after i.v. prednisolone phosphate.",Pharmacokinetics and pharmacodynamics of three different prednisolone prodrugs: effect on circulating lymphocyte subsets and function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6237151/),%,76,241744,DB00635,Prednisone
,6237151,AUIC,"After i.v. prednisolone phthalate or oral prednisone, the mean AUC of unbound prednisolone were 45 and 61% of that obtained after i.v. prednisolone phosphate, and the corresponding AUIC were 76 and 68%, respectively, indicating lower systemic availability of prednisolone and less of an immunosuppressive effect in plasma after i.v. prednisolone phthalate or oral prednisone than after i.v. prednisolone phosphate.",Pharmacokinetics and pharmacodynamics of three different prednisolone prodrugs: effect on circulating lymphocyte subsets and function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6237151/),%,68,241745,DB00635,Prednisone
,6237151,maximal,"After steroid doses corresponding to 1 mg/kg of prednisolone, a transient inhibition of 80% of IL 2 production was observed with all three glucocorticoids given, whereas the maximal inhibition of the IL 2 production was 60, 30, and 22% after a low dose (0.1 mg/kg) of prednisolone phosphate, prednisone, or prednisolone phthalate, respectively.",Pharmacokinetics and pharmacodynamics of three different prednisolone prodrugs: effect on circulating lymphocyte subsets and function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6237151/),,60,241746,DB00635,Prednisone
,6237151,maximal,"After steroid doses corresponding to 1 mg/kg of prednisolone, a transient inhibition of 80% of IL 2 production was observed with all three glucocorticoids given, whereas the maximal inhibition of the IL 2 production was 60, 30, and 22% after a low dose (0.1 mg/kg) of prednisolone phosphate, prednisone, or prednisolone phthalate, respectively.",Pharmacokinetics and pharmacodynamics of three different prednisolone prodrugs: effect on circulating lymphocyte subsets and function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6237151/),,30,241747,DB00635,Prednisone
,6237151,maximal,"After steroid doses corresponding to 1 mg/kg of prednisolone, a transient inhibition of 80% of IL 2 production was observed with all three glucocorticoids given, whereas the maximal inhibition of the IL 2 production was 60, 30, and 22% after a low dose (0.1 mg/kg) of prednisolone phosphate, prednisone, or prednisolone phthalate, respectively.",Pharmacokinetics and pharmacodynamics of three different prednisolone prodrugs: effect on circulating lymphocyte subsets and function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6237151/),,22,241748,DB00635,Prednisone
,17132721,peak serum concentration,"The population mean peak serum concentration of asparaginase enzymatic activity was 1 IU/mL, the elimination half-life was 7 days, and the volume of distribution was 2.43 L/m2.",Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17132721/),[iu] / [ml],1,247719,DB00635,Prednisone
,17132721,elimination half-life,"The population mean peak serum concentration of asparaginase enzymatic activity was 1 IU/mL, the elimination half-life was 7 days, and the volume of distribution was 2.43 L/m2.",Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17132721/),d,7,247720,DB00635,Prednisone
,17132721,volume of distribution,"The population mean peak serum concentration of asparaginase enzymatic activity was 1 IU/mL, the elimination half-life was 7 days, and the volume of distribution was 2.43 L/m2.",Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17132721/),[l] / [m2],2.43,247721,DB00635,Prednisone
,17132721,enzymatic activity,A pharmocodynamic correlation model showed minimal enzymatic activity of 0.2 IU/mL for optimal asparagine depletion.,Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17132721/),[iu] / [ml],0.2,247722,DB00635,Prednisone
,8058612,area under the curve (AUC),Chronic inflammation produced a significant increase in the area under the curve (AUC) of prednisolone compared to control animals (6594 +/- 2144 vs 3530 +/- 2164 micrograms.hr/L).,Effects of acute and chronic inflammation on the pharmacokinetics of prednisolone in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058612/),[h·μg] / [l],6594,248461,DB00635,Prednisone
,8058612,area under the curve (AUC),Chronic inflammation produced a significant increase in the area under the curve (AUC) of prednisolone compared to control animals (6594 +/- 2144 vs 3530 +/- 2164 micrograms.hr/L).,Effects of acute and chronic inflammation on the pharmacokinetics of prednisolone in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058612/),[h·μg] / [l],3530,248462,DB00635,Prednisone
,8058612,AUC,The effect of acute inflammation was not significant (AUC = 4996 +/- 3813).,Effects of acute and chronic inflammation on the pharmacokinetics of prednisolone in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058612/),,4996,248463,DB00635,Prednisone
,8058612,AUC,"The AUC of free prednisolone after chronic inflammation was 3141 micrograms.hr/L, compared to 1121 micrograms.hr/L in the control group and 1823 micrograms.hr/L after acute inflammation.",Effects of acute and chronic inflammation on the pharmacokinetics of prednisolone in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058612/),[h·μg] / [l],3141,248464,DB00635,Prednisone
,8058612,AUC,"The AUC of free prednisolone after chronic inflammation was 3141 micrograms.hr/L, compared to 1121 micrograms.hr/L in the control group and 1823 micrograms.hr/L after acute inflammation.",Effects of acute and chronic inflammation on the pharmacokinetics of prednisolone in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058612/),[h·μg] / [l],1121,248465,DB00635,Prednisone
,8058612,AUC,"The AUC of free prednisolone after chronic inflammation was 3141 micrograms.hr/L, compared to 1121 micrograms.hr/L in the control group and 1823 micrograms.hr/L after acute inflammation.",Effects of acute and chronic inflammation on the pharmacokinetics of prednisolone in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058612/),[h·μg] / [l],1823,248466,DB00635,Prednisone
,1564126,area under concentration,"For example, for free prednisolone, the intravenous area under concentration was 1,144 +/- 195 ng.h/mL and 1,244 +/- 140 ng.h/mL, and the systemic availability after oral prednisone was 53 +/- 10% and 51 +/- 12% with placebo and tenidap, respectively.",Effect of the anti-inflammatory agent tenidap on the pharmacokinetics and pharmacodynamics of prednisolone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564126/),[h·ng] / [ml],"1,144",251239,DB00635,Prednisone
,1564126,area under concentration,"For example, for free prednisolone, the intravenous area under concentration was 1,144 +/- 195 ng.h/mL and 1,244 +/- 140 ng.h/mL, and the systemic availability after oral prednisone was 53 +/- 10% and 51 +/- 12% with placebo and tenidap, respectively.",Effect of the anti-inflammatory agent tenidap on the pharmacokinetics and pharmacodynamics of prednisolone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564126/),[h·ng] / [ml],"1,244",251240,DB00635,Prednisone
,1564126,systemic availability,"For example, for free prednisolone, the intravenous area under concentration was 1,144 +/- 195 ng.h/mL and 1,244 +/- 140 ng.h/mL, and the systemic availability after oral prednisone was 53 +/- 10% and 51 +/- 12% with placebo and tenidap, respectively.",Effect of the anti-inflammatory agent tenidap on the pharmacokinetics and pharmacodynamics of prednisolone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564126/),%,53,251241,DB00635,Prednisone
,1564126,systemic availability,"For example, for free prednisolone, the intravenous area under concentration was 1,144 +/- 195 ng.h/mL and 1,244 +/- 140 ng.h/mL, and the systemic availability after oral prednisone was 53 +/- 10% and 51 +/- 12% with placebo and tenidap, respectively.",Effect of the anti-inflammatory agent tenidap on the pharmacokinetics and pharmacodynamics of prednisolone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564126/),%,51,251242,DB00635,Prednisone
,1564126,renal clearance,"The renal clearance of prednisolone was significantly reduced after tenidap pretreatment, however (from 143 to 77 mL/min/1.73 m2).",Effect of the anti-inflammatory agent tenidap on the pharmacokinetics and pharmacodynamics of prednisolone. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564126/),[ml] / [1.73·m2·min],143 to 77,251243,DB00635,Prednisone
,11422002,area under the methylprednisolone concentration-time curve,Itraconazole increased the mean area under the methylprednisolone concentration-time curve from 2773 ng ml-1 h to 7011 ng ml-1 h (P < 0.001) and the elimination half-life from 3.2 h to 5.5 h (P < 0.001).,Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422002/),[h·ng] / [ml],2773,252860,DB00635,Prednisone
,11422002,area under the methylprednisolone concentration-time curve,Itraconazole increased the mean area under the methylprednisolone concentration-time curve from 2773 ng ml-1 h to 7011 ng ml-1 h (P < 0.001) and the elimination half-life from 3.2 h to 5.5 h (P < 0.001).,Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422002/),[h·ng] / [ml],7011,252861,DB00635,Prednisone
,11422002,elimination half-life,Itraconazole increased the mean area under the methylprednisolone concentration-time curve from 2773 ng ml-1 h to 7011 ng ml-1 h (P < 0.001) and the elimination half-life from 3.2 h to 5.5 h (P < 0.001).,Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422002/),h,3.2,252862,DB00635,Prednisone
,11422002,elimination half-life,Itraconazole increased the mean area under the methylprednisolone concentration-time curve from 2773 ng ml-1 h to 7011 ng ml-1 h (P < 0.001) and the elimination half-life from 3.2 h to 5.5 h (P < 0.001).,Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422002/),h,5.5,252863,DB00635,Prednisone
,24521993,Ctrough,"Geometric mean Ctrough was 83·13 μg/mL in the intravenous group and 134·58 μg/mL in the subcutaneous group (ratio 1·62, 90% CI 1·36-1·94), showing non-inferiority of subcutaneous rituximab.",Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521993/),[μg] / [ml],83·13,253189,DB00635,Prednisone
,24521993,Ctrough,"Geometric mean Ctrough was 83·13 μg/mL in the intravenous group and 134·58 μg/mL in the subcutaneous group (ratio 1·62, 90% CI 1·36-1·94), showing non-inferiority of subcutaneous rituximab.",Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521993/),[μg] / [ml],134·58,253190,DB00635,Prednisone
,11903387,area under the concentration curve (AUC),"Morning doses were adjusted to reach a day-time area under the concentration curve (AUC) of 7,800 ng hour/ml (utilizing 2 hour and 6 hour levels) and evening doses were adjusted to a morning trough of 300 ng/ml.",Diurnal cyclosporine dosing optimizes exposure and reduces the risk of acute rejection after kidney transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903387/),[h·ng] / [ml],"7,800",254508,DB00635,Prednisone
,11903387,trough,"Morning doses were adjusted to reach a day-time area under the concentration curve (AUC) of 7,800 ng hour/ml (utilizing 2 hour and 6 hour levels) and evening doses were adjusted to a morning trough of 300 ng/ml.",Diurnal cyclosporine dosing optimizes exposure and reduces the risk of acute rejection after kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903387/),[ng] / [ml],300,254509,DB00635,Prednisone
,7697949,peak concentration,"Grapefruit juice increased the peak concentration of cyclosporine by 185 ng/ml (95% confidence interval, 60 to 310; p = 0.008).",The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7697949/),[ng] / [ml],185,255923,DB00635,Prednisone
,7875641,peak serum cyclophosphamide levels,The peak serum cyclophosphamide levels ranged from 15.7 to 29.4 mg/L.,Pharmacokinetics of cyclophosphamide in patients with systemic necrotizing angiitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875641/),[mg] / [l],15.7 to 29.4,259068,DB00635,Prednisone
,7875641,elimination half-life,The mean cyclophosphamide elimination half-life was 6.2 +/- 1.3 h (mean +/- SD).,Pharmacokinetics of cyclophosphamide in patients with systemic necrotizing angiitis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875641/),h,6.2,259069,DB00635,Prednisone
,7875641,apparent volume of distribution,"The mean apparent volume of distribution and mean total plasma clearance were, respectively, 0.75 +/- 0.22 L/kg (mean +/- SD) and 83 +/- 22 mL/min (mean +/- SD).",Pharmacokinetics of cyclophosphamide in patients with systemic necrotizing angiitis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875641/),[l] / [kg],0.75,259070,DB00635,Prednisone
,7875641,total plasma clearance,"The mean apparent volume of distribution and mean total plasma clearance were, respectively, 0.75 +/- 0.22 L/kg (mean +/- SD) and 83 +/- 22 mL/min (mean +/- SD).",Pharmacokinetics of cyclophosphamide in patients with systemic necrotizing angiitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875641/),[ml] / [min],83,259071,DB00635,Prednisone
,24548445,AUC0-12 h,There were variable MPA AUC0-12 h levels between 14 and 67 mg×h/L (mean: 37 ± 14).,[Use of limited sampling strategy for estimating area under concentration-versus-time curve of mycophenolate sodium in renal allograft recipients]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24548445/),,37,260384,DB00635,Prednisone
,6734709,area under the plasma concentration versus time curves,"After an oral dose of prednisone, women on oral contraceptive steroids (n = 10) had higher mean (+/- SD) area under the plasma concentration versus time curves of total (428 +/- 67 micrograms/ml/min vs 188 +/- 28 micrograms/ml/min, p less than 0.001) and unbound prednisolone (64 +/- 10 micrograms/ml/min vs 41 +/- 10 micrograms/ml/min, p less than 0.001) than women not taking oral contraceptive steroids (n = 10).",Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734709/),[μg] / [min·ml],428,261415,DB00635,Prednisone
,6734709,area under the plasma concentration versus time curves,"After an oral dose of prednisone, women on oral contraceptive steroids (n = 10) had higher mean (+/- SD) area under the plasma concentration versus time curves of total (428 +/- 67 micrograms/ml/min vs 188 +/- 28 micrograms/ml/min, p less than 0.001) and unbound prednisolone (64 +/- 10 micrograms/ml/min vs 41 +/- 10 micrograms/ml/min, p less than 0.001) than women not taking oral contraceptive steroids (n = 10).",Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734709/),[μg] / [min·ml],188,261416,DB00635,Prednisone
,6734709,area under the plasma concentration versus time curves,"After an oral dose of prednisone, women on oral contraceptive steroids (n = 10) had higher mean (+/- SD) area under the plasma concentration versus time curves of total (428 +/- 67 micrograms/ml/min vs 188 +/- 28 micrograms/ml/min, p less than 0.001) and unbound prednisolone (64 +/- 10 micrograms/ml/min vs 41 +/- 10 micrograms/ml/min, p less than 0.001) than women not taking oral contraceptive steroids (n = 10).",Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734709/),[μg] / [min·ml],64,261417,DB00635,Prednisone
,6734709,area under the plasma concentration versus time curves,"After an oral dose of prednisone, women on oral contraceptive steroids (n = 10) had higher mean (+/- SD) area under the plasma concentration versus time curves of total (428 +/- 67 micrograms/ml/min vs 188 +/- 28 micrograms/ml/min, p less than 0.001) and unbound prednisolone (64 +/- 10 micrograms/ml/min vs 41 +/- 10 micrograms/ml/min, p less than 0.001) than women not taking oral contraceptive steroids (n = 10).",Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734709/),[μg] / [min·ml],41,261418,DB00635,Prednisone
,744499,bioavailability,"After prednisone (10 mg) was given by mouth and by vein to similar groups of volunteers and 11 additional patients with CALD, bioavailability of oral prednisone approximated 100% of the intravenous dose and no differences were found in the pharmacokinetics of prednisolone.",Oral prednisone for chronic active liver disease: dose responses and bioavailability studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/744499/),%,100,261570,DB00635,Prednisone
<,16045952,fT4,One 9.9-year-old administered prednisone 0.5mg/kg p.o. was found to be hypothyroid (TSH: 351microIU/mL; fT4: <2pg/mL; fT3: <1pg/mL); four age-matched normal boys (aged 6.6+/-4.9 years) served as a control group.,Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[pg] / [ml],2,262136,DB00635,Prednisone
<,16045952,fT3,One 9.9-year-old administered prednisone 0.5mg/kg p.o. was found to be hypothyroid (TSH: 351microIU/mL; fT4: <2pg/mL; fT3: <1pg/mL); four age-matched normal boys (aged 6.6+/-4.9 years) served as a control group.,Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[pg] / [ml],1,262137,DB00635,Prednisone
,16045952,total AUC,"In comparison with the controls, the hypothyroid boy showed a marked increase in the total AUC of prednisone (3360microg h/L versus 215+/-83microg h/L) and prednisolone (4040microg h/L versus 724+/-77microg h/L), and an altered pattern of endogenous cortisol, which is known to be impaired in hypothyroid subjects.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],3360,262138,DB00635,Prednisone
,16045952,total AUC,"In comparison with the controls, the hypothyroid boy showed a marked increase in the total AUC of prednisone (3360microg h/L versus 215+/-83microg h/L) and prednisolone (4040microg h/L versus 724+/-77microg h/L), and an altered pattern of endogenous cortisol, which is known to be impaired in hypothyroid subjects.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],215,262139,DB00635,Prednisone
,16045952,total AUC,"In comparison with the controls, the hypothyroid boy showed a marked increase in the total AUC of prednisone (3360microg h/L versus 215+/-83microg h/L) and prednisolone (4040microg h/L versus 724+/-77microg h/L), and an altered pattern of endogenous cortisol, which is known to be impaired in hypothyroid subjects.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],4040,262140,DB00635,Prednisone
,16045952,total AUC,"In comparison with the controls, the hypothyroid boy showed a marked increase in the total AUC of prednisone (3360microg h/L versus 215+/-83microg h/L) and prednisolone (4040microg h/L versus 724+/-77microg h/L), and an altered pattern of endogenous cortisol, which is known to be impaired in hypothyroid subjects.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],724,262141,DB00635,Prednisone
,16045952,AUCs,"After 6 months of thyroxine replacement therapy (75microg/day), the AUCs of prednisone and prednisolone returned to normal values (prednisone: 248microg h/L; prednisolone: 528microg h/L), as did the pattern of circadian cortisol secretion.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],248,262142,DB00635,Prednisone
,16045952,AUCs,"After 6 months of thyroxine replacement therapy (75microg/day), the AUCs of prednisone and prednisolone returned to normal values (prednisone: 248microg h/L; prednisolone: 528microg h/L), as did the pattern of circadian cortisol secretion.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],528,262143,DB00635,Prednisone
,25117615,tmax,"Over the evaluated dose range, plasma abiraterone concentrations increased with dose, with median tmax 2-3 h.",Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25117615/),h,2-3,262377,DB00635,Prednisone
,29733485,apparent oral clearance,"During pregnancy, prednisone apparent oral clearance increased with dose (35.1 ± 11.4 L/h with 5 mg, 52.6 ± 5.2 L/h with 10 mg, and 64.3 ± 6.9 L/h with 20 mg, P = .001).",Prednisone Pharmacokinetics During Pregnancy and Lactation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29733485/),[l] / [h],35.1,264449,DB00635,Prednisone
,29733485,apparent oral clearance,"During pregnancy, prednisone apparent oral clearance increased with dose (35.1 ± 11.4 L/h with 5 mg, 52.6 ± 5.2 L/h with 10 mg, and 64.3 ± 6.9 L/h with 20 mg, P = .001).",Prednisone Pharmacokinetics During Pregnancy and Lactation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29733485/),[l] / [h],52.6,264450,DB00635,Prednisone
,29733485,apparent oral clearance,"During pregnancy, prednisone apparent oral clearance increased with dose (35.1 ± 11.4 L/h with 5 mg, 52.6 ± 5.2 L/h with 10 mg, and 64.3 ± 6.9 L/h with 20 mg, P = .001).",Prednisone Pharmacokinetics During Pregnancy and Lactation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29733485/),[l] / [h],64.3,264451,DB00635,Prednisone
,29733485,renal clearance,"In addition, prednisolone renal clearance increased with dose (0.3 ± 0.3 L/h with 5 mg, 0.5 ± 0.4 L/h with 10 mg, and 1.3 ± 1.1 L/h with 20 mg, P = .002).",Prednisone Pharmacokinetics During Pregnancy and Lactation. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29733485/),[l] / [h],0.3,264452,DB00635,Prednisone
,29733485,renal clearance,"In addition, prednisolone renal clearance increased with dose (0.3 ± 0.3 L/h with 5 mg, 0.5 ± 0.4 L/h with 10 mg, and 1.3 ± 1.1 L/h with 20 mg, P = .002).",Prednisone Pharmacokinetics During Pregnancy and Lactation. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29733485/),[l] / [h],0.5,264453,DB00635,Prednisone
,29733485,renal clearance,"In addition, prednisolone renal clearance increased with dose (0.3 ± 0.3 L/h with 5 mg, 0.5 ± 0.4 L/h with 10 mg, and 1.3 ± 1.1 L/h with 20 mg, P = .002).",Prednisone Pharmacokinetics During Pregnancy and Lactation. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29733485/),[l] / [h],1.3,264454,DB00635,Prednisone
,24354889,central volume of distribution,The mean (interindividual standard deviation) estimated central volume of distribution was 2.3 l (36%) and systemic clearance was 0.019 l h(-1) (37%).,Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24354889/),l,2.3,265445,DB00635,Prednisone
,24354889,systemic clearance,The mean (interindividual standard deviation) estimated central volume of distribution was 2.3 l (36%) and systemic clearance was 0.019 l h(-1) (37%).,Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24354889/),[l] / [h],0.019,265446,DB00635,Prednisone
,22337718,Total clearance,Total clearance was 9.43 mL/h and Vd(ss) was 9.61 l.,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),[ml] / [h],9.43,266008,DB00635,Prednisone
,22337718,Vd(ss),Total clearance was 9.43 mL/h and Vd(ss) was 9.61 l.,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),l,9.61,266009,DB00635,Prednisone
,22337718,clearance,Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),[ml] / [h],8.21,266010,DB00635,Prednisone
,22337718,clearance,Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),[ml] / [h],12.68,266011,DB00635,Prednisone
,22337718,t(1/2β),Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),d,30.7,266012,DB00635,Prednisone
,22337718,t(1/2β),Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),d,24.7,266013,DB00635,Prednisone
,7141787,steady-state volume of distribution (Vss,"A larger steady-state volume of distribution (Vss = 3.4 vs. 1.2 l/kg) was observed in active disease than in remission, suggesting greater availability of the steroid to tissues.",Effect on nephrotic syndrome on absorption and disposition of prednisolone in children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7141787/),[l] / [kg],3.4,270293,DB00635,Prednisone
,7141787,steady-state volume of distribution (Vss,"A larger steady-state volume of distribution (Vss = 3.4 vs. 1.2 l/kg) was observed in active disease than in remission, suggesting greater availability of the steroid to tissues.",Effect on nephrotic syndrome on absorption and disposition of prednisolone in children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7141787/),[l] / [kg],1.2,270294,DB00635,Prednisone
,6721988,AUC,Total serum prednisolone levels were significantly lower during the active phase than in remission (AUC: 2452 +/- 207 vs 3392 +/- 293 ng ml-1 h respectively).,Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6721988/),[h·ng] / [ml],2452,271659,DB00635,Prednisone
,6721988,AUC,Total serum prednisolone levels were significantly lower during the active phase than in remission (AUC: 2452 +/- 207 vs 3392 +/- 293 ng ml-1 h respectively).,Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6721988/),[h·ng] / [ml],3392,271660,DB00635,Prednisone
,6721988,AUC,Free prednisolone levels during the active phase did not differ significantly from those observed during remission (AUC: 937 +/- 128 vs 847 +/- 81 ng ml-1 h respectively).,Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6721988/),[h·ng] / [ml],937,271661,DB00635,Prednisone
,6721988,AUC,Free prednisolone levels during the active phase did not differ significantly from those observed during remission (AUC: 937 +/- 128 vs 847 +/- 81 ng ml-1 h respectively).,Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6721988/),[h·ng] / [ml],847,271662,DB00635,Prednisone
,1545348,systemic availability (F),Methylprednisolone systemic availability (F) was 49-57% after iv administration and approximately 35% after oral administration.,Bioavailability and nonlinear disposition of methylprednisolone and methylprednisone in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545348/),%,49-57,271663,DB00635,Prednisone
,1545348,systemic availability (F),Methylprednisolone systemic availability (F) was 49-57% after iv administration and approximately 35% after oral administration.,Bioavailability and nonlinear disposition of methylprednisolone and methylprednisone in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545348/),%,35,271664,DB00635,Prednisone
,1545348,Apparent systemic clearance (CL),"Apparent systemic clearance (CL) of methylprednisolone was 21 mL/min (low dose), approximately twice the liver blood flow.",Bioavailability and nonlinear disposition of methylprednisolone and methylprednisone in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545348/),[ml] / [min],21,271665,DB00635,Prednisone
,8339389,Peak plasma DOX levels,"Peak plasma DOX levels were higher after the bolus injection than after continuous administration (1509 +/- 80 ng/ml vs 11.6 +/- 1.8 ng/ml, respectively), whereas the plasma area under the curve (AUC) levels were similar.",Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339389/),[ng] / [ml],1509,274180,DB00635,Prednisone
,8339389,Peak plasma DOX levels,"Peak plasma DOX levels were higher after the bolus injection than after continuous administration (1509 +/- 80 ng/ml vs 11.6 +/- 1.8 ng/ml, respectively), whereas the plasma area under the curve (AUC) levels were similar.",Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339389/),[ng] / [ml],11.6,274181,DB00635,Prednisone
,8339389,Maximum DOX cellular concentrations,Maximum DOX cellular concentrations were 8629 +/- 2902 ng/10(9) cells (bolus injection) and 2745 +/- 673 ng/10(9) cells (96 h infusion).,Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339389/),[ng] / [10(9)·cells],8629,274182,DB00635,Prednisone
,8339389,Maximum DOX cellular concentrations,Maximum DOX cellular concentrations were 8629 +/- 2902 ng/10(9) cells (bolus injection) and 2745 +/- 673 ng/10(9) cells (96 h infusion).,Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339389/),[ng] / [10(9)·cells],2745,274183,DB00635,Prednisone
